Oncology Research : Featuring Preclinical and Clinical Cancer Therapeutics

Editors: Alan C. Sartorelli, Edward Chu, Romano Danesi & Kazuo Umezawa

Volume 22

ISSN: 0965-0407; E-ISSN: 1555-3906

Softbound

6 Issues per year

Subscription Level

Aims & Scope

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.

Manuscripts are to be submitted to This e-mail address is being protected from spambots. You need JavaScript enabled to view it  , where authors will be required to set up an online account. You may contact the Editorial Office with any questions regarding the submission process. There is a $100.00 submission non-refundable fee.

American Office (for submissions from American and European countries): Professor Alan C. Sartorelli or Professor Edward Chu. Publication Office: Helen Seow, Associate Editor, Oncology Research, c/o Department of Pharmacology, Yale University, 333 Cedar Street, SHM I-228, New Haven, CT 06520-8066. E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

European Office (for submissions from European countries): Professor Romano Danesi, Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, 55, Via Roma, 56126 Pisa, Italy. Tel: +39 (050) 99-2632, Fax: +39 (050) 56-2020, E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Asian Office (for submissions from Asian countries): Professor Kazuo Umezawa, Department of Molecular Target Medicine Screening, Aichi Medical University School of Medicine, Nagakute 480-1195, Japan. Tel/Fax: 81-561-61-1959, E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it mss submissions to: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Open Access:
The journal follows rules governed by open access publications. Accepted refereed articles published in the journal will be placed on the internet and will be publicly accessible, free of charge. In order to cover the costs of the journal, authors are expected to pay a publication fee. At the time of acceptance, you will be asked to confirm that you will pay the relatively inexpensive open access fee of $1,000.00 for less than 5 pages, or $1,500.00 for 5-12 pages and $100.00 for each additional page over 12 when billed. There is a $100.00 submission fee. 

Types of Contributions: The Journal publishes full-length papers and short communications, in English, describing the results of original experiments in basic and clinical cancer research. Commentaries, short research editorials of between 3,000 and 5,000 words in length (12–20 typewritten pages, double-spaced) are also published. These are editorial statements intended to stimulate thought on selected topics and should not be exhaustive reviews. They can be controversial and can focus on areas subject to much activity, or draw attention to relatively neglected fields in which there are both opportunities and the need for research. Authors may present personal views on the state of the subject on which they are reporting, and give their view as to where in the near or distant future the subject may be moving. Authors are encouraged to take issue with popular dogmas. Manuscripts are published in the shortest time possible commensurate with scientific quality.

 

Submission Requirements: Authors are requested to submit the original manuscript (and revised manuscript if needed) electronically via email to one of the offices listed above. Send the text portion of the manuscript, including tables and figure legends, as an email attachment in either PDF or Microsoft Word (IBM compatible) format. Send the figures as separate files in PDF format (or in Microsoft Word, or as tiff or jpeg). Note that large graphic files, especially color, may need to be compressed (zipped) to send via email. PDF format is preferred for figure files. If the quality of the materials is not suitable, authors will be requested to provide them by postal mail.

 

 

Include a cover letter, and insert “Oncology Research Submission” in the subject line of the email. The cover letter should contain the name, address, telephone, and fax number and electronic mail address of the author responsible for correspondence. Follow the General Manuscript Form guidelines below to prepare the manuscript, figures, and tables. When the manuscript is accepted for publication, the author(s) will be required to provide two hard copies of the manuscript, two high-quality copies of all artwork, and a CD or disk (see Final Accepted Manuscript/Disk below).
Manuscripts are accepted for consideration with the understanding that they have not been published elsewhere except in abstract form and are not concurrently under review elsewhere. Material accepted for publication will not be released publicly prior to its appearance in the journal.

 

 

General Manuscript Form: Papers should be typed in English, double spaced throughout with at least 3-cm margins on paper approximately 22 × 28 cm (8 1/2 × 11 in.) in size. Please consult the most recent issue of the journal for style and format. Number all pages consecutively, beginning with the title page. Use metric units of measure; other units may be given in parentheses. Typically, only three levels of headings are recognized. The paper should be organized as follows.

 

 

Title Page: The title should be brief and specific. The title page should contain in the following order: title, name(s) and affiliation(s) of author(s) including city, state, postal code, and country, and a suggested short title for the running head of not more than 50 characters and spaces. Also indicate the author to whom correspondence should be addressed, with complete mailing address, telephone and fax numbers, and e-mail address.

 

 

Abstract/Key Words: An abstract of 300 words or less should begin on page 2. It should contain a concise summary of the results, conclusions, and other significant points. For the purpose of subject indexing, provide four to six key words immediately following the abstract.

 

 

Text: Arrange the text with main headings of Introduction, Materials and Methods, Results, Discussion, Acknowledgments (and source of funding), References, Tables, Figure legends (together, and separate from the figures), and Figures (each on a separate page). Use generic names of drugs. Give name, city and state, and country of the manufacturer of any chemicals, equipment, or software mentioned in the text. Define all nonstandard abbreviations the first time they appear in the text.

 

 

References/Reference List: Within the text references should be cited with sequential numbers in parentheses. The reference list should be numbered sequentially by order of appearance in the text. Follow the style samples given below. Journal citations in the reference list should contain the following: (a) surnames and initials of all authors (surnames precede initials); (b) title of article; (c) journal title abbreviated as listed in the List of Journals Indexed in Index Medicus; (d) volume, inclusive pages, and year.
Journal Article:
1. Moskowitz, N. K.; Borao, F. J.; Dardashti, O.; Cohen, H. D.; Germino, F. J. The amino terminus of cdk2 binds p21. Oncol. Res. 8:348–352; 1996.
Book
1. Sambrook, J.; Fritsch, E. F.; Maniatis, T. Molecular cloning: A laboratory manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
Chapter in Edited Book:
1. Den Otter, E.; Dullens Hub, F. J.; Van Govern, H.; Pels, E. Antitumor effects of macrophages injected into animals: A review. In: MacBride, J. K.; Stuart, A., eds. The macrophage and cancer. Edinburgh: Econoprint; 1987:119–141.

 

 

Tables: Tables should be numbered and cited sequentially in the text. Prepare each table as a separate page at the end of the manuscript text, after the references. Avoid very wide or long tables that would not fit a printed page. Each table should have a title, and each column in the table should have a brief heading. Define all abbreviations in the table footnote at the bottom of the table.

 

 

Figures: Figures should be numbered and cited sequentially in the text. Prepare figures to provide high-quality hard copy output for final accepted submission (see Final Accepted Manuscript). Avoid light lettering and shading that will not reproduce well. Figure dimensions and scaling should be suitable for reduction (if necessary) to fit column or page size. Care must be taken that letters and other symbols do not become so small that they are illegible when the figure is reduced. Complex formulas should be prepared as illustrations. (Do not embed figures within the manuscript text. Prepare as separate files or at the end of the manuscript, after tables and figure legends.) The author is required to bear the costs for the publication of color figures (costs and color authorization form will be provided at proof stage).

 

 

Figure Legends: List all figure legends sequentially on one or more pages at the end of the manuscript text, after the references, and identify all symbols used in the figures. The figure legend should be as clear as possible and should fully describe the contents of the figure. (Do not include the figure legend as part of the figure.) If the figure is from a previously published article, indicate that permission has been obtained from the original publisher.

Permissions: If data from any other source is used in tables or figures it is the responsibility of the author(s) to obtain permission to reproduce such material. Provide proof that permission has been granted from the original publisher and indicate the source.

 

 

Final Accepted Manuscript/Disk: When the manuscript is accepted for publication, the author(s) must provide two hard copies of the manuscript, two high-quality copies of all artwork (glossy paper is preferred for photomicrographs and color figures), and a CD or disk. Ensure that the hard copy and electronic file match exactly. Photocopies or poor quality copies of figures are not acceptable. The final manuscript file (including tables and figure legends) must be submitted in IBM-compatible form, either as a Word document or as a plain text (ASCII) file. A PDF file at this stage is not acceptable. Identify all figures on the back with figure number, first author’s name, and indication of top of figure.

At the time of acceptance you will be asked to confirm that you will pay the relatively inexpensive open access fee of $1,000.00 for less than 5 pages, or $1,500.00 for 5-12 pages and $100.00 for each additional page over 12 when billed. There is a $100.00 submission fee.

 

 

Page Proofs and Offprints: All material accepted for publication is subject to copyediting. Authors all editorial changes at this point. Only minor corrections are allowed at proof stage. Along with the page proofs, the corresponding author will receive a form for ordering reprints and full copies of the issue in which the article appears. All coauthor reprint requirements should be included on the Offprint Order Form.

 

 

 

ETHICS STATEMENT
The publishers and editorial board of Oncology Research have adopted the publication ethics and malpractice statements of the Committee on Publication Ethics (COPE) (http://publicationethics.org/resources/guidelines). These guidelines highlight what is expected of authors and what they can expect from the reviewers and editorial board in return. They also provide details of how problems will be handled. Briefly:

Author Responsibilities:
Authors listed on a manuscript must have made a significant contribution to the study and/or writing of the manuscript. During revisions, authors cannot be removed without their permission and that of the other authors. All authors must also agree to the addition of new authors. It is the responsibility of the corresponding author to ensure that this occurs.

Financial support and conflicts of interest for all authors must be declared. Further information on this can be obtained from the International Committee for Medical Journal Editors (http://www.icmje.org/).

The reported research must be novel and authentic and the authors should confirm that the same data has not been and is not going to be submitted to another journal (unless already rejected). Statements made in the introduction and discussion should be supported by appropriate references and sufficient experimental detail should be provided to allow for repetition of the study by another group. Plagiarism of the text/data will not be tolerated and could result in retraction of an accepted article. Any text or figures reproduced for another source require the permission of the original copyright holders (normally the publishers).

Any manipulation of figures should be equally applied and described in the text including pseudocoloring and must not change the meaning of the figure.

When humans, animals or tissue derived from them have been used, then mention of the appropriate ethical approval must be included in the manuscript.

Reviewer Responsibilities: Reviewers are expected to not possess any conflicts of interest with the authors and research. They should review the science objectively and provide recommendations for improvements where necessary. When aware of relevant published work not being cited, the reviewers should recommend inclusion of these references. If the reviewer feels that they would be unable to repeat the study as described, then additional methodological details should be requested. Any unpublished information read by a reviewer should be treated as confidential.

Editorial Responsibilities: The section editors are expected to select an appropriate number of reviewers for the manuscript so that they can make an informed decision about whether to reject/accept a manuscript. Their decision must be based only on the paper’s importance, originality and clarity and whether it is suitable for the journal. They must not have a conflict of interest with the authors or work described. The anonymity of the reviewers must be maintained.

NIH Public Access Policy: Cognizant Communication Corporation does not upload manuscripts on the author’s behalf to PubMedCentral. The authors of NIH-funded manuscripts are granted permission to upload the final version of the manuscript themselves to PubMedCentral so that they remain in compliance with the NIH Public Access Policy. A PDF of the article is provided to the Corresponding Author for this purpose. Authors have the opportunity to download their articles from open access files http://www.ingentaconnect.com/content/cog/ct

Should problems come to light after acceptance then the editors agree to promote the publication of corrections and/or retractions as deemed necessary.

Publishing Responsibilities: The publishers agree to ensure that to the best of their abilities, the information that they publish is genuine and ethically sound. If publishing ethics issues come to light, not limited to accusations of fraudulent data or plagiarism, during or after the publication process, they will be investigated by the editorial board including contact with the author’s institutions if necessary, so that a decision on the appropriate corrections, clarifications or retractions can be made. The publishers agree to publish this as necessary so as to maintain the integrity of the academic record.

(Scroll down to view tables of contents for all Volumes and Issues)

Volume 21, Number 3

Laboratory Research

Involvement of Ubiquitin-Conjugating Enzyme E2C in Proliferation and Invasion of Prostate Carcinoma Cells
Song Shuliang, Cui Lei, Jing Guangwu, and Liu Changjie

MicroRNA-200c Inhibits Apoptosis in Pituitary Adenoma Cells by Targeting the PTEN/Akt Signaling Pathway
Chuangxin Liao, Wenli Chen, Xiang Fan, Xiaobing Jiang, Lubing Qiu, Chunhua Chen, Yonghong Zhu, and Haijun Wang

Curcumin Lowers Erlotinib Resistance in Non-Small Cell Lung Carcinoma Cells With Mutated EGF Receptor
Shanqun Li, Zilong Liu, Fen Zhu, Xiaohong Fan, Xiaodan Wu, Heng Zhao, and Liyan Jiang

MicroRNA-210 Promotes Proliferation and Invasion of Peripheral Nerve Sheath Tumor Cells Targeting EFNA3
Zhengguang Wang, Bangliang Yin, Bing Wang, Zemin Ma, Weidong Liu, and Guohua Lv

The Sirtuin Inhibitor Tenovin-6 Upregulates Death Receptor 5 and Enhances Cytotoxic Effects of 5-Fluorouracil and Oxaliplatin in Colon Cancer Cells
Takunori Ueno, Shinji Endo, Rie Saito, Mitsuaki Hirose, Sachiko Hirai, Hideo Suzuki, Kenji Yamato, and Ichinosuke Hyodo

Leptin Promotes Metastasis by Inducing an Epithelial–Mesenchymal Transition in A549 Lung Cancer Cells
Helin Feng, Qingyi Liu, Ning Zhang, Lihua Zheng, Meixiang Sang, Jiangang Feng, Jinming Zhang, Xiangyun Wu, and Baoen Shan

Volume 21, Number 2

Laboratory Research

Ran GTPase Induces EMT and Enhances Invasion in Non-Small Cell Lung Cancer Cells Through Activation of PI3K-AKT Pathway
Jinfeng Ning, Wei Liu, Jinfeng Zhang, Yaoguo Lang, and Shidong Xu

RNAi Targeting of CCR2 Gene Expression Induces Apoptosis and Inhibits the Proliferation, Migration, and Invasion of PC-3M Cells
Ji Gao, Anna Wang, Muchun Zhang, Hongyan Li, Kaichen Wang, Yuping Han, Zhixin Wang, Chaoling Shi, and Weihua Wang

MiR-138 Induces Renal Carcinoma Cell Senescence by Targeting EZH2 and Is Downregulated in Human Clear Cell Renal Cell Carcinoma
Jiaqian Liang, Yajing Zhang, Guosong Jiang, Zhouqiang Liu, Wei Xiang, Xuanyu Chen, Zhaohui Chen, and Jun Zhao

Wnt Antagonist, Secreted Frizzled-Related Protein 4 (sFRP4), Increases Chemotherapeutic Response of Glioma Stem-Like Cells
Sudha Warrier, Senthil Kumar Balu, Alan Prem Kumar, Michael Millward, and Arunasalam Dharmarajan

The Insulin-Like Growth Factor-I Receptor Inhibitor Picropodophyllin-Induced Selective Apoptosis of Hepatocellular Carcinoma Cell Through a Caspase-Dependent Mitochondrial Pathway
Changyong E, Jing Li, Dan Shao, Dan Zhang, Yue Pan, Li Chen, and Xuewen Zhang

FOXC2 Often Overexpressed in Glioblastoma Enhances Proliferation and Invasion in Glioblastoma Cells
Weihua Li, Xin Fu, Rongyao Liu, Chunming Wu, Jingyang Bai, Yousong Xu, Yongshun Zhao, and Yinghui Xu

Volume 21, Number 1

Induction of Apoptosis by 4-(3-(tert-butylamino)imidazo[1,2-α]pyridine-2-yl) Benzoic Acid in Breast Cancer Cells via Upregulation of PTEN
Sumit Siddharth, Purusottam Mohapatra, Ranjan Preet, Dipon Das, Shakti Ranjan Satapathy, Tathagata Choudhuri, and Chanakya Nath Kundu

Anti-inflammatory Effect of Full-Length Adiponectin and Proinflammatory Effect of Globular Adiponectin in Esophageal Adenocarcinoma Cells
Rong Zhang, Jie Wu, Dong Liu, Hu Shan, and Jun Zhang

Restoration of INK4a/ARF Gene Inhibits Cell Growth and Cooperates With Imatinib Mesylate in Philadelphia Chromosome-Positive Leukemias
Yuansong Bai, Zhenxia Lu, Yumei Lin, Butong Sun, Shibao Wang, and Guanjun Wang

Overexpression of Bmi-1 Induces the Malignant Transformation of Gastric Epithelial Cells In Vitro
Yinting Chen, Guoda Lian, Qiubo Zhang, Linjuan Zeng, Chenchen Qian, Shaojie Chen, and Kaihong Huang

Inhibition of Cell Proliferation and Increase of Chemosensitivity by Simultaneous Knockdown of XIAP and Survivin in Pancreatic Carcinoma Cells
Jianyi Yang, Jianhui Ouyang, Linqi Ouyang, Lu Ouyang, Yuxiang Chen

In Vitro Characterization of Stem Cell-Like Properties of Drug-Resistant Colon Cancer Subline
Dong Yang, Haijuan Wang, Jinlong Zhang, Chunxiao Li, Zhong Lu, Jin Liu, Chen Lin, Guixin Li, and Haili Qian

Involvement of Oncogenic Protein β-Catenin in LPS-Induced Cytotoxicity in Mouse Mononuclear Leukemia RAW 264.7 Cells
Naoki Koide, Yoshikazu Naiki, Erdenezaya Odkhuu, Bilegtsaikhan Tsolmongyn, Takayuki Komatsu, Kiyoaki Ito, Tomoaki Yoshida, and Takashi Yokochi

Volume 20, Number 12

Laboratory Research

Hydroxyurea Potentiates the Caspase-Independent Killing of B-Cell Lines by Rituximab and GA101
Ian Daniels, Abdulmunem Abulayha, and Andrew P. Haynes

MiR-378 Inhibits Progression of Human Gastric Cancer MGC-803 Cells by Targeting MAPK1 In Vitro
Bojian Fei and Haorong Wu

Zinc Finger X-Chromosomal Protein (ZFX) Promotes Solid Agar Colony Growth of Osteosarcoma Cells
Rui Jiang, Jin-cheng Wang, Mei Sun, Xing-yi Zhang, and Han Wu

Synergistic Effect of 5-Azacytidine and NF-kB Inhibitor DHMEQ on Apoptosis Induction in Myeloid Leukemia Cells
Tomiteru Togano, Makoto Nakashima, Mariko Watanabe, Kazuo Umezawa, Toshiki Watanabe, Masaaki Higashihara, and Ryouichi Horie

Inhibition of Lymphatic Metastases by a Survivin Dominant-Negative Mutant
Guang-Chao Xu, Peng Zhang, Fei Leng, Li Pan, Zhi-Yong Li, Dan-Dan Yu, Yan Shan, Qing-Zhong Yuan, Yuan Wen, Bo Mu, Hua-Shan Shi, Xiang Chen, and Chun-Ting Wang

Cancer Stem Cell-Like Cells Exist in Mucoepidermoid Carcinoma Cell Line MC3
Louqiang Zhang, Yichao Xia, Longjiang Li, Yin Wang, Ying Liu, Chunjie Li, and Tao Yu

Volume 20 Subject and Author Index

Volume 20, Number 11

Laboratory Research

Downregulation of LIMK1 Level Inhibits Migration of Lung Cancer Cells and Enhances Sensitivity to Chemotherapy Drugs
Qingyong Chen, Demin Jiao, Huizhen Hu, Jia Song, Jie Yan, Lijun Wu, and Li-Qun Xu

Anticancer Effects of Cinnamic Acid in Lung Adenocarcinoma Cell Line H1299-Derived Stem-Like Cells
Yanyan Huang, Fang Zeng, Liyun Xu, Jihang Zhou, Xiaoguang Liu, and Hanbo Le

Mechanical Strain and Growth Factors Regulate Expression of Tenascin-C by OS Cells Additively
Yucai Wang, Yan Han, Yong Ding, Baoan Ma, Xiuchun Qiu, Qingyu Fan, and Lianhe Zheng

Two-Stage Model of Chemically Induced Hepatocellular Carcinoma in Mouse
Min Luo, Fan Yang, Sheng-xin Huang, Zhi-peng Kuang, Xiao-ling Luo, Yuan-dong Li, Ji-ning Wu, and Yu-an Xie

Characterization of Ovarian Cancer Cell Metabolism and Response to Chemotherapy by 31P Magnetic Resonance Spectroscopy
Yoram Abramov, Shani Carmi, Shaoul O. Anteby, and Israel Ringel

Enhancement of Proliferation and Invasion by MicroRNA-590-5p via Targeting PBRM1 in Clear Cell Renal Carcinoma Cells
Xiangcheng Xiao, Cene Tang, Shan Xiao, Chunyan Fu, and Pingping Yu

Volume 20, Number 10

Laboratory Research

RITA Inhibits Growth of Human Hepatocellular Carcinoma Through Induction of Apoptosis
Haihe Wang, Guofu Chen, Hongzhi Wang, and Chunbo Liu

Enhancement of Antitumor Activity by Combination of Tumor Lysate-Pulsed Dendritic Cells and Celecoxib in a Rat Glioma Model
Hongtao Zhang, Miao Tian, Chunming Xiu, Yunbo Wang, and Guotai Tang

BTG2 Overexpression Increases the Radiosensitivity of Breast Cancer Cells In Vitro and In Vivo
Xudong Hu, Ligang Xing, Yang Jiao, Jiaying Xu, Xingwu Wang, Anqin Han, and Jinming Yu

The Role of HOXA9 in Human Laryngeal Squamous Cell Carcinoma
Xin Sun, Bin Liu, Wenyue Ji, Xiaolin Ma, Xinqi Wang, and Hui Gu

Inhibition of Tumor Growth and Alteration of Associated Macrophage Cell Type by an HO-1 Inhibitor in Breast Carcinoma-Bearing Mice
Rui Deng, Shi-Min Wang, Tao Yin, Ting-Hong Ye, Guo-Bo Shen, Ling Li, Jing-Yi Zhao, Ya-Xiong Sang, Xiao-Gang Duan, and Yu-Quan Wei

Clinical Research

Prolonged Disease Stability With Trabectedin in a Heavily Pretreated Elderly Patient With Metastatic Leiomyosarcoma of the Thigh and Renal Failure: A Case Report and Review of the Literature
Danilo Galizia, Erica Palesandro, Anna Maria Nuzzo, Ymera Pignochino, Sandra Aliberti, Massimo Aglietta, and Giovanni Grignani

Volume 20, Number 9

Laboratory Research

CD40 Signal Regulates CXCR4 Mediating Ovarian Carcinoma Cell Migration: Implications for Extrapelvic Metastastic Factors
Qiu-Xia Qu, Qin Huang, Jian Xu, Li-Ting Duan, Yi-Bei Zhu, and Xue-Guang Zhang

Hepatocyte Growth Factor-Mediated Gastrin-Releasing Peptide Induces IL-8 Expression Through Ets-1 in Gastric Cancer Cells
Kyung Hee Lee, Sung Ae Koh, and Jae-Ryong Kim

Invasion of Histiocytic Sarcoma Into the Spinal Cord of HTLV-1 Tax Transgenic Mice With HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis-Like Disease
Takeo Ohsugi, Makoto Wakamiya, Saki Morikawa, Kumi Matsuura, Jerald Mahesh Kumar, Toshio Kumasaka, and Kazunari Yamaguchi

Inhibition of Gastric Cancer Cell Growth In Vivo by Overexpression of Adeno-Associated Virus-Mediated Survivin Mutant C84A
Yuan Weng, Bojian Fei, Alfred L. Chi, and Ming Cai

Therapeutic Effect of Oncolytic Adenovirus Expressing Relaxin in Radioresistant Oral Squamous Cell Carcinoma
Sei Young Lee, Haeng Ran Park, Junghoon Rhee, Young Min Park, and Se-Heon Kim

Reactive Center Loop Moiety Is Essential for the Maspin Activity on Cellular Invasion and Ubiquitin–Proteasome Level
Chakkrit Khanaree, Kongthawat Chairatvit, Sittiruk Roytrakul, and Ariyaphong Wongnoppavich

Volume 20, Number 8

Laboratory Research
Deregulation of HER2 Downstream Signaling in Breast Cancer Cells by a Cocktail of Anti-HER2 scFvs
Foroogh Nejatollahi, Reza Ranjbar, Vahid Younesi, and Mahdi Asgharpour

Upregulation of Glycoprotein Nonmetastatic B by Colony-Stimulating Factor-1 and Epithelial Cell Adhesion Molecule in Hepatocellular Carcinoma Cells
Feng Tian, Chang Liu, Qifei Wu, Kai Qu, Ruitao Wang, Jichao Wei, Fandi Meng, Sinan Liu, and Hulin Chang

Simvastatin Inhibits Proliferation and Induces Apoptosis in Human Lung Cancer Cells
Xiaofeng Yu, Yinghua Pan, Housheng Ma, and Wenjun Li

Triptolide Induces Apoptosis and Inhibits the Growth and Angiogenesis of Human Pancreatic Cancer Cells by Downregulating COX-2 and VEGF
Jian-Xia Ma, Yun-Liang Sun, Yi-Qian Wang, Hong-Yu Wu, Jing Jin, and Xiao-Feng Yu

Oldhamianoside II, a New Triterpenoid Saponin, Prevents Tumor Growth via Inducing Cell Apoptosis and Inhibiting Angiogenesis
Feng-Ling Wang, Jing-Yong Sun, Yan Wang, Yan-Ling Mu, Yu-Ji Liang, Zhao-Zhong Chong, San-Hai Qin, and Qing-Qiang Yao

Knockdown of Pokemon Protein Expression Inhibits Hepatocellular Carcinoma Cell Proliferation by Suppression of AKT Activity
Xiaosan Zhu, Yichen Dai, Zhangxin Chen, Junpei Xie, Wei Zeng, and Yuanyuan Lin

Volume 20, Number 7

Laboratory Research

Delivery of Paclitaxel and Berbamine by Polymeric Carriers to Cure Gastric Cancer
Lingjun Zhu, Bin Zhang, Xiaowei Lu, Yongqian Shu, and Baorui Liu

In Vitro Repolarized Tumor Macrophages Inhibit Gastric Tumor Growth
Hao Liu, Xiaolin Wu, Shanmei Wang, Wei Deng, Lipin Zan, and Shuangjiang Yu

Alterations of Axis Inhibition Protein 1 (AXIN1) in Hepatitis B Virus-Related Hepatocellular Carcinoma and Overexpression of AXIN1 Induces Apoptosis in Hepatocellular Cancer Cells
Jiequn Li, Hu Quan, Qiang Liu, Zhongzhou Si, Zhijun He, and Haizhi Qi

In Vivo Selection of High-Metastatic Subline of Bladder Cancer Cell and its Characterization
Naoki Sugiyama, Mihoko Sutoh Yoneyama, Shingo Hatakeyama, Hayato Yamamoto, Akiko Okamoto, Takuya Koie, Hisao Saitoh, Kanemitsu Yamaya, Tomihisa Funyu, Takamitsu Inoue, Tomonori Habuchi, Chikara Ohyama, and Shigeru Tsuboi

Ultrasound-Mediated Vascular Endothelial Growth Factor C (VEGF-C) Gene Microbubble Transfection Inhibits Growth of MCF-7 Breast Cancer Cells
Qiuhua Xu, Ting Sun, Hua Tian, Changqian Wang, and Huihong Zhou

Autocrine-Derived Epidermal Growth Factor Receptor Ligands Contribute to Recruitment of Tumor-Associated Macrophage and Growth of Basal Breast Cancer Cells In Vivo
Nicole K. Nickerson, Christopher P. Mill, Hsin-Jung Wu, David J. Riese II, and John Foley

FIM-A, a Phosphorus-Containing Sirolimus, Inhibits the Angiogenesis and Proliferation of Osteosarcomas
Wei-Nan Liu, Jian-Hua Lin, Yuan-Rong Cheng, Li Zhang, Jie Huang, Zhao-Yang Wu, Fa-Sheng Wang, Sheng-Gui Xu, Wen-Ping Lin, Wen-Bin Lan, and Guo-Xin Yang

Clinical Research

A Phase II Study of Preoperative Chemotherapy With Modified FOLFOX6 Followed by Surgery and Postoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma
Shao-shui Chen, Xiao-chun Yang, Feng Chi, Wen-zheng Yu, Zhen-bo Wang, Fang-ling Ning, Ze-shun Yu, Yan-zhang Hao, Mian-li Li, Feng Wang, Dian-zhong Geng, Li-hua Liu, Xin-Jun Dong, Xian-zhong Peng, and Chun-xiang Ji

Volume 20, Number 5-6

Laboratory Research

Simvastatin Downregulates HER2 via Upregulation of PEA3 to Induce Cell Death in HER2-Positive Breast Cancer Cells
Zhen Zhao, Xiangming Cao, Yukai Pan, Sha Sha, Tao Zhao, and Tingrong Zhang

MicroRNA-375 Is Downregulated in Pancreatic Cancer and Inhibits Cell Proliferation In Vitro
Jian Zhou, Shiduo Song, Jiannong Cen, Dongming Zhu, Dechun Li, and Zixiang Zhang

LRIG1 Enhances Cisplatin Sensitivity of Glioma Cell Lines
Xiongwei Wang, Qungen Xiao, Xihong Xing, Chunlei Tian, Huaqiu Zhang, Fei Ye, Feng Wan, Baofeng Wang, Dongsheng Guo, and Ting Lei

Hypoxia-Inducible Factor-1α Suppressed Hepatocellular Carcinoma Cell Apoptosis Through Influencing on Omi/HtrA2 Expression and Its Releasing From the Mitochondrion
Zongquan Xu, Xiaoping Chen, Cheng Peng, Enyu Liu, Yunguang Li, Changhai Li, and Jun Niu

The Relationship Between EGFR Gene Mutation Status and ERCC1 in Lung Adenocarcinoma of Chinese Patients Receiving Platinum-Based Neoadjuvant Chemotherapy
Hong-Gang Ke, Xiao-Yu Zhou, Yi Shen, Qing-Sheng You, Yu Yan, and Zhen-Ya Shen

Inhibition of Cellular Growth and Migration by Suppression of Endothelial Protein C Receptor (EPCR) in Lung Carcinoma Cells
Wei Heng, Jian-An Huang, and Zhao-Yue Wang

Gene Amplification and Overexpression of Aurora-C in Breast and Prostate Cancer Cell Lines
Ali Zekri, Vahid Lesan, Seyed H. Ghaffari, Mina Hajifaraj Tabrizi, and Mohammad Hussein Modarressi

Hypoxia-Induced Autophagy Confers Resistance of Breast Cancer Cells to Ionizing Radiation
Wen-Shan He, Xiao-Fang Dai, Min Jin, Cui-Wei Liu, and Jing-Hua Ren

Case Study

The Efficacy and Tolerability of a Sunitinib 3-Week Administration Schedule in Metastatic Renal Cell Carcinoma Patients: Report of Three Cases
B. Neri, A. Vannini, R. Tassi, M. Brugia, S. Rangan, M. Rediti, and C. Cerullo

Volume 20, Number 4

Laboratory Research

The Identification of miR-375 as a Potential Biomarker in Distal Gastric Adenocarcinoma
Wen-Hui Zhang, Jun-Hao Gui, Chang-Zheng Wang, Qing Chang, Shi-Ping Xu, Chang-Hao Cai, Ying-Nan Li, Ya-Ping Tian, Li Yan, and Benyan Wu

c-Myc Overexpression Promotes Osteosarcoma Cell Invasion Via Activation of MEK-ERK Pathway
Gang Han, Yan Wang, and Wenzhi Bi

Downregulation of JWA Expression in Human Esophageal Squamous Cell Carcinoma and its Clinical Significance
Jian Zhou, Zhijun Ge, Yongfei Tan, Guojun Jiang, Juncheng Feng, Hongmin Wang, and Guozhen Shi

Mir-373 Affects Human Lung Cancer Cells’ Growth and its E-Cadherin Expression
Weihua Wu, Xiaoyan He, Jing Kong, and Bin Ye

The Role of ZFX in Non-Small Cell Lung Cancer Development
Mei Jiang, Shaofa Xu, Wentao Yue, Xiaoting Zhao, Lina Zhang, Chunyan Zhang, and Yue Wang

Clinical Research

Factors Exacerbating Peripheral Neuropathy Induced by Paclitaxel Plus Carboplatin in Non-small Cell Lung Cancer
Kazuyoshi Kawakami, Takashi Tunoda, Tomomi Takiguchi, Keiko Shibata, Takayuki Ohtani, Junko Kizu, Makoto Nishio, Takeshi Horai, Toshihiro Hama, and Kyoji Taguchi

Volume 20, Numbers2–3

Laboratory Research

Antitumor Properties of Taxol in Combination With Cyclooxygenase-1 and Cyclooxygenase-2 Selective Inhibitors on Ovarian Tumor Growth In Vivo
Wei Li, Lingyun Zhai, Yunxian Tang, Jiahui Cai, Meilin Liu, and Jun Zhang

Fentanyl Inhibits Progression of Human Gastric Cancer MGC-803 Cells by NF-κB Downregulation and PTEN Upregulation In Vitro
Yi Qin, Li Li, Jing Chen, Xiaoman Tang, Chunjie Liao, Yubo Xie, and Qiang Xiao

Impacts and Predictors of Cytotoxic Anticancer Agents in Different Breast Cancer Subtypes
Takashi Ishikawa, Daisuke Shimizu, Akimitsu Yamada, Takeshi Sasaki, Satoshi Morita, Mikiko Tanabe, Kae Kawachi, Akinori Nozawa, Takashi Chishima, Mariko Kimura, Yasushi Ichikawa, and Itaru Endo

Quinacrine-Mediated Autophagy and Apoptosis in Colon Cancer Cells Is Through a p53- and p21-Dependent Mechanism
Purusottam Mohapatra, Ranjan Preet, Dipon Das, Shakti Ranjan Satapathy, Tathagata Choudhuri, Michael D. Wyatt, and Chanakya Nath Kundu

Nonangiogenic Function of VEGF and Enhanced Radiosensitivity of HeLa Cells by Inhibition of VEGF Expression
Xiaokang Hu, Lina Xing, Xing Wei, Xiao Liu, Ranran Pang, Li Qi, and Shigang Song

Growth Inhibition of Pancreatic Cancer by Experimental Treatment With 4-Phenylbutyrate Is Associated With Increased Expression of Connexin 43
Dmitriy I. Dovzhanskiy, Werner Hartwig, Nóra G. Lázár, Alexandra Schmidt, Klaus Felix, Beate K. Straub, Thilo Hackert, Dmitri V. Krysko, and Jens Werner

PTEN Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib
Zhi-Ping Ruan, Rui Xu, Yi Lv, Tao Tian, Wen-Juan Wang, Hui Guo, and Ke-Jun Nan

Epigenetic Inactivation of Wnt Inhibitory Factor-1 in Human Esophageal Squamous Cell Carcinoma
Song-Hua Yang, Sheng-Lei Li, Zi-Ming Dong, and Quan-Cheng Kan

Clinical Research

Relationship of Circulating Tumor Cells to the Effectiveness of Cytotoxic Chemotherapy in Patients With Metastatic Non-Small-Cell Lung Cancer
Takashi Hirose, Yasunori Murata, Yasunari Oki, Tomohide Sugiyama, Sojiro Kusumoto, Hiroo Ishida, Takao Shirai, Masano Nakashima, Toshimitsu Yamaoka, Kent

Volume 20, Number 1

Laboratory Research

The Role of the Cysteine-Rich Domain and Netrin-Like Domain of Secreted Frizzled-Related Protein 4 in Angiogenesis Inhibition In Vitro
David Longman, Frank Arfuso, Helena M. Viola, Livia C. Hool, and Arunasalam M. Dharmarajan

Structure–Activity Relationship of 9-Methylstreptimidone, a Compound That Induces Apoptosis Selectively in Adult T-Cell Leukemia Cells
Masatoshi Takeiri, Eisuke Ota, Shigeru Nishiyama, Hiromasa Kiyota, and Kazuo Umezawa

TLR4 Signaling Promotes Immune Escape of Human Colon Cancer Cells by Inducing Immunosuppressive Cytokines and Apoptosis Resistance
Xiaoyan Tang and Youqing Zhu

Lack of Association of Genetic Variations of Deoxycytidine Kinase With Toxicity or Survival of Non-Small-Cell Lung Cancer Patients Treated With Gemcitabine Plus Cisplatin
Jeong-Seon Ryu, Hyun-Jung Kim, Eun-Soon Shin, Hae-Seong Nam, Jae-Hwa Cho, and Jong-Eun Lee

Energy Controllable Steep Pulse (ECSP) Treatment Suppresses Tumor Growth in Rats Implanted With Walker 256 Carcinosarcoma Cells Through Apoptosis and an Antitumor Immune Response
Xiao-Dong Luo, Jiang-Chuan Sun, Feng Liu, Li-Na Hu, Xiao-Jing Dong, Di-Na Sun, and Jin Xiao

Nimotuzumab Increases Chemosensitivity of Human Lung Adenocarcinoma Cell Lines to Docetaxel
Hai-Zhu Song, Jun Yi, Jing Chen, and Long-Bang Chen

Volume 19, Number 12

Laboratory Research

Cyclin D1 G870A Polymorphism and Breast Cancer Risk: A Meta-Analysis Involving 23,998 Subjects
June Yang, Hong Liu, Su Lu, Maolong Gao, Qiuyue Du, and Shou-Ching Tang

RIN1–Ras–ERK Pathway Plays an Important Role in Carcinogenesis in Colon Cancer Cell Line LoVo
Takeshi Inoue, Takanori Goi, Yasuo Hirono, Kanji Katayama, and Akio Yamaguchi

Gene Silence-Induced Downregulation of Survivin Inhibits Bladder Cancer Cells
Xin Gou, Hua-An Yang, Wei-Yang He, Ming-Chao Xioa, and Ming Wang

Decrease of the Regulatory T-Cell Population by Adoptive T-Cell Transfer in a Mouse Colorectal Cancer Transplant Model
Tsuguhiro Matsumoto, Satoshi Kokura, Takeshi Ishikawa, Jun Funaki, Satoko Adachi, Koji Mori, Naoyuki Sakamoto, Kazuhiro Katada, Kazuhiro Kamada, Nobuaki Yagi, Osamu Handa, Tomohisa Takagi, Kazuhiko Uchiyama, Yuji Naito, and Toshikazu Yosikawa

CXCR4-Positive Subset of Glioma Is Enriched for Cancer Stem Cells
Xuesheng Zheng, QingSong Xie, Shiting Li, and Wenchuan Zhang

PIK3CA Is Critical for the Proliferation, Invasiveness, and Drug Resistance of Human Tongue Carcinoma Cells
Yu Chen, Qingyi Hou, Wangxiang Yan, Jing Luo, Dan Chen, Zhiguo Liu, Shuqi He, and XueQiang Ding

Inhibition of SPHK1 Suppresses Phorbol 12-Myristate 13-Acetate-Induced Metastatic Phenotype in Colorectal Cancer HT-29 Cells
Meng-Bin Qin, Jie-An Huang, Shi-Quan Liu, Guo-Du Tang, and Hai-Xing Jiang

Volume 19 Subject and Author Index

Volume 19, Numbers 10-11

Review

The Potential of Protein Disulfide Isomerase as a Therapeutic Drug Target
Maola M. G. Khan, Siro Simizu, Makoto Kawatani, and Hiroyuki Osada

Laboratory Research

Coenzyme Q10 Decreases Basic Fibroblast Growth Factor (bFGF)-Induced Angiogenesis by Blocking ERK Activation
Jae-Sun Choi, Shi-Young Park, Eui-Yeun Yi, Yung-Jin Kim, and Joo-Won Jeong

Targeted Repression of Overexpressed CD30 Downregulates NF-κB and ERK1/2 Pathway in Hodgkin Lymphoma Cell Lines
Mariko Watanabe, Kazumi Nakano, Tomiteru Togano, Makoto Nakashima, Masaaki Higashihara, Marshall E. Kadin, Toshiki Watanabe, and Ryouichi Horie

The Effect of Acquired Cisplatin Resistance on Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Cells
Jin Kyung Rho, Yun Jung Choi, You Ri Choi, Sun Ye Kim, Su Jin Choi, Chang-Min Choi, Im Il Na, and Jae Cheol Lee

Enhancement of IL-2-Induced Cytotoxicity by Interferon-α in Renal Cell Carcinoma
Michio Naoe, Yoshio Ogawa, Yuki Hasebe, Jun Morita, Takeshi Shichijo, Atsushi Igarashi, Kozo Fuji, Sanju Iwamoto, Toru Suzuki, and Shuji Terao

Separation of Circulating Cancer Cells by Unique Microfluidic Chip in Colorectal Cancer
H. X. Du, Z. G. Wang, Z. L. Yang, D. Chen, J. D. Chen, and R. J. Hu

Overexpression of LIMK1 Promotes Migration Ability of Multidrug-Resistant Osteosarcoma Cells
Hanyang Zhang, Yan Wang, Fengjuan Xing, Jincheng Wang, Yang Wang, Hong Wang, Yudan Yang, and Zhongli Gao

Clinical Research

Effects of Reduced Dose Intensity of Modified FOLFOX6 in Patients With Metastatic or Recurrent Colorectal Cancer
Sakiko Mochinaga, Tomoyo Okahashi, Shinobu Koga, Yukitaka Nakano, Tomomi Yakabe, Kenji Sumi, Kenji Kitahara, Hirokazu Noshiro, Shinya Kimura, and Hiroshi Fujito

Volume 19, Numbers 8-9

Laboratory Research

Prostate-Specific Antigen Gene Expression and Telomerase Activity in Breast Cancer Patients: Possible Relationship to Steroid Hormone Receptors
A. Mohajeri, N. Zarghami, M. Pourhasan Moghadam, B. Alani, V. Montazeri, A. Baiat, and A. Fekhrjou

The Expression of DNA Damage Checkpoint Proteins and Prognostic Implication in Metastatic Brain Tumors
Ho Jun Seol, Hae Yong Yoo, Juyoun Jin, Kyeung Min Joo, Hyeong-Seok Kim, Su Jin Yoon, Seung Ho Choi, Yonghyun Kim, Hong Ryull Pyo, Do-Hoon Lim, Wook Kim, Hong-Duck Um, Jong Hyun Kim, Jung-II Lee, and Do-Hyun Nam

The Role of Peroxiredoxin V in (−)-Epigallocatechin 3-gallate-Induced Multiple Myeloma Cell Death
Lina Ren, Hee-Young Yang, Hoon-In Choi, Kyoung-Jin Chung, Ung Yang, Il-Kwon Lee, Hyeoung-Joon Kim, Dong-Seok Lee, Byung-Ju Park, and Tae-Hoon Lee

Clinical Research

Subacute Transient Encephalopathy Induced by Erlotinib
Takako Okyuama, Yuki Akazawa, Junji Uchida, Kazumi Nishino, Toru Kumagai, and Fumio Imamura

Compassionate Use of Everolimus in a Patient With a Neuroendocrine Tumor: A Case Report and Discussion of the Literature
Sara Pusceddu, Massimo Milione, and Giuseppe Procopio

Review

A Novel Prosurvival Model for Cancer Under Environmental Challenge: The “Heart-Felt” Message for Therapeutic Intervention
John A. Loudon

Volume 19, Number 7

Laboratory Research

Combretastatin A4 Phosphate Induces Programmed Cell Death in Vascular Endothelial Cells
Xueqiang Ding, Zhaoqiang Zhang, Su Li, and Anxun Wang

5-Fluorouracil Increases the Chemopreventive Potentials of Resveratrol Through DNA Damage and MAPK Signaling Pathway in Human Colorectal Cancer Cells
Purusottam Mohapatra, Ranjan Preet, Maitrayee Choudhuri, Tathagata Choudhuri, and Chanakya Nath Kundu

Antiproliferative Effect of Newcastle Disease Virus Strain D90 on Human Lung Cancer Cell Line A549
Fang Fu, Ming Zhao, Yu-Ju Yang, Guang-Zhi Tong, Bao-Feng Yang, Chun Song, and Xi Li

Fibronectin–Integrin (α5β1) Modulates Migration and Invasion of Murine Melanoma Cell Line B16F10 by Involving MMP-9
Hrishikesh Sil, Triparna Sen, and Amitava Chatterjee

Single-Agent Inhibition of Chk1 Is Antiproliferative in Human Cancer Cell Lines In Vitro and Inhibits Tumor Xenograft Growth In Vivo
Kurtis D. Davies, Michael J. Humphries, Francis X. Sullivan, Ira von Carlowitz, Yvan Le Huerou, Peter J. Mohr, Bin Wang, James F. Blake, Michael A. Lyon, Indrani Gunawardana, Mark Chicarelli, Eli Wallace, and Stefan Gross

Clinical Research

An Imbalance in Oxidant/Antioxidant Dynamics: Correlation With Therapeutic Response in Patients With Carcinoma of Posterior One Third of the Tongue
Manoj Sharma, Medha Rajappa, Abhigyan Satyam, and Alpana Sharma

Volume 19, Number 6

Laboratory Research

Tea Polyphenols Induce Apoptosis Through Mitochondrial Pathway and by Inhibiting Nuclear Factor-βB and Akt Activation in Human Cervical Cancer Cells
Madhulika Singh, Richa Singh, Kulpreet Bhui, Shilpa Tyagi, Zafar Mahmood, and Yogeshwer Shukla

Melatonin and β-Glucan Alone or in Combination Inhibit the Growth of Dunning Prostatic Adenocarcinoma
Levent Kabasakal, Göksel Şener, Jale Balkan, Semra Doğru-Abbasoğlu, Meral Keyer-Uysal, and Müjdat Uysal

Evaluation of an 18F-Labeled Oligonucleotide Probe Targeting p21WAF1 Transcriptional Changes in Human Tumor Cells
I. Koslowsky, S. Shahhosseini, R. Mirzayans, D. Murray, and J. Mercer

Antidiabetic Drug Metformin Induces Apoptosis in Human MCF Breast Cancer via Targeting ERK Signaling
Ahmed Malki and Amal Youssef

A Conjugate of Gemcitabine With Bisphosphonate (Gem/BP) Shows Potential as a Targeted Bone-Specific Therapeutic Agent in an Animal Model of Human Breast Cancer Bone Metastases
A. A. El-Mabhouh, P. N. Nation, J. T. Abele, T. Riauka, E. Postema, A. J. B. McEwan, and J. R. Mercer

Regulation of Matrix Metalloproteinases and Invasion by Gα12/13 Proteins in NIH3T3 Mouse Fibroblast Cells
Eun-Sook Kim, Kyung-Min Lee, Dong-Young Noh, and Aree Moon

 

Volume 19, Numbers 1-5

Volume 18, Numbers 11/12

Volume 18, Numbers 1-10

Volume 17, Numbers 1-12

Volume 16, Numbers 1-12

Volume 15, Numbers 1-12

Volume 14, Numbers 1-12

Volume 13, Numbers 1-12

Volume 12, Numbers 1-12

Volume 11, Numbers 1-12, 1999

Co-Editor-in-Chief
Alan C. Sartorelli, Yale University School of Medicine

Co-Editor-in-Chief
Edward Chu, University of Pittsburgh Medical Center

European Co-Editor-in-Chief
Romano Danesi, University of Pisa

Asian Co-Editor-in-Chief
Kazuo Umezawa, Aichi Medical University

Senior Editor
Helen A. Seow

EDITORIAL ADVISORY BOARD

American Continent: Alan C. Sartorelli, Co-Editor-in-Chief, and Edward Chu, Co-Editor-in-Chief
K. W. Bair, EntreMed, Inc., Rockville, MD, USA
J. R. Bertino, Cancer Institute of New Jersey, USA
R. A. Bradshaw, University of California, Irvine, USA
Y.-C. Cheng, Yale University School of Medicine, USA
R. L. Erikson, Harvard University, USA
S. M. Hecht, University of Virginia, USA
L. H. Hurley, Arizona Cancer Center, Tucson, USA
P. A. Jones, University of Southern California, USA
J. S. Lazo, University of Pittsburgh School of Medicine, USA
G. Litwack, Jefferson Cancer Institute, Philadelphia, PA, USA
J. W. Lown, University of Alberta, Canada
L. A. Loeb, University of Washington, USA
S. Pestka, UMDNJ-Robert Wood Johnson Medical School, USA
G. R. Pettit, Cancer Research Institute, Arizona, USA
Y. G. Pommier, National Cancer Institute, Bethesda, MD, USA
G. Powis, Arizona Cancer Center, USA
M. Reiss, Cancer Institute of New Jersey, USA
J. Siegfried, University of Pittsburgh School of Medicine, USA
E. J. Stanbridge, University of California, Irvine, USA
C. Stein, Albert Einstein College of Medicine, USA

European Continent: Romano Danesi, Co-Editor-in-Chief
C. Bailly, Institute de Recherchés sur le Cancer de Lille, France
M. Beato, Philipps-Universität, Germany
A. H. Calvert, University of Newcastle upon Tyne, United Kingdom
M. D'Incalci, Institute di Ricerche Farmacologiche, Italy
W. Fiers, University of Ghent, Belgium
L. Frati, University of Rome, Italy
D. Givol, The Weizmann Institute of Science, Israel
A. L. Harris, Churchill Hospital, United Kingdom
I. Hickson, Cancer Research UK, Oxford, United Kingdom
A. Levitzki, Hebrew University of Jerusalem, Israel
M. F. Rajewsky, Universität Essen, Germany
D. Shugar, Academy of Sciences, Poland 
D. Thurston, King's College London, United Kingdom
A. S. Tsiftsoglou, Aristotle University of Thessaloniki, Greece
G. Vecchio, Università Degli Studi di Napoli Federico II, Italy
M. J. Waring, University of Cambridge, United Kingdom
P. Workman, CRC Center for Cancer Therapeutics, United Kingdom

Asia and Pacific Rim: Kazuo Umezawa, Co-Editor-in-Chief
Y.-J. Bang, SNU Cancer Research Institute, Korea
B. C. Baguley, Auckland Cancer Society Research Center, New Zealand
A.-Y. Chang, National University Hospital, Singapore
Atsuko Deguchi, Tokyo Women’s Medical University, Japan
W. A. Denny, University of Auckland, New Zealand
Shamil Gantsev, Bashkirian State Medical University, Russia
T. Irimura, University of Tokyo, Japan
Eiji Kikuchi, Keio University, Japan 
C.-M. Kim, National Cancer Center, Korea
K. Kohno, University of Occupational & Environmental Health, Kitakyushu, Japan
Naoki Koide, Aichi Medical University, Japan
J.-K. Lin, National Taiwan University, Republic of China
Y. Maehara, Kyushu University, Japan
A. Matsuda, Hokkaido University, Japan
K. Miyazaki, Yokohama University, Japan
Osamu Ohno, Keio University, Japan
H. Osada, RIKEN, Japan
Mototsugu Oya, Keio University
I. Saiki, Toyama Medical and Pharmaceutical University, Japan
T. Sakai, Kyoto Prefectural University of Medicine, Japan
Yukiko Sasazawa, Keio University
Y. Satoh, Tohoku University, Japan
C. Shou, Beijing Institute for Cancer Research, China
E. Suzuki, Tokyo University of Agriculture and Technology, Japan
Masatoshi Takeiri, Kyoto University 
K. Umezawa, Keio University, Japan

Author & Subject Indexes: Volumes 11-19  (Scroll down)

Volume 20
Author Index

Abramov, Y., 529
Abulayha, A., 545
Aglietta, M., 483
Aliberti, S., 483
Anteby, S. O., 529
Arfuso, F., 1
Asgharpour, M., 333

Bi, Wenzhi, 149
Brugia, M., 259

Cai, Chang-Hao, 139
Cai, Jiahui, 49
Cai, Ming, 411
Cao, Xiangming, 187
Carmi, S., 529
Cen, Jiannong, 197
Cerullo, C., 259
Chairatvit, K., 427
Chang, Hulin, 341
Chang, Qing, 139
Chen, Guofu, 437
Chen, Jing, 39
Chen, Jing, 61
Chen, Long-Bang, 39
Chen, Qingyong, 491
Chen, Shao-shui, 327
Chen, Xiang, 579
Chen, Xiaoping, 213
Chen, Zangxin, 377
Cheng, Yuan-Rong, 319
Chi, A. L., 411
Chi, Feng, 327
Chishima, T., 71
Cho, Jae-Hwa, 25
Chong, Zhao-Zhong, 369
Choudhuri, T., 81

Dai, Xiao-Fang, 251
Dai, Yichen, 377
Daniels, I., 545
Das, D., 81
Deng, Rui, 473
Deng, Wei, 275
Dharmarajan, A. M., 1
Ding, Yong, 509
Dong, Xiao-Jing, 31
Dong, Xin-Jun, 327
Dong, Zi-Ming, 123
Dovzhanskiy, D. I., 103
Duan, Li-Ting, 383
Duan, Xiao-Gang, 473

Endo, I., 71
Fan, Qingyu, 509
Fei, Bojian, 411, 557
Felix, K., 103
Feng, Juncheng, 157
Foley, J., 303
Fu, Chunyan, 537
Funyu, T., 289

Galizia, D., 483
Ge, Zhijun, 157
Geng, Dian-zhong, 327
Ghaffari, S. H., 241
Grignani, G., 483
Gu, Hui, 467
Gui, Jun-Hao, 139
Guo, Dongsheng, 205
Guo, Hui, 113

Habuchi, T., 289
Hackert, T., 103
Hama, T., 179
Han, Anqin, 457
Han, Gang, 149
Han, Yan, 509
Hao, Yan-zhang, 327
Hartwig, W., 103
Hatakeyama, S., 289
Haynes, A. P., 545
He, Wen-Shan, 251
He, Xiaoyan, 163
He, Zhijun, 281
Heng, Wei, 231
Higashihara, M., 571
Hirose, T., 131
Hool, L. C., 1
Horai, T., 179
Horie, R., 571
Hu, Huizhen, 491
Hu, Li-Na, 31
Hu, Xiaokang, 93
Hu, Xudong, 457
Huang, Jian-An, 231
Huang, Jie, 319
Huang, Qin, 383
Huang, Sheng-xin, 517
Huang, Yanyan, 499

Ichikawa, Y., 71
Inoue, T., 289
Ishida, H., 131
Ishikawa, T., 71

Ji, Chun-xiang, 327
Ji, Wenyue, 467
Jiang, Guojun, 157
Jiang, Mei, 171
Jiang, Rui, 565
Jiao, Demin, 491
Jiao, Yang, 457
Jin, Jing, 359
Jin, Min, 251

Kan, Quan-Cheng, 123
Kawachi, K., 71
Kawakami, K., 179
Ke, Hong-Gang, 221
Khanaree, C., 427
Kim, Hyun-Jung, 25
Kim, Jae-Ryong, 393
Kim, Se-Heon, 419
Kimura, M., 71
Kiyota, H., 7
Kizu, J., 179
Koh, Sung Ae, 393
Koie, T., 289
Kong, Jing, 163
Krysko, D. V., 103
Kuang, Zhi-peng, 517
Kumar, J. M., 403
Kumasaka, T., 403
Kundu, C. N., 81
Kusumoto, S., 131

Lan, Wen-Bin, 319
Lázár, N. G., 103
Le, Hanbo, 499
Lee, Jong-Eun, 25
Lee, Kyung Hee, 393
Lee, Sei Young, 419
Lei, Ting, 205
Leng, Fei, 579
Lesan, V., 241
Li, Changhai, 213
Li, Chunjie, 589
Li, Dechun, 197
Li, Jeiqun, 281
Li, Li, 61
Li, Ling, 473
Li, Longjiang, 589
Li, Mian-li, 327
Li, Sheng-Lei, 123
Li, Wei, 49
Li, Wenjun, 351
Li, Ying-Nan, 139
Li, Yuan-dong, 517
Li, Yunguang, 213
Li, Zhi-Yong, 579
Liang, Yu-Ji, 369
Liao, Cunjie, 61
Lin, Jian-Hua, 319
Lin, Wen-Ping, 319
Lin, Yuanyuan, 377
Liu, Baorui, 265
Liu, Bin, 467
Liu, Chang, 341
Liu, Chunbo, 437
Liu, Cui-Wei, 251
Liu, Enyu, 213
Liu, Feng, 31
Liu, Hao, 275
Liu, Li-hua, 327
Liu, Meilin, 49
Liu, Qiang, 281
Liu, Sinan, 341
Liu, Wei-Nan, 319
Liu, Xiao, 93
Liu, Xiaoguang, 499
Liu, Ying, 589
Longman, D., 1
Lu, Xiaowei, 265
Luo, Min, 517
Luo, Xiao-Dong, 31
Luo, Xiao-ling, 517
Lv, Yi, 113

Ma, Baoan, 509
Ma, Housheng, 351
Ma, Jian-Xia, 359
Ma, Xiaolin, 467
Matsuura, K., 403
Meng, Fandi, 341
Mill, C. P., 303
Modarressi, M. H., 241
Mohapatra, P., 81
Morikawa, S., 403
Morita, S., 71
Mu, Bo, 579
Mu, Yan-Ling, 369
Murata, Y., 131

Nakashima, Makoto, 571
Nakashima, Masano, 131
Nam, Hae-Seong, 25
Nan, Ke-Jun, 113
Nejatollahi, F., 333
Neri, B., 259
Nickerson, N., K., 303
Ning, Fang-ling, 327
Nishio, M., 179
Nishiyama, S., 7
Niu, Jun, 213
Nozawa, A., 71
Nuzzo, A. M., 483

Ohmori, T., 131
Ohnishi, T., 131
Ohsugi, T., 403
Ohtani, T., 179
Ohyama, C., 289
Okamoto, A., 289
Oki, Y., 131
Okuda, K., 131
Ota, E., 7

Palesandro, E., 483
Pan, Li, 579
Pan, Yinghua, 351
Pan, Yukai, 187
Pang, Ranran, 93
Park, Haeng Ran, 419
Park, Young Min, 419
Peng, Cheng, 213
Peng, Xian-zhong, 327
Pignochino, Y., 483
Preet, R., 81

Qi
, Haizhi, 281
Qi, Li, 93
Qin, San-Hai, 369
Qin, Yi, 61
Qiu, Xiuchun, 509
Qu, Kai, 341
Qu, Qiu-Xia, 383
Quan, Hu, 281

Rangan, S., 259
Ranjbar, R., 333
Rediti, M., 259
Ren, Jing-Hua, 251
Rhee, Junghoon, 419
Riese II, D. J., 303
Ringel, I., 529
Roytrakul, S., 427
Ruan, Zhi-Ping, 113
Ryu, Jeong-Seon, 25

Saitoh, H., 289
Sang, Ya-Xiong, 473
Sasaki, T., 71
Satapathy, S. R., 81
Schmidt, A., 103
Sha, Sha, 187
Shan, Yan, 579
Shen, Guo-Bo, 473
Shen, Yi, 221
Shen, Zhen-Ya, 221
Shi, Guozhen, 157
Shi, Hua-Shan, 579
Shibata, K., 179
Shimizu, D., 71
Shin, Eun-Soon, 25
Shirai, T., 131
Shu, Yongqian, 265
Si, Zhongzhou, 281
Song, Hai-Zhu, 39
Song, Jia, 491
Song, Shiduo, 197
Song, Shigang, 93
Straub, B. K., 103
Sugiyama, N., 289
Sugiyama, T., 131
Sun, Di-Na, 31
Sun, Jiang-Chuan, 31
Sun, Jing-Yong, 369
Sun, Mei, 565
Sun, Ting, 297
Sun, Xin, 467
Sun, Yun-Liang, 359

Tabrizi, M. H., 241
Taguchi, K., 179
Takeiri, M., 7
Takiguchi, T., 179
Tan, Yongfei, 157
Tanabe, M., 71
Tang, Cene, 537
Tang, Guotai, 447
Tang, Xiaoman, 61
Tang, Xiaoyan, 15
Tang, Yunxian, 49
Tassi, R., 259
Tian, Chunlei, 205
Tian, Feng, 341
Tian, Hua, 297
Tian, Miao, 447
Tian, Tao, 113
Tian, Ya-Ping, 139
Togano, T., 571
Tsuboi, S., 289
Tunoda, T., 179

Umezawa, K., 7, 571

Vannini, A., 259
Viola, H. M., 1

Wakamiya, M., 403
Wan, Feng, 205
Wang, Baofeng, 205
Wang, Changqian, 297
Wang, Chang-Zheng, 139
Wang, Chun-Ting, 579
Wang, Fa-Sheng, 319
Wang, Feng, 327
Wang, Feng-Ling, 369
Wang, Haihe, 437
Wang, Hongmin, 157
Wang, Hongzhi, 437
Wang, Jin-cheng, 565
Wang, Ruitao, 341
Wang, Shanmei, 275
Wang, Shi-Min, 473
Wang, Wen-Juan, 113
Wang, Xingwu, 457
Wang, Xinqi, 467
Wang, Xiongwei, 205
Wang, Yan, 149
Wang, Yan, 369
Wang, Yin, 589
Wang, Yi-Qian, 359
Wang, Yucai, 509
Wang, Yue, 171
Wang, Yunbo, 447
Wang, Zhao-Yue, 231
Wang, Zhen-bo, 327
Watanabe, M., 571
Watanabe, T., 571
Wei, Jichao, 341
Wei, Xing, 93
Wei, Yu-Quan, 473
Wen, Yuan, 579
Weng, Yuan, 411
Werner, J., 103
Wongnoppavich, A., 427
Wu, Benyan, 139
Wu, Han, 565
Wu, Haorong, 557
Wu, Hong-Yu, 359
Wu, Hsin-Jung, 303
Wu, Ji-ning, 517
Wu, Lijun, 491
Wu, Qifei, 341
Wu, Weihua, 163
Wu, Xaiolin, 275
Wu, Zhao-Yang, 319
Wyatt, M. D., 81

Xia, Yichao, 589
Xiao, Jin, 31
Xiao, Qiang, 61
Xiao, Qungen, 205
Xiao, Shan, 537
Xiao, Xiangcheng, 537
Xie, Junpei, 377
Xie, Yu-an, 517
Xie, Yubo, 61
Xing, Ligang, 457
Xing, Lina, 93
Xing, Xihong, 205
Xiu, Chunming, 447
Xu, Jian, 383
Xu, Jiaying, 457
Xu, Li-Qun, 491
Xu, Liyun, 499
Xu, Qiuhua, 297
Xu, Rui, 113
Xu, Shaofa, 171
Xu, Sheng-Gui, 319
Xu, Shi-Ping, 139
Xu, Zongquan, 213
Xy, Guang-Chao, 579

Yamada, A., 71
Yamaguchi, K., 403
Yamamoto, H., 289
Yamaoka, T., 131
Yamaya, K., 289
Yan, Jie, 491
Yan, Li, 139
Yan, Yu, 221
Yang, Fan, 517
Yang, Guo-Xin, 319
Yang, Song-Hua, 123
Yang, Xiao-chun, 327
Yao, Qing-Qiang, 369
Ye, Bin, 163
Ye, Fei, 205
Ye, Ting-Hong, 473
Yi, Jun, 39
Yin, Tao, 473
Yoneyama, M. S., 289
You, Qing-Sheng, 221
Younesi, V., 333
Yu, Dan-Dan, 579
Yu, Jimming, 457
Yu, Pingping, 537
Yu, Shuangjiang, 275
Yu, Tao, 589
Yu, Wen-zheng, 327
Yu, Xiaofeng, 351
Yu, Xiao-Feng, 359
Yu, Ze-shun, 327
Yuan, Qing-Zhong, 579
Yue, Wentao, 171

Zan, Lipin, 275
Zekri, A., 241
Zeng, Fang, 499
Zeng, Wei, 377
Zhai, Lingyun, 49
Zhang, Bin, 265
Zhang, Chunyan, 171
Zhang, Hongtao, 447
Zhang, Huaqiu, 205
Zhang, Jun, 49
Zhang, Li, 319
Zhang, Lina, 171
Zhang, Louqiang, 589
Zhang, Peng, 579
Zhang, Tingrong, 187
Zhang, Wen-Hui, 139
Zhang, Xing-yi, 565
Zhang, Xue-Guang, 383
Zhang, Zixiang, 197
Zhao, Jing-Yi, 473
Zhao, Tao, 187
Zhao, Xiaoting, 171
Zhao, Zhen, 187
Zheng, Lianhe, 509
Zhou, Huihong, 297
Zhou, Jian, 157
Zhou, Jian, 197
Zhou, Jihang, 499
Zhou, Xiao-Yu, 221
Zhu, Dongming, 197
Zhu, Lingjun, 265
Zhu, Xiaosan, 377
Zhu, Yi-Bei, 383
Zhu, Youqing, 15

Subject Index

ABCG2, 589
Adeno-associated virus (AAV), 411
Adenovirus, 419
Adult T-cell leukemia, 7
Amphiregulin, 303
Angiogenesis, 1, 359, 369
Antiangiogenesis, 319
Antimitotic drugs, 529
Antiproliferation, 319
Apoptosis, 1, 31, 49, 81, 93, 197, 351, 369, 411, 437, 545
Apoptosis resistance, 15
Arginase, 275
Aurora-C kinase, 241
Autophagy, 81, 251
Axis inhibition protein 1 (AXIN1), 281
5-Azacytidine (AZA), 571

B-cell translocation gene, member 2 (BTG2), 457
Berbamine (BA), 265
Biomarker, 139
Bladder cancer, 289
Breast cancer, 71, 251, 303, 427, 457
Breast cancer cells, 187

Calcium signaling, 1
Cancer, 241, 351
Cancer stem cells (CSCs), 499, 589
Carbon tetrachloride (CCl4), 517
CD20, 545
CD24, 589
CD40, 383
CD44, 589
CD133, 499
Celecoxib, 49, 447
Cell cycle arrest, 171
Cell death, 187
Cell progression, 557
Cell proliferation, 49, 171
Cervical cancer, 93
Chemoradiotherapy, 327
Chemoresistance, 39
Chemotherapy, 71, 131, 221, 327
Cinnamic acid (CINN), 499
Circulating tumor cells (CTCs), 131
Cisplatin, 205, 491, 499
Clinicopathological features, 197
Clinicopathologic factors, 157
c-Myc, 149, 341
Colon cancer, 15, 81
Colony-stimulating factor-1 (CSF-1), 341
Connexin 43 (Cx43), 103
Cox proportional hazard analysis, 179
Creatinine clearance, 179
CXCR4, 383
Cyclic strain, 509
Cyclin D1, 49
Cyclooxygenase 2 (COX-2), 359, 447
Cytokine, 275

Dehydroxymethylepoxyquinomicin (DHMEQ), 571
Dendritic cells (DCs), 447
Deoxycytidine kinase, 25
Diethylnitrosamine (DEN), 517
Distal gastric adenocarcinoma (DGAC), 139
Docetaxel (DTX), 39

E-Cadherin, 163
Energy controllable steep pulse (ECSP), 31
EPCR, 231
Epidermal growth factor (EGF), 509
Epidermal growth factor receptor (EGFR), 39, 204, 221, 303
Epithelial cell adhesion molecule (EpCAM), 341
ERCC1, 221
Esophageal squamous cell carcinoma (ESCC), 157
Ethanol, 517
Ets-1, 393
Extravasation, 289

Fentanyl, 61
FIM-A, 319
FOLFOX6, 327

GA101, 545
Gap junction intercellular communication, 103
Gastric cancer (GC), 61, 265, 327, 411, 557
Gastrin-releasing peptide (GRP), 393
Gemcitabine, 25, 491
Gene amplification, 241
Gene expression, 163
Gene therapy, 281, 297, 411, 579
Glioma, 205, 447
Glycerophosphocholine, 529
Glycoprotein nonmetastatic B (GPNMB), 341
Growth, 231

has-mir-373, 163
Heme oxygenase (HO-1), 473
Hepatocellular carcinoma (HCC), 113, 281, 341, 437, 517
Hepatocyte growth factor (HGF), 393
HepG2 cell apoptosis, 213
HepG2 cells, 377
HER2, 187
Histiocytic sarcoma, 403
Histone deacetylase inhibitors, 103
HOXA9, 467
HTLV-1-associated myelopathy/tropical spastic paarparesis (HAM/TSP), 403
Human epidermal growth factor receptor 2 (HER2) signaling mediators, 333
Human esophageal squamous cell carcinoma (ESCC), 123
Human lung cancer A549 cells, 163
Human T-cell leukemia virus type 1 (HTLV-1), 403
Hydroxyurea, 545
Hypoxia-inducible factor-1α (HIF-1α), 213

IL-8, 393
Immune escape, 15
Immune response, 31
Immunotherapy, 275, 447
In vivo selection, 289
Insulin-like growth factor (IGF-1), 509
Invasion, 149, 537

JWA
, 157

Laryngeal squamous cell carcinoma (LSCC), 467
Leiomyosarcoma, 483
Leukemia, 571
LIM kinase 1 (LIMK1), 491
LRIG1, 205
Lung adenocarcinoma, 39, 221
Lung cancer, 25, 231, 491, 499
Lung metastases, 483
Lymphangiogenesis, 579
Lymphatic metastasis, 579
Lymphocytes, 31
Lymphoma, 545

M1/M2 macrophages, 275
Macrophage, 7
Macrophage colony-stimulating factor-1 (MCSF-1), 303
Magnetic resonance spectroscopy (MRS), 529
MAPK, 557
Maspin, 427
MEK-ERK pathway, 149
Metastatic renal cell carcinoma, 259
9-Methylstreptimidone, 7
Mice, 103, 403
MicroRNA-375, 197
MicroRNA-590-5p, 537
MicroRNAs, 139
Migration, 123, 383, 467, 491
miR-375, 139
MiR-378, 557
Mouse forestomach carcinoma (MFC), 275
Mouse model, 517
mRNA overexpression, 241
mTOR, 319
Mucoepidermoid carcinoma (MEC), 589
Mutation, 221, 281, 579

Nanoparticle, 265
Neoadjuvant, 71
NF-κB, 61, 571
Nimotuzumab (h-R3), 39
Nitric oxide synthase (iNOS), 275
Non-small cell lung cancer (NSCLC), 131, 171, 179
Notch, 437

Oct4, 589
Oldhamianoside II, 369
Omi/HtrA2, 213
Oncogene, 467
Oral cancer, 419
Oral squamous cell carcinoma (OSCC), 419
Osteosarcoma (OS), 149, 319, 509, 565
Ovarian cancer, 383, 529
Ovarian carcinoma, 49

p21, 81
p53, 81
Pack-year, 179
Paclitaxel (PTX), 265, 529
Paclitaxel + carboplatin ± bevacizumab, 179
Pancreatic cancer, 103, 197, 359
PEA3, 187
Pelvic metastasis, 383
Peripheral neuropathy, 179
Pharmacogenetics, 25
4-Phenylbutyrate (4-PB), 103
Phospholipid metabolites, 529
PI3K/Akt, 377
PMRM1, 537
Pokemon, 377
Polymorphism, 25
Predictive factor, 71, 131
Prognostic indicator, 157
Proliferation, 123, 351, 467, 537
Promoter hypermethylation, 123
Proteomic, 427
PTEN, 61, 113

Quinacrine (QC), 81

Radioresistance, 251, 419
Radiosensitivity, 93, 457
RBP-J-interacting and tubulin-associated (RITA), 437
Reactive center loop (RCL), 427
Relaxin (RLX), 419
Renal carcinoma, 537
Rituximab, 545
RNA interference, 93, 251

Saponin, 369
SC-560, 49
Secreted frizzled-related protein 4 (sFRP4), 1
SERPIN, 427
Serum, 139
shRNA, 171
Simvastatin, 187
Single chain fragment variable (scFv), 333
Small interference RNA, 231
Small interfering RNA (siRNA), 565
Soft tissue sarcoma, 483
Sorafenib, 113
Spastic paraparesis, 403
Spinal cord tumor, 403
Statins, 351
Streptovitacin, 7
Sunitinib, 259
Survivin, 411, 579
Survivin mutant C84A, 411

4T1, 473
Targeted therapy, 333
Taxol, 49
Tenascin-C (TIN-C), 509
Thigh, 483
TLR4, 15
Trabectedin, 483
Transforming growth factor-α (TGF-α), 303
Triptolide (TPL), 359
Tumor-associated macrophages (TAMs), 473
Tumorigenesis, 565
Tumor metastasis, 289, 369
Tumor progression, 61
Tumor suppressor, 427

Ultrasound-mediated microbubble, 297

Vascular endothelial growth factor (VEGF), 93, 359
Vascular endothelial growth factor C (VEGF-C), 297

Walker 256 carcinosarcoma cells, 31
3-Week schedule, 259
Wnt inhibitory factor-1 (WIF1), 123

Xenograft, 457

Zinc finger protein, X-linked (ZFX), 171
Zinc finger X-chromosomal protein (ZFX), 565
ZnPPIX, 473

Volume 19

Author Index

Abele, J. T., 287
Adachi, S., 543
Akazawa, Y., 399
Alani, B., 375
Aragane, N., 111
Arora, N., 179
Asano, T., 217
Asano, T., 217

Babu, S., 99
Baek, K. J., 237
Baiat, A., 375
Balkan, J., 259
Bansal, M. P., 179
Barros-Angueira, F., 45
Bhanushali, A. A., 99
Bhui, K., 245
Bi, J.-B., 125
Blake, J. F., 349
Bocklage, T. J., 93
Bunning, J. T., 93

Chada, V. D., 1
Chakrabarty, S., 105
Chatterjee, A., 335
Chen, D., 487
Chen, D., 563
Chen, J. D., 487
Chen, K., 171
Chen, X., 35
Chen, Y., 563
Chen, Y.-J., 149
Chheda, P., 99
Chicarelli, M., 349
Cho, C.-K., 115
Cho, S.-B., 115
Choi, C.-M., 471
Choi, E. Y., 67
Choi, H.-I., 391
Choi, J.-S., 455
Choi, S. H., 381
Choi, S. J., 471
Choi, S.-K., 115
Choi, Y. J., 471
Choi, Y. R., 471
Choudhuri, M., 311
Choudhuri, T., 311
Chung, I.-J., 115
Chung, K.-J., 391

Das, B. R., 99
Davies, K. D., 349
Dhawan, D. K., 1
Ding, X., 303, 563
Diz, P. G., 45
Doğru-Abbasoğlu, S., 259
Du, H. X., 487
Du, Q., 519
Du, W. 35

El-Mabhouh, A. A., 287

Fekhrjou, A., 375
Feng, Y., 193
Ferlini, C., 13
Ferrandina, G., 13
Filippetti, F., 13
Fu, F., 323
Fuji, K., 479
Fujita, N., 23
Fujito, H., 511
Fukushima, N., 111
Funaki, J., 543
Funyu, T., 85

Gao, M., 519
Gao, S., 131
Gao, Z., 501
García-García, A., 45
Goel, S., 165
Goi, T., 527
Gou, X., 535
Gross, S., 349
Gu, G., 193
Guan, L., 77
Guang, J., 131
Gunawardana, I., 349

Handa, O., 543
Hao, L., 193
Hasebe, Y., 479
Hashimoto, Y., 85
Hatakeyama, S., 85
Hayashi, S., 111
He, S., 563
He, W.-Y., 535
He, Y., 35
Heo, Y.-H., 115
Higashihara, M., 463
Hirono, Y., 527
Horie, R., 463
Horiguchi, A., 217
Hou, Q., 563
Hu, R. J., 487
Huang, J.-A., 573
Huang, S., 35
Huerou, Y. L., 349
Humphries, M. J., 349

Ide, M., 111
Igarashi, A., 479
Imamura, F., 399
Inoue, T., 527
Ishikawa, T., 543
Ito, K., 217
Iwamoto, S., 479

Jang, B. I., 67
Jeong, J.-W., 455
Jeong, Y.-M., 237
Jia, H., 125
Jiang, H.-X., 573
Jiang, Q., 77
Jin, J., 381
Jing, H.-W., 125
Joo, K. M., 381
Joo, Y.-E., 115
Jung, B. C., 67

Kabasakal, L., 259
Kadin, M. E., 463
Kamada, K., 543
Kapettu, S., 105
Katada, K., 543
Katayama, K., 527
Katayama, R., 23
Kawatani, M., 445
Keyer-Uysal, M., 259
Khan, M. M. G., 445
Khandige, S., 105
Kim, D.-S., 237
Kim, E.-S., 297
Kim, H.-J., 391
Kim, H.-S., 381
Kim, J. H., 381
Kim, J.-R., 67
Kim, K.-K., 115
Kim, M. K., 67
Kim, S. W., 67
Kim, S. W., 67
Kim, S. Y., 237
Kim, S. Y., 471
Kim, S., 115
Kim, T. N., 67
Kim, W., 381
Kim, Y., 381
Kim, Y.-J., 455
Kimura, S., 111, 511
Kitahara, K., 511
Koga, S., 511
Koh, Y.-S., 115
Koie, T., 85
Koike, S., 23
Kokura, S., 543
Kong, C.-Z., 125
Koslowsky, I., 265
Koul, A., 179
Kumagai, T., 399
Kundu, C. N., 311
Kwon, N. S., 237
Lee, D.-S., 391
Lee, I.-K., 391
Lee, J. C., 471
Lee, J.-I., 381
Lee, K. H., 67
Lee, K.-M., 297
Lee, S. H., 67
Lee, S.-J., 93
Lee, T.-H., 391
Lee, W.-S., 115
Li, B., 131
Li, D., 141
Li, H., 237
Li, H., 149
Li, H., 171
Li, S., 303
Li, S., 555
Li, X., 323
Li, X., 35
Li, X., 149
Li, Z., 77
Li, Z.-H., 125
Li, Z., 149
Li, Z.-L., 125
Liang, J., 225
Liang, Y., 149
Liao, F., 203
Libby, E., 93
Lim, D.-H., 381
Lin, L., 125
Liu, B., 131
Liu, H., 171
Liu, H., 519
Liu, S.-Q., 573
Liu, T., 125
Liu, W., 35
Liu, X.-K., 125
Liu, Z., 131
Liu, Z., 563
Long, Y., 149
Loudon, J. A., 55, 407
Lu, S., 225
Lu, S., 519
Luo, J., 563
Lv, Z., 131
Lyon, M. A., 349

Mahmood, Z., 245
Malik, M. A., 165
Malki, A., 275
Mariani, M., 13
Matsumoto, T., 543
McEwan, A. J. B., 287
Mercer, J., 265
Mercer, J. R., 287
Milione, M., 403
Mirzayans, R., 265
Misawa, A., 23
Mittal, B., 165
Miwa, N., 203
Mochinaga, S., 111, 511
Moghadam, M. P., 375
Mohajeri, A., 375
Mohapatra, P., 311
Mohr, P. J., 349
Montazeri, V., 375
Moon, A., 297
Mori, K., 543
Morita, J., 479
Mozzetti, S., 13
Murray, D., 265
Myung, S. C., 237

Na, I. I., 471
Naito, Y., 543
Nakamura, T., 85
Nakamura, T., 111
Nakano, K., 463
Nakano, Y., 511
Nakashima, M., 463
Nam, D.-H., 381
Naoe, M., 479
Nation, P. N., 287
Nishino, K., 399
Noh, D.-Y., 297
Noshiro, H., 511

Ogawa, Y., 479
Ohyama, C., 85
Okahashi, T., 511
Okamoto, A., 85
Okyuama, T., 399
Osada, H., 445

Park, B.-J., 391
Park, C.-H., 115
Park, S.-J., 115
Park, S.-Y., 455
Park, Y.-L., 115
Pérez-Sayáns, M., 45
Pillai, R., 99
Po, H. R., 381
Postema, E., 287
Preet, R., 311
Prislei, S., 13
Procopio, G., 403
Pusceddu, S., 403

Qin, D., 193
Qin, M.-B., 573
Qing, C., 149

Rabinowitz, I., 93
Rajappa, M., 365
Raspaglio, G., 13
Ren, L., 391
Rey, J. M. G., 45
Rho, J. K., 471
Riauka, T., 287

Saitoh, H., 85
Saitoh, Y., 203
Sakamoto, N., 543
Sato, A., 217
Sato, T., 85
Satyam, A., 365
Sayar, H., 93
Scambia, G., 13
Sen, T., 335
Şener, G., 259
Seol,  H. J. , 381
Shahhosseini, S., 265
Shanbhogue, V. V., 105
Shao, Q., 225
Sharma, A., 365
Sharma, K., 165
Sharma, M., 365
Shi, K., 77
Shichijo, T., 479
Shukla, Y., 245
Sil, H., 335
Simizu, S., 445
Singh, M., 245
Singh, R., 245
Somoza-Martín, J. M., 45
Song, C., 323
Song, S. K., 67
Sueoka, E., 111
Sullivan, F. X., 349
Sumi, K., 511
Sumitomo, M., 217
Sutoh, M., 85
Suzuki, T., 479

Takagi, T., 543
Tang, G.-D., 573
Tang, S.-C., 171, 519
Terao, S., 479
Thangapandi, V. R., 99
Togano, T., 463
Tomida, A., 23
Tong, G.-Z., 323
Tsuboi, S., 85
Tyagi, S., 245

Uchida, J., 399
Uchiyama, K., 543
Um, H.-D., 381
Ureshino, N., 111
Uysal, M., 259

von Carlowitz, I., 349

Wallace, E., 349
Wang, A., 303
Wang, B., 349
Wang, G., 193
Wang, H., 501
Wang, J., 501
Wang, M., 535
Wang, R., 141
Wang, T., 171
Wang, T., 193
Wang, W., 141
Wang, Y., 501
Wang, Y., 501
Watanabe, M., 463
Watanabe, T., 23, 463

Xiao, H., 35
Xie, Q., 555
Xie, X., 131
Xing, F., 501
Xioa, M.-C., 535
Xu, C., 77
Xu, M.-K., 125
Xun, P., 171

Yagi, N., 543
Yakabe, T., 511
Yamaguchi, A., 527
Yamamoto, H., 85
Yamaya, K., 85
Yan, W., 563
Yang, B.-F., 323
Yang, H.-A., 535
Yang, H.-Y., 391
Yang, J., 519
Yang, L., 35
Yang, U., 391
Yang, W.-F., 125
Yang, Y., 77
Yang, Y., 225
Yang, Y., 501
Yang, Y.-J., 323
Yang, Z. L., 487
Yi, E.-Y., 455
Yin, J., 131
Yoneyama, T., 85
Yoo, H. Y., 381
Yoon, S. J., 381
Yosikawa, T., 543
Youssef, A., 275
Yu, M., 149
Yu, Y., 141
Yun, H.-Y., 237

Zargar, S. A., 165
Zarghami, N., 375
Zhang, H., 501
Zhang, J., 35
Zhang, W., 555
Zhang, X., 149
Zhang, Y., 149
Zhang, Z. G., 487
Zhang, Z., 141
Zhang, Z., 303
Zhao, M., 323
Zhao, P., 225
Zheng, J., 35
Zheng, X., 555

Volume 19 - Subject Index

A20, 463
Acute myeloid leukemia (AML), 35
Adoptive T-cell transfer (ACT), 543
ADRB2, 45
β-Adrenergic agonist, 45
β-Adrenergic antagonist, 45
β-Adrenergic receptors, 45
β2-Adrenergic receptor, 45
Akt, 245
Aminoglycosides, 55
Angiogenesis, 303, 455
Antioxidant enzymes, 259, 365
Antisense oligonucleotide, 265
AP-1, 115
Apoptosis, 35, 45, 77, 245, 303, 323, 391, 535
Arsenic trioxide, 149
Ataluren, 55
Autophagy, 303
Azadirachta indica, 179

Bacitracin, 445
Bad, 67
Barrett's esophagus, 141
Basic fibroblast growth factor (bFGF), 455
Bax, 275
Bcl-2, 149
Benign prostatic hyperplasia (BHP), 225
β-Adrenergic agonist, 45
β-Adrenergic antagonist, 45
β-Adrenergic receptors, 45
β2-Adrenergic receptor, 45
β-Catenin, 237
β-Glucan, 259
Bilateral breast cancer, 171
Bisphosphonate, 287
Bladder cancer, 125, 535
Bladder tumor, 85
Bone metastases, 287
Breast cancer, 275, 287, 375, 519
Burkitt lymphoma, 149

Cancer, 543
Cancer of posterior one third of the tongue, 365
Cancer stem cell (CSC), 23, 555
Canine models, 225
Cardiac pre-/postconditioning, 407
β-Catenin, 237
CD30, 463
Celecoxib, 131
Cell cycle, 349
Cell growth, 527
Cell invasion, 297
Cell line A549, 323
Cell proliferation, 535
Cervical cancer, 245
Checkpoint kinase 1 (Chk1), 349
Checkpoint, 349
Chemopotentiation, 349
Chemoresistance, 13, 23, 471
Chemotaxis, 45
Chemotherapy, 399
Chemotherapy/radiotherapy resistance, 407
Circulating tumor cells, 487
Cisplatin, 471
Clinicopathology, 141
c-Met tyrosine kinase, 131
Coenzyme Q10 (CoQ10), 455
Colon, 1
Colon cancer, 527
Colorectal cancer, 311, 573
Colorectal neoplasms, 487
Combination therapy, 311
Combretastatin A4 phosphate (CA4P), 303
Compassionate use, 403
Concomitant chemoradiation, 365
Conjugated dienes, 365
CXC chemokine receptor 4 (CXCR4), 555
Cyclin D1 (CCND1), 519
Cyclin-dependent kinase, 349
Cyclooxygenase-2, 245
CYP2C19, 111

Diagnosis, 105
Direct sequencing, 111
DNA damage, 311
DNA damage checkpoint, 381
DNA fragmentation, 203
Dormant cancer, 407
Dose intensity, 511
Doxorubicin, 131

Encephalopathy, 399
Epidermal growth factor receptor (EGFR) inhibitor, 471
(−)-Epigallocatechin 3-gallate (EGCG), 391
Epigenetics, 105
ERK, 275, 455
ERK1/2, 463, 573
Erlotinib, 399
Esophageal adenocarcinoma, 141
Esophageal and gastric cancer, 165
Everolimus, 403
Experimental carcinogenesis, 1

Fibronectin, 335
Fluorine-18, 265
5-Fluorouracil, 311
Fullerene [C60] included in polyethylene glycol, 203

Gα12\13, 297
G870A polymorphism, 519
Gemcitabine, 287
Gene expression, 375
Glioma, 555
β-Glucan, 259
Glutathione, 365

HCT116, 265
Hemaglutinin, 323
Hepatocellular carcinoma, 115, 131
Hepatocyte growth factor (HGF), 67, 93
Hepatocyte growth factor receptor, 131
Hepatoma-derived growth factor (HDGF), 67
Heterodimerization (HD) domain, 99
Hibernating myocardium, 407
Histone deacetylase (HDAC), 217
Hodgkin lymphoma, 463

IκBα, 463
iASPP, 125
Immunohistochemistry, 141
India, 99
Indole-3-carbinol, 237
Inhibitor, 445
Insulin-like growth factor-1 receptor (IGF-1R), 35
Integrin, 335
Interferon-α (IFN-α), 479
Interferon-γ (INF-γ, 543
Interleukin-2 (IL-2), 479
Invadopodia, 85
Invasiveness, 563
Ionizing radiation, 265
Irradiation, 203
Ischemic myocardium, 407

JNK, 275
Juniferdin, 445

Kashmir Valley, 165
KITENIN, 115

Lentivirus, 563
LIMK1, 501
Lipid peroxidation, 259, 365
Lung cancer, 471

MAPK, 115, 311
MatLyLu Dunning prostatic adenocarcinoma, 259
Matrix metalloproteinase-2 (MMP-2), 297
MCL-1, 149
MDA-MB-231, 287
MED19, 193
Melatonin, 259
MET, 93
Meta-analysis, 519
Metastasis, 67
Metastatic brain tumor, 381
Metastatic colorectal cancer, 511
Metastatic phenotype, 573
Metformin, 275
Methylation markers, 105
MG63, 501
Microfluidic analytical techniques, 487
MicroRNA (miRNA), 23
Migration, 237, 501
MMP-9, 335
Modified FOLFOX6 (mFOLFOX6), 511
Multidrug resistance, 501
Multiple myeloma cell, 391
Murine melanoma, 335
Mutated (S351A)RIN1, 527

Natural killer (NK) cell, 479
Neoplasm metastasis, 487
Neuroendocrine tumor, 403
Newcastle disease virus (NDV), 323
NF-κB, 463
Nonsense mutations, 55
Non-small cell lung cancer, 323
Notch-1 receptor, 99
Nuclear factor-κB (NF-κB), 245
NVP-ADW742, 35

Octreotide, 403
Orthotopic mouse model, 131
Osteosarcoma, 193, 501
Ovarian cancer, 13

p21, 265, 275
p53, 275
Peroxiredoxin V (PrdxV), 391
Peroxisome proliferation-activated receptor-γ (PPAR-γ), 141
Phorbol 12-myristate 13-acetate (PMA), 573
Phosphorylated Chk1 (P-Chk1), 381
Photodynamic therapy (PDT), 203
Phytochemicals, 179
PIK3CA, 563
PIN3 Ins16bp polymorphism, 165
Primary cancer, 105
Prognosis, 105, 171
Programmed cell death, 303
Proliferating cell nuclear antigen, 131
Proliferation, 125, 193, 563
Proline, glutamic acid, serine, threonine-rich (PEST) domain, 99
Prostate cancer, 237
Prostate-specific antigen (PSA), 225, 375
Prosurvival factors, 407
Protein disulfide isomerase, 445
Protein kinase Cα (PKCα), 77

Quenching probe, 111

Radioresistance, 381
Reactive oxygen species (ROS), 77, 203
Regulatory T cells (Tregs), 543
Renal cancer, 217
Renal cell cancer (RCC), 479
Resveratrol, 311
Ribosomal read-through, 55
RIN1 gene, 527
Risk, 519
RNA interference, 125, 193
RON, 13

shRNA, 535, 563
Side population (SP), 23
Signaling, 335
Single nucleotide polymorphism, 111
Skin tumors, 179
Sodium selenite, 77
Sphingosine kinase 1 (SPHK1), 573
Suberoylanilide hydroxamic acid (SAHA), 217
Survivin, 149, 535

Targeted therapies, 403
T-Cell acute lymphoblastic leukemia (T-ALL), 99
Tea polyphenols, 245
Telomerase, 375
Therapeutic response, 365
Three-dimensional conformal stereotactic radiation therapy (3D-CRT), 225
Thromboembolism, 93
Thrombosis, 93
Tongue cancer, 563
TopBP1, 381
Topotecan, 217
Transcription factors, 179
Transient, 399
Treatment and follow-up, 171
Treg cell, 479
Tumor invasion, 85
Tumor suppressor proteins, 55
Tyrosine kinase receptor, 13

Ultrastructure, 1
Unilateral breast cancer, 171
UTG1A1, 111

Vascular endothelial growth factor (VEGF), 67
VEGF, 149
Vincristine, 501
Vitamin C, 365
Vitamin E, 365

Zinc, 1

Volume 18

Author Index

Adachi, M., 337
Advani, R., 287
Albrecht, C. F., 365
Amrani, M., 185
Ariga, T., 575
Attaleb, M., 185

Bachleitner-Hofmann, T., 83
Baek, J. Y., 203
Bai, J., 437
Balachandran, C., 193
Barabasz, A., 229
Beder, L., 509
Behravan, J., 9
Benbacer, L., 185
Benchekroun, N., 185
Benider, A., 185
Bergevoet, S. M., 349
Bonorden, M. J. L., 269
Borkoskyk, S. S., 509
Bose, P., 469
Boucharaba, A., 173
Boukes, G. J., 365

Cabera, A., 395
Camci, C., 583
Cao, Y., 117
Cao, Z., 305
Castro, B., 395
Chadha, V. D., 17
Chakosari, R. J., 25
Chang, K.-T., 259
Chaudhry, P., 549
Chen, J., 437
Chen, K., 561
Chen, L., 503
Chen, W., 519
Chen, Y.-L., 279
Cheng, W.-F., 279
Choi, S.-H., 401
Choi, Y. J., 445
Chu, T.-C., 279
Chung, H. C., 213
Chung, H. H., 453
Cipriano, C., 409
Ciszak, L., 127
Cleary, M. P., 269
Clézardin, P., 173  (357*)
Costarelli, L, 409
Cui, L., 305

Dan, L., 593
Daniels, B. B., 365
Demiryürek, A. T., 583
Demiryürek, S., 583
Dhawan, D. K., 17
Dikilitas, M., 583
Dou, Y., 519
Duan, X., 117
Duanmu, Z., 437

Elahian, F., 9
El hamadani, W., 185
El Mzibri, M., 185
Emanuelli, M., 409
Eviatar, E., 537

Fadden, P., 229
Farhangi, S., 95, 469
Foley, B., 229
Frydecka, I., 127
Fuji, K., 153, 493
Fukagai, T., 493

Gangwar, R., 329
Gao, Z., 519
Gasparini, N., 409
Geng, Y., 133
Ghahremani, M. H., 221
Giacconi, R., 409
Goi, T., 541
Gong, Y., 437
Grossmann, M. E., 269
Gu, P., 133
Guan, H., 117
Guan, X.-X., 503
Guillet, B., 173
Gunduz, E., 509
Gunduz, M., 509
Guo, J., 519

Habler, L., 537
Haghighi, M. M., 57
Hall, S., 229
Han, Y. H., 315
Har, Y. C., 65
Harish, C. C., 461
He, Z.-Y., 503
Henze, G., 95, 469
Heubner, M., 343
Hirono, Y., 541
Hirose, T., 337
Hneino, M., 173
Holtkamp, N., 95
Hong, J.-H., 259
Hoppe, R., 287
Horning, S. J., 287
Hosono, T., 575
Hosono-Fukao, T., 575
Hsieh, C.-Y., 279
Hu, H., 561
Hu, Z., 305
Huang, C.-Y., 279
Huang, F., 1
Huang, G., 31
Huang, H., 437
Huang, H.-Z., 377
Huang, K., 229
Huang, L., 203
Huang, X.-Y., 503

Iitsuka, Y., 575
Iwamoto, S., 493

Jai, T., 73
Jain, M., 41
Jansen, J. B. M. J., 349
Janssen, M. J. R., 349
Jelodar, M. H., 323
Jeung, H. C., 213
Ji, W., 561
Johannsen, A., 287
Ju, W., 47

Kalalinia, F., 9
Kalender, M. E., 583
Kandefer-Szerszeń, M., 419
Kang, S.-B., 453
Kanwar, S. S., 243
Kasimir-Bauer, S., 343
Katase, N., 509
Katayama, K., 541
Kaur, J., 481
Kayed, H., 133
Kazemi, M., 25, 323
Kessler, A., 537
Khyatti, M., 185
Kim, B. K., 453
Kim, C. H., 445
Kim, H. T., 445
Kim, H.-R., 445
Kim, I.-J., 47
Kim, J. J., 213
Kim, J. W., 47, 453
Kim, J., 453
Kim, J.-R., 107
Kim, J. S., 203
Kim, K. S., 203
Kim, K.-S., 259
Kim, S. C., 47
Kim, S. H., 141
Kim, Y. M., 445
Kim, Y.-J., 141
Kimming, R., 343
Kizilyer, A., 583
Kleinerman, E. S., 31, 117
Koh, J. S., 141, 445
Kohrt, H., 287
Kook, E. H., 445
Koshkina, N. V., 31
Kosmaczewska, A., 127
Krieger-Hinck, N., 387
Kushima, M., 153
Kusumoto, S., 337
Kwon, Y.-J., 141

Laba, A., 127
Laheij, R. J. F., 349
Lee, C. H., 453
Lee, E.-J., 401
Lee, G.-D., 259
Lee, H. P., 47
Lee, J. C., 445
Lee, J.-H., 401
Lee, K. H., 107
Lee, P. P., 287
Lee, S. J., 141
Lee, S., 259
Lee, Y. K., 203
Lei, W., 73
Li, F.-Y., 503
Li, J., 359
Li, T., 305
Li, Y., 561
Li, Z., 1
Liao, Z.-W., 503
Lin, M.-C., 279
Liu, A., 519
Liu, Y., 519
Long, F., 401
López-Cortés, A., 395

Mahmoudi, T., 57
Mainetti, L. E., 601
Malavolta, M., 409
Mangoldt, D., 95
Matar, P., 601
Matoušek, J., 163
Matoušek, J., 163
McClelland, M., 401
Menaa, F., 173
Mittal, B., 41, 329
Mittal, R. D., 329
Mizuno, N. K., 269
Mladosievicova, B., 607
Mocchegiani, E., 409
Mohebbi, S. R., 57
Mollah, M. L., 259
Mollasalehi, H., 323
Moon, H. J., 315
Morita, J., 153, 493
Müller, A., 387
Muñoz,  M. J., 395

Nagai, N., 509
Nagatsuka, H., 509
Nagini, S., 193
Naidu, R., 65
Naoe, M., 153, 493
Narasimhan, M. L., 269
Nehru, B., 243
Nguyen, T. V., 349
Ninomiya, Y., 529

Ogawa, Y., 153, 493
Ohmori, T., 337
Ohnishi, T., 337
Okuda, K., 337
Olevson, Y., 537
Orlando, F., 409
Ostad, S. N., 221
Ota, H., 153
Otterbach, F., 343
Ouyang, Z., 593
Oztuzcu, S., 583

Paduch, R., 419
Palacios, A., 395
Pan, C.-B., 377
Pan, H., 1
Park, C.-H., 259
Park, J. H., 141
Park, K. H., 213
Park, N.-H., 453
Park, S.-Y., 453
Park, W. H., 315
Park, Y. S., 203
Patel, F. D., 549
Paz-y-Miño, C., 395
Paz-y-Miño, N., 395
Perbellini, L., 409
Peters, W. H. M., 349
Peyruchaud, O., 173  (357*)
Piacenza, F., 409
Pierpaoli, S., 409
Piersiak, T., 419
Podzimek, T., 163
Poučková, P., 163
Prasanna, R., 461

Radpour, R., 57
Raibowol, K., 95
Ray, A., 269
Reddanna, P., 243
Reimann, K., 343
Ren, Y., 1
Rha, S. Y., 213
Rho, J. K., 445
Riabowol, K., 469
Rice, J. W., 229
Rico, M. J., 601
Rodrigues, A. P., 509
Roh, J.-W., 453
Rosenberg, S. A., 287
Roth, E., 83
Roy, K. R., 243
Rozados, V. R., 601
Roziakova, L., 607
Ryoo, Z. Y., 259

Salehi, Z., 25
Salehi, Z., 323
Sánchez, M. E., 395
Sandbank, J., 537
Sanyal, S. N., 243, 481
Sasaki, A., 509
Sawai, K., 541
Scharovsky, O. G., 601
Schumacher, U., 387
Scott, A., 229
Seki, T., 575
Sevinc, A., 583
Seyedabadi, M., 221
Shah, S., 95
Shichijo, T., 153, 493
Shimada, C., 529
Shirai, T., 337
Siffert, W., 343
Singh, H., 41, 329
Singh, M. P., 293
Singh, S. M., 293
Singh, V., 293
Sinn, B., 469
Škvor, J., 163
Sokolchik, I., 269
Song, J.-C., 259
Song, Y.-S., 453
Souček, J., 163
Srinivasan, R., 549
Srivastava, S., 329
Steed, P., 229
Stehlík, J., 163
Sturlan, S., 83
Su, Z., 73
Sugiyama, T., 337
Sun, X.-F., 133
Suzuki, E., 529
Suzuki, H., 409
Suzuki, K., 95
Szteblich, A., 127



Taib, N. A., 65
Takeshita, K., 153, 493
Tallen, G., 95, 469
Tamamura, R., 509
Tamannai, M., 95, 469
Tanaka, Y., 575
Tang, C., 437
te Morsche, R. H. M., 349
Terao, S., 153, 493
Tesei, S., 409
Truss, M., 95, 469
Tsujigiwa, H., 509

Umezawa, K., 529

Vahedi, M., 57
Vaiman, M., 537
Valentiner, U., 387
van Asten, H., 349
van de Venter, M., 365
van Oijen, M. G. H., 349
van Wijnen, A., 173
Veal, J. M., 229
Verma, V. K., 293
Vinothini, G., 193
von Deimling, A., 95, 469

Wang, A., 377
Wang, C., 561
Wang, H., 359
Wang, H., 519
Wang, J., 359
Wang, J.-G., 377
Wang, M.-W., 133
Wang, Y., 401
Wang, Z., 359
Wen, W., 73
Wessner, B., 83
Wimberger, P., 343
Wiritsch, M., 83
Wojtowicz, M., 127
Wolowiec, D., 127
Wu, Y., 1
Wurm, R., 469

Xiao, C., 561
Xing, L., 1
Xu, C., 1
Xu, J.-H., 377
Xu, Y., 359
Xue, M., 503
Xue, X., 561

Yamaguchi, A., 541
Yamaoka, T., 337
Yamochi, T., 153
Yan, Z., 519
Yang, J., 437
Yang, Y., 1
Yang, Y., 519
Yildiz, R., 583
Yoo, B. C., 47
You, B. R., 315
Yu, Y., 561
Yue, W., 359

Zacarías Fluck, M. F., 601
Zahmatkesh, R., 323
Zali, M. R., 57
Zehari, S., 537
Zentgraf, H., 133
Zhan, W., 593
Zhang, B., 377
Zhang, H., 561
Zhang, S., 305
Zhang, W., 305
Zhang, Z.-Y., 133
Zhao, X., 519
Zheng, J., 561
Zhou, B., 437
Zhou, Z., 117
Zhu, X., 73
Zhu, Z.-L., 133
Zhuang, L., 437

*Corrected in an Erratum.

 

Subject Index

A549, 315
Accelerated partial breast irradiation, 503
Adenocarcinoma, 453
Adenovirus expressing promyelocytic leukemia protein (Ad-PML), 305
Adiponectin, 269
Adjuvant therapy, 279, 409
AKT/mTor, 73
Allelic loss, 509
Alternative splicing, 213
Ameloblastoma, 509
Angiogenesis, 95, 173
Angiopoietins, 95
Anticancer activity of synthones, 461
Anticarcinogenic and antiproliferative nucleases, 163
Apoptosis, 1, 73, 83, 127, 193, 243, 259, 315, 365, 377, 469, 481, 519, 561
Apoptotic-related proteins, 1
Array analysis, 409
Arsenic trioxide (As2O3), 83, 305
Aurora kinase B, 141

β variant, 213
Bax, 481
B-cell chronic lymphocytic leukemia, 127
Bcl-2, 481
Bcl-2 family, 549
BCRP, 9
Bladder cancer, 153, 395
Breast cancer, 9, 25, 65, 193, 213, 221, 409, 461
Breast cancer cells, 173
Breast carcinoma, 583
Breast neoplasm, 503
Bulnesia sarmienti, 259

Ca+ homeostasis, 243
cagA, 323
Cancer, 365
Canine mammary tumors, 193
Caspase-3, 377
Cervical cancer, 41, 185, 329, 401, 453, 519
Chemical hypoxia, 221
Chemoresistant tumors, 47
Chemosensitive tumors, 47
Chemotherapy, 377, 437
Cidofovir (CDV), 519
Cisplatin, 73, 377
Clinical stage, 593
Coculture, 419
Codon 72, 25
Colon cancer, 541
Colon cancer cells, 575
Colon carcinogenesis, 243
Colon carcinoma, 419
Colorectal cancer, 437
Covalent binding, 529
CpG methylation, 31
Cyclin D2, 127
Cyclin Y (CCNY), 359
Cyclophosphamide, 601
CYP1A1, 343
Cytochrome c, 481
Cytokine, 41
Cytotoxic drugs, 419
Cytotoxicity, 259

Dexamethasone, 9
DMEQ, 529
Diagnostic methods, 607
Diallyl trisulfide, 575
Dibutenyl trisulfide, 575
Diclofenac, 481
Dihydropyrimidine dehydrogenase (DPD), 153
Dimethyl indan-1-one, 461
Dimethylhydrazine, 17
Disease-free survival, 279
DNA methylation, 401
DNA repair capacity, 329
Doxorubicin (ADM), 561
Dyspepsia, 349

E-cadherin, 185, 445
Endocrine toxicity, 607
Endometrial cancer, 593
Endoreduplication, 365
Epidermal growth factor receptor (EGFR), 229
Epidermal growth factor receptors, 445
Epithelial ovarian cancer, 549
Epstein-Barr virus, 287
Erlotinib, 229
Esophageal squamous cell carcinoma (ESCC), 141
Estradiol, 193
Estrogen receptors, 537
Ewing's sarcoma, 117

Fas family, 549
Fas gene, 31
Fibroblast growth factors receptor-4 (FGFR4), 65
FIGO state, 279
5-Fluorouracil (5-FU), 153
Folate, 57
Four-dimensional computed tomography, 503
Full-length, 213
FXYD3, 133

γδ T cells, 493
Garlic, 575
Gastric adenocarincoma, 323
Gastric cancer, 349
Gefitinib, 445
Gender dimorphism, 293
Gene expression, 47
Gene therapy, 561
Genetic polymorphism(s), 349, 583
Genetic susceptibility, 329
Glioblastoma multiforme (GBM), 95, 469
Glioma, 133, 359
Glucocorticoids, 9
Glutathione (GSH), 315
Glutathione S-transferase, 349
GPX-1, 395
Growth arrest, 561
GSH and GPX, 1

H460 cells, 259
Heat shock protein, 47, 141
Helicobacter pylori, 323
Hematopoietic stem cell transplantation, 607
Hep-2 cells, 73
Hepatic cell carcinoma, 305
Hepatocellular carcinoma (HCC), 561
Hepatocyte growth factor (HGF), 107
HER-2/neu, 409
Histopathological differentiation, 593
H. lupulus, 163
Hodgkin's disease, 287
hScrib, 593
Hsp90, 229
hTERT, 213
Human melanoma, 163
Human papillomavirus (HPV), 519
Hypermethylation, 185

IL-12, 203
ile58thr, 395
Immune response, 287, 601
Immunohistochemistry, 133
Indomethacin, 9
ING family, 509
Inhibition of tumor progression, 203
Inhibitor of growth 1 (ING1), 95, 469
iNOS, 529
Intracellular pH, 243
Invasion, 173, 541
Irinotecan, 437
Irreversible inhibition, 529

Kiss-1, 107

Late effects, 607
Leptin, 269
L. esculentum,, 163
Lipid peroxidation, 83
Lipophilicity, 575
Low-dose irinotecan, 337
Lung cancer, 337, 445
Lymph node metastasis, 593
Lymphocyte, 287
Lymphoma, 601
Lysophosphatidic acid (LPA), 173

Matrix metalloproteinase-9 (MMP-9), 107
MDA-7/IL-24, 561
Membrane dynamics, 17
Meta-analysis, 437
Metastasis, 107, 561, 583
Methylenetetrahydrofolate reductase (MTHFR), 57
Metronomic chemotherapy, 601
MG132, 315
Microsatellite, 509
Migration, 173
Mitochondrial membrane potential (ΔΨM), 481
Mitogen-activated protein kinase (MAPK), 315
MnSOD, 395
Monocytic leukemia RAW264.7 cells, 529
Multidrug resistance, 9

Na+/H+ exchange, 243
Natural substances, 409
Neuroblastoma, 387
NF-κB, 529
Nicotiana bethamina, 163
Nitric oxide synthase, 221
Nitric oxide, 419
NOGOR, 401
Nonfamilial colorectal cancer, 57
Non-small cell lung cancer (NSCLC) , 229

Orotate phosphoribosyltransferase (OPRT), 153
Osmotin, 269
Osteoclastogenesis, 173
Osteolysis, 117
Osteosarcoma, 31
Ovarian cancer, 47, 343
Overall survival, 279
Oxaliplatin, 437

p16INK4a, 185
p21 codon 31, 453
p53, 25
p53 codon 72, 453
PAK6, 401
Papillary carcinoma, 537
Pathogenesis, 607
Periostin, 141
Physical exercise, 293
Plant infiltration, 163
Platinum resistance, 343
Platinum-based chemotherapy, 549
Polymorphism, 25, 41, 57, 65, 329, 343, 453
Polyunsaturated fatty acids, 83
PPAR-γ agonists, 387
pro198leu, 395
Proinflammatory cytokines, 419
Proliferating cell nuclear antigen (PCNA), 519
Proliferation, 127, 173
Prostate cancer, 269, 493
Pyrosequencing, 57

RANKL, 117
Rapamycin, 73
Reactive oxygen species (ROS), 315, 419
Response, 549
Rho kinase, 583
RNAi, 359
Rooperol, 365
Rosiglitazone, 387

Saxatilin, 203
SCID mouse, 387
Selenomethionine, 1
shRNA, 377
Signal transducer and activator of transcription 3 (STAT3), 561
Small cell carcinoma, 279
SNX-2112, 229
Sodium selenite, 1
Spermatogenesis, 163
Sphingosine 1-phosphate (S1P), 173
Survivin, 377
Survivin-3B, 541
Synergistic inhibition, 305
Synthetic anticancer drugs, 461
Systematic review, 437

T47D, 221
Tamoxifen, 221
TC-1 cancer cells, 203
T-cell lymphoma, 293
Thimidine phosphorylase (TP), 153
Thymidylate synthase (TS), 153
Thyroid gland, 537
Tongue cancer, 377
Toxicity, 337
TRAMP mice, 269
TRAMP-C2 cells, 269
Transforming growth factor, 41
Trichostatin A, 469
Tumor cells, 83
Tumor progression, 293
Tumor suppressor, 593
Tumor suppressor genes, 509
Tumor xenografts, 163

UGT1A1*28 genotype, 337
Ultrasound, 503
Uterine cervix, 279

VEGF165, 117

XPC
, 329

Zinc, 17
Zoledronate, 493

Author & Subject Indexes: Volumes 11-17

VOLUME 17

Author Index

AUTHOR INDEX
Abbondanza, C., 33
Acquati, F., 69
Agarwal, A., 127
Akutsu, M., 137
Aldinucci, D., 103
Amato, A., 115
Amirghofran, Z., 447
Andrzejewski, T., 257
Antonaci, A., 495
Arbab, A. S., 257
Asawakarn, S., 301
Aurello, P., 405

Bae, K.-H., 601
Barkhout, M., 347
Bauer, S. M., 205
Bechi, P., 559
Beder, L., 273
Begum, F. D., 43
Bellagamba, R., 405
Bertollo, C. M., 473
Bhagat, M., 387
Bid, H. K., 367
Biswas, D., 397
Blaakær, J., 43
Bonovolias, I. D., 535
Bordonaro, M., 1
Borkosky, S. S., 273
Bose, C. K., 231
Bozkurt, B., 353
Burns, A. J., 93

Cao, T., 373
Cattaruzza, L., 103
Chakrabarti, S., 397
Chan, C.-K., 283
Chandra Mohan, K. V. P., 75, 193
Chang, L.-S., 311
Charbonneau, M., 223
Chashoo, G., 387
Chatterjee, S., 397
Chattopadhyay, N., 367
Chaturvedi, R., 127
Chaudhary, P., 367
Chen, D., 621
Chen, G., 183
Chi, S.-G., 571
Chi, S.-W., 601
Chiani, M., 549
Chien, C.-M., 311
Chiu, C.-C., 311
Choi, E. Y., 23
Christensen, L., 43
Ciardi, A., 405
Cicchini, C., 405
Cipriani, G., 559
Colombatti, A., 103
Consorti, F., 495
Correa, C. R., 473
Crisci, A., 565
Cutts, S. M., 283

Daneshbod, Y., 447
Dang, Y.-W., 183
D'Angelo, F., 405
Danova, K., 51
Danyluk, A., 257
Deeb, D., 257
Della Melina, A., 565
Delmani, F. A., 425
Del Monte, S. R., 405
de Metz, M., 323
Demirkazik, A., 455
Deng, C., 613
de Nigris, F., 33
De Rosa, C., 33
Devlin, A. H., 93
Di Leonardo, A., 115
Do, S.-I., 269
Dong, H., 373
Dulchavsky, S. A., 257
Dutta, S., 387

Elhan, A. H., 455
Ergul, G., 353
Eun, J. R., 23

Fang, J., 437
Feng, Z.-B., 183
Fregona, D., 103
Fujioka, M., 593
Fukushima, M., 137
Furukawa, Y., 137

Gao, J.-L., 519
Gao, X., 257
García-Herdugo, G., 425
Gardiner, T. A., 93
Garg, V. K., 127
Gautam, S. C., 257
Gelboin, H. V., 75, 193
Gholijani, N., 447
Ghoshal, U. C., 167
Giovagnini, L., 103
Giovannone, G., 495
Goes, A. M., 473
Goi, T., 593
Gomez-Santos, L., 437
González-Víltchez, F., 425
Goto, H., 581
Grifoni, R., 559
Groenendaal, N., 323
Guan, L., 373
Gümüs-Akay, G., 455
Gunduz, E., 273
Gunduz, M., 273
Gur-Dedeoglu, B., 353

Han, B., 373
Hanibuchi, M., 581
Hara, Y., 75, 193
Harata, Y., 247
Hatipoglu, O. F., 273
Hayashi, Y., 11
Higashi, N., 437
Hirabayashi, K., 137
Hirono, Y., 593
Hiroshima, K., 239
Hirst, D. G., 93
Høgdall, C. K., 43
Høgdall, E. V., 43
Howell, A. P., 205
Hu, Y., 59
Hua, F., 373
Huang, H., 175, 621
Huo, Q., 217
Hyun, M. S., 23

Igarashi, S., 137
Ikuta, K., 581
Inoue, K., 137
Insalaco, L., 115
Ioannou, M. G., 413
Irimura, T., 437
Izawa, R., 437
Izumi, T., 137

Jacobs, I. J., 43
Jain, M., 87, 167
Jang, B. I., 23
Jin, Y., 59

Kakeya, H., 11
Kakiuchi, S., 581
Kakumoto, M., 527
Kamiyama, H., 11
Kang, M.-J., 571
Kang, S., 601
Kano, Y., 137
Kast, R. E., 383
Katano, S., 137
Katase, N., 273
Katayama, K., 593
Kim, D. S., 601
Kim, H., 331
Kim, H. S., 151
Kim, J. H., 23
Kim, J.-R., 23
Kim, M., 601
Kim, M. K., 23
Kim, S. E., 331
Kim, S. H., 601
Kim, S. W., 23
Kim, T. N., 23
Kim, Y., 601
Kim, Y. H., 571
Kim, Y. W., 269
Kinugasa, T., 217
Kirito, K., 137
Kjær, S. K., 43
Kobayashi, H., 137, 527
Konu, O., 353
Konwar, R., 367
Koukoulis, G. K., 413
Kuman, S., 167, 367
Kuriyama, T., 239
Kuroki, M., 217
Kuroki, M., 217
Lazarova, D. L., 1

Lee, D. H., 601
Lee, E. S., 151
Lee, K. H., 23
Lee, S. C., 601
Lee, S. M.-Y., 519
Lee, W. C., 339
Lee, W. W., 331
Lee, Y. M., 151
Lefeuvre, M., 273
Lentini, L., 115
Lin, K.-L., 311
Lin, S.-R., 311
Logan, I. D., 93
Lorenzon, D., 103
Lo Russo, G., 69
Luo, D.-Z., 183

Malekzadeh, K., 159
Mardente, S., 495
Mashayekhi, R., 549
Mathus-Vliegen, E. M. H., 347
McKeown, S. R., 93
Mirsattari, D., 549
Mishra, D., 367
Mitra, A. K., 127
Mittal, B., 87, 167
Miwa, N., 247
Mohebbi, S. R., 549
Molaei, M., 549
Molinara, E., 559, 565
Momparler, L. F., 223
Momparler, R. L., 223
Monti, L., 69
Moreno, J., 425
Mukherjee, A., 387

Nagai, N., 273
Nagashima, T., 137
Nagatsuka, H., 273
Nagengast, F. M., 323, 347
Nagini, S., 75, 193, 483
Najjar Sadeghi, R., 549
Nakamura, M., 239
Napoli, C., 33
Neri, B., 559, 565
Nicita, G., 565
Nishikawa, K., 11
Nishioka, Y., 581
Nodera, Y., 437
Noonan, D., 69
Nudelman, A., 283

Ogino, H., 581
Oh, S.-H., 339
Ohashi, Y., 437
Ohmine, K., 137
Ohnishi, N., 527
Okayasu, H., 247
O'Keeffe, M. B., 93
Okumura, K., 527
Osada, H., 11
Otsuka, S., 581
Ozawa, K., 137

Pan, C., 621
Pan, H., 373
Pan, J.-J., 339
Pantaleo, P., 559, 565
Pantalone, D., 559
Park, B. C., 601
Park, H. C., 571
Park, H.-R., 269
Park, S. G., 601
Park, S.-H., 151
Park, S. Y., 331
Park, Y.-K., 269
Park, Y.-N., 151
Peters, W. H. M., 323, 347
Petersen, B. E., 339
Phillips, D. R., 283
Poddar, S., 397
Prawettongsopon, C., 301
Puca, G. A., 33

 

Ramacciato, G., 405
Rangan, S., 559, 565
Rath, S. K., 127
Raugei, A., 565
Ravaioli, M., 405
Raynal, N. J.-M., 223
Ren, Y., 373
Rephaeli, A., 283
Rodolfo, M., 69 (191)
Roelofs, H. M. J., 323, 347
Rossiello, R., 33
Ryan, A., 43

Sachan, R., 87
Saini, R. K., 505
Saitoh, Y., 247
Sakaeda, T., 527
Sanyal, S. N., 505
Sanyal, T., 387
Sartorelli, A. C., 1
Sato, K., 137
Sawaguchi, T., 437
Saxena, A. K., 387
Schillaci, T., 115
Schwarz, E., 205
Seckin, S., 353
Sengupta, B., 397
Sengupta, S., 397
Senthil Murugan, R., 483
Sharma, M., 127
Shekari, M., 159
Shen, S., 463
Shi, J.-M., 519
Shibaguchi, H., 217
Shim, H. K., 331
Shimada, H., 239
Shimizu, K., 273
Shoji, M., 11
Simkova, I., 51
Singh, A., 127
Singh, H., 87
Singh, N., 127
Smith, E. S., 205
Sobti, R. C., 159
Son, M. S., 571
Sone, S., 581
Song, S. K., 23
Stegeman, J. J., 75, 193
Sunguroglu, A., 455
Suri, V., 159
Suthiphongchai, T., 301

Tada, Y., 239
Taddei, A., 559
Tagawa, M., 239
Takahashi, T., 581
Takami, N., 217
Takara, K., 527
Takeuchi, H., 437
Takiguchi, Y., 239
Talukder, G., 397
Tamamura, R., 273
Tamandani, D. M. K., 159
Tanaka, M., 137
Tanaka, T., 217
Tang, X.-L., 183
Tanigawara, Y., 527
Taramelli, R., 69
Tatsumi, K., 239
te Morsche, R. H. M., 323, 347
Teramukai, S., 137
Tominaga, S., 273
Tonelli, P., 559
Torreblanca, J., 425
Tsiftsoglou, A. S., 535
Tsunoda, S., 137
Tükün, A., 455

Ueno, S., 437
Ueyama, T., 239
Ugarenko, M., 283
Uhm, K.-O., 151
Ünal, A. E., 455
Upadhyay, R., 167
Urban, L., 51
Urbanova, D., 51
Usami, K., 437
Usui, T., 11

Vageli, D., 413
Vahedi, M., 549
Valeri, A., 559
van der Logt, E. M. J., 323
van der Stappen, J. W., 323
Vannini, A., 559
Vidjaya Letchoumy, P., 75, 193
Vilaplana, R., 425
Villari, D., 565
Vinothini, G., 483

Wang, A., 175, 621
Wang, H., 59
Wang, J., 621
Wang, L., 217
Wang, Y.-T., 519
Wei, W., 373
Williams, M. A., 205

Xiao, J., 613
Xiao, L., 247
Xu, C., 373
Xu, Y., 59, 463

Yamada, T., 581
Yamaguchi, A., 593
Yamanaka, N., 273
Yang, T., 373
Yang, Y., 373
Yano, S., 581
Ying, X., 59
Yokoyama, T., 527
Yu, F., 463
Yulug, I. G., 353

Zali, M. R., 549
Zauderer, M., 205
Zeng, R., 175
Zhang, B., 621
Zhang, Q.-W., 519
Zhao, J., 217
Zojaji, H., 549
Zou, Q., 59

 

Subject Index

Acute lymphoblastic leukemia, 447
Acute myeloid leukemia, 103
Acute promyelocytic leukemia-derived NB4 cells, 373
Adenovirus, 239
Aggressive lymphoma, 137
Akt, 257
All-trans retinoic acid, 175
Ambrisentan, 383
AN-9, 283
Androgen independent, 301
Aneuploidy, 115
Angiogenesis, 93, 193, 519
Anthracyclines, 51
Antiangiogenesis, 11
Antibody-dependent cellular cytotoxicity (ADCC), 217
Anticancer drug, 527
Antineoplastic agents, 103
Antioxidants, 193
Antitumor, 11
Antitumor agent, 387
Antitumor drugs, 425
Antitumorigenic activity, 69
aPCK inhibitor, 59
Apoptosis, 1, 23, 257, 301, 373, 483, 495, 613
Aurora A/STK15, 115
5-Aza-2´-deoxycytidine, 223

BAD, 23
Base excision repair (BER), 127
B cell, 463
Bcl-2, 447
Bcl-2 family, 373
Bcr-Abl kinase, 535
B16 Differential in-gel electrophoresis (DIGE), 601
Berberine, 519
Beta-catenin, 1
Black tea polyphenols, 75
Bladder tumor, 93
Bmi-1, 613
Bone marrow, 339
Bone metastasis model, 581
Borderline ovarian tumors, 43
Breast cancer, 353, 367, 473, 483
Butyrate, 1

Cancer, 33, 205
Cancer risk, 167
Cancer susceptibility, 167
Carcinoembryonic antigen (CEA), 217
Carcinogen activation, 193
Cardiotoxicity, 51
Cardiotoxin III, 311
C57BL/6 mouse, 463
CD40, 463
Cell cycle, 175
Cell line, 473
Cell proliferation, 193, 483
Centrosome amplification, 115
Cervical cancer, 87, 159
Characterization, 473
Chemokine receptor, 87
Chemoprevention, 75, 193
Chemotherapy, 223, 559, 565
Cholangiocarcinoma, 151
Chronic lymphocytic thyroiditis, 495
CIN, 115
Clinical trial, 239
CML cell, 535
CNS lymphoma, 137
Colorectal cancer, 1, 323, 593
Colorectal carcinoma cells, 437
Confidence interval, 127
Corydalis yanhusuo, 519
Curcumin, 257
Cyclooxygenase-2, 347
Cytotoxicity, 387

DCIK/DCIK-P cells, 59
Dendritic cells, 205
Digoxin, 527
9/10-Dimethylbenz[a]anthracene, 505
Dkk-3, 273
DMBA, 75
Docetaxel, 565
Doxazosin, 527
Doxorubicin, 283
Drug resistance, 223
Duodenal adenomatosis, 347
 
 
 
 
 

 

EGF-EGFR interactions, 167
Endogenous reference genes, 353
Endothelin, 383
Epigenetic, 223
Epirubicin, 565
Epithelial ovarian cancer (EOC), 231, 383
Eposyquinoid, 11
ER81, 413
Esophageal cancer, 167
Establishment, 473

Familial adenomatous polyposis, 347
FDG-PET, 331
Fibrillarin, 425
Follicle stimulating hormone receptor (FSHR), 231
Formaldehyde, 283
Frequency, 43
5-FU, 59
Fusion proteins, 205

Gastric cancer, 455, 549, 571
Gastric carcinoma, 405, 613
Gastritis, 549
G-CSF, 137
Gemcitabine, 559
Gene polymorphism, 397
Gene therapy, 239, 621
Genetic polymorphism, 87, 323, 347
Genetic susceptibility, 87
Genistein, 223
Genomic imbalances, 455
Global genome methylation, 549
Glucose transporter, 331
Glut-1, 93

Hamster buccal pouch carcinogenesis, 75
hASIP, 59
Head and neck squamous cell carcinoma, 273
Hemin, 535
Heparanase, 183
Hepatic asialoglycoprotein receptor, 437
Hepatocellular carcinoma, 183, 463
Hepatocyte growth factor (HGF), 23
Her2, 413
Hexokinase, 331
Histone deacetylase inhibitors, 1
Hodgkin lymphoma, 331
HR-CGH, 455
hTERT, 413
Human breast cancer, 59
Human oral squamous cell carcinoma (OSCC), 175
Human telomerase reverse transcriptase, 621
Human tongue carcinoma, 247
HUVEC, 519
Hypermethylation, 151, 571
Hypomethylation, 549
Hypoxia, 93

IgA, 217
IGF-II, 269
IL-1RN, 367
IL-4, 367
Imatinib mesylate, 535
Immunohistochemistry, 183
Immunotherapy, 217, 463
IMP3, 269
Interleukin-18, 159
Invasion, 301
In vivo assay, 387
Irinotecan, 559

KOC, 269

L523S, 269
Lentiviral vector, 621
Leukemia, 223
Liver metastasis, 437
Loss of heterozygosity, 273
Lung adenocarcinoma, 581

MCF-7 cells, 301
MDR1/P-glycoprotein, 527
Medicinal inorganic chemistry, 103
Melanoma, 601
Melanoma model, 69
Mesothelioma, 239
Metaplasia, 383
Metastasis, 301, 601
Methylation-specific PCR, 151
Mice lung tumorigenesis, 505
Microenvironment, 339
Micrometastases, 383
Microsatellite instability, 43
Microsatellite instability-high, 43
Microsatellite instability-low, 43
Microvessel density (MVD), 93, 405
Mitogen activated protein kinase (MAPK), 23
MSI, 549
Multidrug resistance, 527
Mutation, 397
Myeloid antigens, 447

Natriuretic peptides, 51
Neutral pH hydrogen-enriched electrolyzed water, 247
Neutrophils, 217
New nitrosourea, 387
NF-kB, 257, 301
Nonsteroidal anti-inflammatory drugs, 505
Normalization factor, 353
North Indian women, 127

Odds ratio, 127
8-OH-dG, 75
Oncogenes, 495
Oral cancer, 397
Oral squamous cell carcinoma, 621
Organ microenvironment, 437
Osteoblastic bone metastasis, 581
Osteolytic bone metastasis, 581
Osteosarcoma, 33, 269
Ovarian cancer, 43
Ovarian surface epithelium (OSE), 231
Oxidative stress, 483

11p15.2, 273
Palladium compounds, 103
Pancreatic cancer, 339, 559
Papillary thyroid carcinoma, 495
PCR, 273
PCR-SSP, 159
Pericyte, 93
Phosphoinositide 3-kinase (PI3K), 23
PI3K, 301
Pluronics, 283
Polymorphism, 159, 367
Population, 397
Progenitor cell, 339
Proliferation, 613
Prostate cancer, 257, 301
Prostate carcinoma, 565
Protection, 535
Proteomics, 601
Pyrosequencing, 549

Q-RT real-time PCR, 413 

RAP, 425
Reactive oxygen species, 247, 373
Real-time quantitative RT-PCR, 353
Relative risk, 127
Reversal, 527
RIN1 gene, 593
Risk, 367
RIZ, 33
RNA interference (RANi), 613, 621
RNASET2

Single nucleotide polymorphism (SNP), 127
Sodium butyrate, 175
Sodium selenite, 373
Splicing variant, 593

Tazarotene-induced gene 1 (TIG1), 571
TCC-NHL-91, 137
Telomerase activity, 455
Telomerase regulation, 455
Therapeutic index, 103
Tissue microarray, 183
Tobacco, 397
Toxicological assay, 387
TRAIL, 257
Tumor cells, 387
Tumor repression, 247
Tumor suppressor gene, 69, 151, 273
Tumorigenesis, 339

UBF, 425
UDP-glucuronosyltransferase 2B7, 323
Ultrasound, 283
Urothelial carcinoma, 93

Vascular endothelial growth factor (VEGF), 11, 405
VEGF-C, 405

Weekly regiman, 565
Whole protein extracts, 425
Wnt, 1

Xenobiotic-metabolizing enzymes, 75

YY1, 33


VOLUME 16

Author Index

Agarwal, A., 587
Aizawa, H., 235
Akutsu, M., 85
Amarantidis, K., 281
Annegers, J. F., 383
Aoki, D., 289
Arunakaran, J., 57
Arunkumar, A., 67
Ates, U., 195
Ayla, S., 225

Baccini, M., 535
Baguley, B. C., 1
Balicki, A., 299
Balzarotti, M., 245, 453
Bartolini, P., 75
Bastounis, E., 129
Bergoc, R., 55*
Biagetti, S., 157
Biggeri, A., 535
Bilir, A., 195, 225
Boiardi, A., 245, 453
Boratynski, J., 415
Brody, J. L., 35
Bryant, I., 179
Budzynska, R., 415

Caciagli, B., 143
Calatozzolo, C., 453
Camoutsis, C., 129
Campos-Aranda, M., 211
Capaccioli, S., 143
Caprodossi, S., 157
Carpagnano, F., 375
Carpagnano, G. E., 375
Castagnini, C., 535
Cavalieri, D., 535
Cawkwell, L., 497
Chak, E. C. W., 273
Chandra Mohan, K. V. P., 167
Chang, K. T., 325
Chang, S., 383
Chang, Y., 479
Chaturvedi, R., 587
Chatzaki, E., 281
Chen, D., 313
Chen, G. G., 273
Chen, Y.-H., 75
Chène, P., 549
Chiang, C.-T., 119
Chiara, G. D., 157
Ching, L.-M., 1
Chiu, C.-C., 479
Chueh, P.-J., 299
Chyczewska, E., 49, 445
Cianchi, F., 535
Ciusani, E., 245, 453
Cocca, C., 55*
Comert, E., 423
Crescenti, E., 55*
Cricco, G., 55*
Croci, D., 245, 453
Croci, M., 55*
Curci, C., 375
Czerwenka, K., 465

Dalay, N., 43
De Filippo, C., 535
de Grazia, U., 453
DeGregorio, M. W., 251
Dharmarajan, A., 67
Di Gioia, G., 375
Ding, X.-Q., 313
Dirven, C. M. F., 471
Dolara, P., 535
Donnini, M., 143
Drew, P. J., 497
Dubaele, S., 549
Duydu, Y., 423

Edakuni, N., 235
Elhan, A., 423
Endo, K., 57

Fanelli, M., 157
Fang, K., 479
Feng, X., 405
Fontana, F., 245
Foschino Barbaro, M. P., 375
Fujii, H., 85
Furukawa, Y., 85

Gal, S., 35
Galluzzi, L., 157
Garg, V. K., 587
Geldof, A. A., 471
Gelmini, S., 535
Geromichalos, G. D., 129
Gerritsen, W. R., 471
Getoff, N., 389
Ghoshal, U. C., 437
Gilleron, P., 107
Goksel, G., 225
Goossens, J.-F., 107
Goto, H., 15
Goya, S., 489
Gupta, B., 351
Gutiérrez, A., 55*
Guvenc, G., 423

Hamada, J., 217
Hamatake, M., 333
Hara, Y., 167
Harada, M., 341
Harasym, T. O., 361
Harris, A. L., 35
Harvie, P., 361
Hassan, N. M. M., 217
Heinze, G., 465
Hénichart, J.-P., 107
Hiraike, H., 431
Hiraike, O., 431
Hirst, D. G., 569
Houhouli, K., 281
Houssin, R., 107
Hwang, H., 479

Idema, S., 471
Ikuta, K., 235
Ilangovan, R., 67
Inoue, K., 85
Inoue, N., 217
Irimura, T., 289
Ishii, K., 57
Issever, H., 43
Itoh, K., 341
Izumi, T., 85
Izycki, T., 49, 445
 
 
 
 

Jagiello, M., 415
Jain, M., 437
Jo, H., 205
Johnstone, S. A., 361

Kadehci, Z., 43
Kakolyris, S., 281
Kanagaraj, P., 67
Kang, G. H., 205
Kang, S.-B., 205
Kano, Y., 85
Kanska, U., 415
Karamanakos, P., 129
Karami-Tehrani, F., 575
Kashiwazaki, H., 217
Katsaros, D., 395
Kawase, I., 489
Kelland, L. R., 97
Kijima, T., 489
Kim, B. S., 325
Kim, C., 299
Kim, J. W., 205
Kim, M. O., 325
Kim, S. H., 325
Kobayashi, H., 85
Kontos, M., 129
Koukoulitsa, C., 129
Kouso, H., 333
Kucucuk, S., 43
Kumada, H., 57
Kumagai, T., 489
Kumar, S., 437
Kumaraguruparan, R., 167
Kuniyoshi, Y., 333
Kuo, K.-L., 119
Kutner, A., 517

Lamfers, M. L. M., 471
Landini, I., 143
Lant, N., 97
Lapucci, A., 143
Lee, H.-P., 205
Lee, S., 325
Lee, T.-H., 325
Lemonie, A., 107
Leodolter, S., 465
Levchenko, T. S., 351
Li, C.-H., 479
Li, H., 261, 405
Li, H., 405
Li, S., 313
Lin, J.-K., 119
Lind, M. J., 497
Lin-Shiau, S.-Y., 119
Liu, H. C., 273
Lu, L., 395
Luceri, C., 535
Lulli, M., 143
Luzzatto, L., 535
Lyrantzopoulos, N., 281

Maciag, K., 535
Maehara, Y., 333
Magnani, M., 157
Majhi, U., 527
Malone, P. R., 35
Mano, H., 85
Marchisano-Karpman, C., 251
Marcinkowska, E., 27
Marras, C., 245
Martí, G., 55*
Matsumori, Y., 15
Matsumoto, Y., 431
Matsumura, A., 57
Matsuoka, H., 489
Matsuoka, K., 341
Matthaios, D., 281
Mayer, L. D., 361
Mazzei, T., 143
Medina, V., 55*
Messerini, L., 535
Milczarek, M., 517
Millet, R., 107
Miloussis, A., 281
Minaguchi, T., 431
Minami, S., 489
Mine, T., 341
Mini, E., 143, 535
Mitra, A. K., 587
Mittal, B., 437
Miyagi, T., 289
Miyamoto, Y., 431
Mizoguchi, J., 314
Mohamad, N., 55*
Moon, E.-Y., 507
Morganti, M., 143, 535
Mori, K., 85
Moriuchi, T., 217
Morré, D. J., 299, 557
Morré, D. M., 299, 557
Muguruma, H., 235
Murai, T., 217

Nagasaka, K., 431
Nagini, S., 167
Nakagawa, S., 431
Nakataki, E., 15, 235
Napoli, C., 535
Naumnik, W., 49, 445
Nevozhay, D., 415
Nicoll, K., 97
Nikolopoulou, M., 129
Nobili, S., 143, 535
Noguchi, M., 341
Nomura, H., 289
Núñez, M., 55*

Obata, Y., 341
Oda, K., 431
Oda, S., 333
Odgerel, T., 85
Ohara, Y., 57
Ohba, T., 333
Oikawa, M., 57
Öktem, G., 195, 225
Omay, S. B., 195
Opolski, A., 415
Orlando, C., 535
Osaki, T., 489
Osoegawa, A., 333
Ossolinska, M., 49, 445
Ozcelik, H., 43

Palladino, G. P., 375
Panjehpour, M., 575
Papatheodorou, K., 281
Papucci, L., 143
Park, G., 179
Park, N.-H., 205
Park, Y. B., 325
Pascual-Carpe, F., 211
Pelicci, P. G., 157
Peng, D., 261
Penington, D. J., 179
Perna, F., 143
Pitfield, S. E., 179
Pommery, N., 107
Puopolo, M., 395
 

Rajkumar, T., 527
Rath, S. K., 587
Ren, C.-P., 261, 405
Resta, O., 375
Riese II, D. J., 179
Rigault de la Longrais, I. A., 395
Rivera, E., 55*
Robertson, J., 97
Robins, D. J., 97
Rogers, P. M., 97
Ruddock, M. W., 569
Ryan, A. J., 15
Ryoo, Z. Y., 325

Saip, P., 43
Sakai, T., 57
Salerno, F., 375
Salmaggi, A., 245, 453
Sato, T., 57
Saydam, G., 225
Schiavone, N., 143
Schittl, H., 389
Schremmer, M., 465
Schuster, E., 465
Seino, A., 217
Selvaluxmi, G., 527
Selvi, N., 195
Shaida, N., 35
Sharma, M., 587
Shibata, Y., 57
Shin, M. J., 325
Sigurdson, A. J., 383
Singh, N., 587
Smith, L., 497
Sobrero, A., 143
Sone, K., 431
Sone, S., 15, 235
Song, J.-H., 507
Song, Y.-S., 205
Sonke, G. S., 383
Spanevello, A., 375
Strom, S. S., 383
Suekane, S., 341
Superat, K., 27
Susumu, N., 289
Suzen, H. S., 423
Suzuki, A., 289
Suzuki, M., 489
Suzuki, N., 289
Sweeney, A. M., 383
Swidzinska, E., 445

Tachibana, I., 489
Tada, M., 217
Taira, M., 289
Takahashi, Y., 217
Takeda, Y., 489
Takenaka, T., 333
Taketani, Y., 431
Takizawa, S., 431
Tamada, Y., 289
Tan, D., 75
Tang, X., 557
Tani, M., 235
Tardi, P. G., 361
Tempestini, A., 143
Tentes, A., 281
Tigli, H., 43
Tonelli, F., 535
Tong, D., 465
Tong, M. C. F., 273
Tonini, G., 535
Torchilin, V. P., 351
Toti, S., 535
Trafalis, D. T. P., 129
Tsai, Y.-J., 119
Tsaroucha, A., 281
Tsuboi, K., 57
Tsunoda, S., 85
Tsuruga, T., 431
Turanli, M., 423

Ueda, E., 75
Ueda, K., 489
Uehara, H., 235
Uysal, A., 195, 225

Valanzano, R., 535
van der Jagt, M., 471
Vandertop, W. P., 471
van Hasselt, C. A., 273
Vatansever, S., 195
Vidjaya Letchoumy, P., 167
Vijayababu, M. R., 67
Vijayalakshmi, N., 527
Vincente-Ortega, V., 211
Vlantis, A. C., 273

Wainscoat, J. S., 35
Walker, A. M., 75
Wang, A.-X., 313
Wang, J., 313
Wang, L., 261, 405
Wang, L.-C., S., 1
Watanabe, M., 431
Watson, M. B., 497
Wedge, S. R., 15
Wei, M. X., 107
Welham, K. J., 497
Weng, M.-S., 119
Wiedocha, A., 27
Wietrzyk, J., 415, 517
Wiley, A., 395
Witort, E., 143
Wlodarczyk, N., 107
Woon, S.-T., 1
Wu, W., 75
Wurz, G. T., 251

Yagiz, K., 299
Yamada, A., 341
Yamamoto, K., 57
Yamamoto, T., 57
Yamazaki, Y., 217
Yañez-Gascón, J., 211
Yang, K.-H., 507
Yano, S., 15, 235
Yano, T., 431
Yao, K., 261, 405
Yasugi, T., 431
Yavasoglu, A., 225
Yazici, H., 43
Yi, H.-M., 261
Yohena, T., 333
Yokota, J., 235
Yokota, S., 489
Yoshida, K., 341
Yoshida, M., 489
Yoshino, I., 333
Yu, D. H., 325
Yu, H., 395
Yurtseven, M. E., 195

Zeillinger, R., 465
Zhang, 217
Zhang, H.-J., 261, 405
Zhao, M., 261
Zhou, W., 405
Zhu, B., 405
 

*Authors from an erratum for the article published in Volume 15, Number 6, pages 301-311.

Subject Index

Acquired resistance, 489
Acute promyelocytic leukemia, 157
Adenosine, 575
Adenosine receptor(s), 575
Akt signaling, 119
Alternative splicing, 557
American ginseng, 251
Amide, 97
Amphiphilic block copolymer micelles, 313
Angiogenesis, 15
Antagonism, 85
Anticancer, 119
Anticancer therapy, 27
Antimelanoma, 97
Antiobesity, 119
Antioxidants, 167
Antisense, 557
Antisense oligo, 157
Antitumor, 415
Antitumor effect, 389
Antivascular, 1
Apoptosis, 67, 273, 453, 497

B16F10 melanoma, 211
Bak, 273
Bax, 273
BCAT1, 405
Bcl-2, 507
Bcl-2 protein, 67
BCNU, 453
Biomarkers, 497
Black tea, 119
Black tea polyphenols, 167
Boron-10 (10B), 57
Boron neutron capture therapy (BNCT), 57
Brain tumor, 351
BRCA gene mutations, 43
Breast cancer, 129, 179, 195, 251, 465, 497, 587
Breast cancer spheroid, 225
Bronchioloalveolar carcinoma, 489

C57BL/6J, 211
Calcitriol and its analogs, 517
cAMP, 575
Cancer, 299, 415, 557
Cancer vaccine, 341
Capecitabine, 281
Carrier, 27
Case-control studies, 383
Caspase-3, 507
Cell cycle, 453
Cell cycle regulatory proteins, 75
Cell-free DNA, 35
Cell polarity, 431
Cervical cancer, 527
Chemoprevention, 167
Chemotherapy, 49, 195, 445, 497
Chlorambucil, 129
Cisplatin, 85, 479, 497, 517
Clear cell adenocarcinoma, 289
Colon cancer, 107
Colon carcinoma, 143
Colorectal cancer, 361
Colorectal cancer prognosis, 535
Combination chemotherapy, 361
Combined antitumor therapy, 517
Conjugates, 415
Connexin-43, 225
Cyclin D, 75
Cyclin D1, 527
Cyclin D1/p16/Rb pathway, 527
Cyclin-dependent kinases 2 and 4, 75
CYP17 polymorphism, 43
CYP1A1, 437
CYP1A1 polymorphism, 587
Cysteaminylphenol, 97

DDX18, 549
DEAD box, 549
Differentiation, 273
1,25 Dihydroxy vitamin D3, 75
Dimethylbenzanthracene (DMBA), 251
DMBA/TPA, 325
DMXAA, 1
Docetaxel, 225, 281, 517
Docking, 129
Doxorubicin, 225
Drug administration schedule, 143
Drug delivery, 27
Drug resistance, 143
Dysplasia, 217

ECTO-NOX, 299
EGFR, 15
Endometrial cancer, 205, 431
eNOS, 195
ENOX2, 557
Epidermal growth factor receptor, 489
ErbB4, 179
Esophageal cancer, 437
Estramustine phosphate, 341
Estrogen receptor, 129
Estrogens, 383
Exhaled breath condensate, 375 

Farnesyltransferase inhibitors, 107
Fatty acid synthase (FAS), 119
FGF-1, 27
FGFR, 27
Flow cytometry, 129
Floxuridine, 361
Fluoro-deoxyglucose, 471
5-Fluorouracil, 143

Gandolinium-157 (157Gd), 57
Gefitinib, 15, 489
Gemcitabine, 281
Gene delivery, 351
Gene expression, 143, 405, 465, 535
Glioma, 245, 453, 471
Green tea, 119
GSTM1, 423
GSTT1, 423

Hamster buccal pouch carcinogenesis, 167
Head and neck cancer, 423
Hela cell, 507
Helicase, 549
HepG2 cells, 119
Histone deacetylase, 453
hK14 promoter, 325
Homo-aza-steroid alkylating esters, 129
HOX, 217
HPV, 527
HPV16 E6/E7, 325
Hug1-1, 431
Human breast cancer cell lines, 575
Human non-small cell lung cancer cells, 479
Hydroxycamptothecin (HCPT), 313
Hypermethylation, 205

IGFBP-3, 49
IGF-I, 49
IL-2, 375
Ileum, 569
Imatinib mesylate, 517
Immunotherapy, 341
INF-a, 211
INF-g, 1
iNOS, 195
Insulin-like growth factor binding protein-3 (IGFBP-3), 67
Inter- and intracellular distribution, 57
Intracranial, 351
Invasion, 245, 465
Irinotecan, 361
Isobologram, 85
Isoflavene, 299

JNK signaling, 119

Keratinocytes, 325

Lactotransferring, 261
Laryngeal cancer, 273
Laryngeal carcinoma, 273
Leptin, 375
Lethal giant larvae, 431
Leukemia, 415
Lipid peroxidation, 167
Liposome, 351
Liposome delivery, 361
Locked nucleic acid, 157
Loss of heterozygosity (LOH), 261, 333
Low molecular weight heparin (LMWH), 245
Lung cancer, 49, 445
Lung metastasis, 15
Lymph node metastasis, 431
Lymphomyosot, 211

Malignant mesothelioma, 235
Mannan, 415
MAP kinase, 75
Maternal exposure, 383
MDR1, 395
Metastasis, 217, 465
Methotrexate, 415
Methylation, 261
1-Methylnicotinamide, 569
Microarrays, 535
Micro-PIXE, 57
Microsatellite marker, 333
MrDb, 549
MTA1, 465
Multicellular spheroid, 471
Mutation, 261
MYO18B, 235

NADH oxidase, 299, 557
Nasopharyngeal carcinoma, 261, 395
Neoplastic tumor suppressor genes, 431
NF-kB, 1
Nicotinamide, 569
Non-small cell lung cancer (NSCLC), 333, 375
N-oxide nicotinamide, 569
 
 

Occludin, 225
Oncolytic virus, 471
Oolong tea, 119
Oral mucosa, 217
Oral squamous carcinoma, 217
Oral squamous cell carcinoma (OSCC), 313
Orthotopic implantation, 235
Ospemifene, 251
Ovarian cancer, 43, 289, 395

+12p11-p12, 405
p16, 572
p16INK4a, 479
p21, 75
Paclitaxel, 507
Pantothenic acid, 389
Parthenolide, 1
Pathologic parameters, 205
Peritoneal dissemination, 289
Phenoxodiol, 299
Phenylephrine, 569
Phosphorylated prolactin, 75
Plasma membrane-associated sialidase, 289
Pleural effusion, 235
PML/RARa, 157
Poly[g-benzyl-L-glutamate] (PBLG), 313
Poly[ethylene glycol] (PEG), 313
Polymorphism(s), 423, 437
Poorly soluble drugs, 313
Positron emission tomography, 471
Premetrexed, 85
Primary cell cultures, 245
Prognosis, 205, 395
Prolactin, 75
Proliferating cell nuclear antigen, 167
Prostate cancer, 35, 341
Proteomics, 497
Pu-erh tea, 119

Quercetin, 67

Ras, 107
RASSF1A, 205
Rat tail artery, 569
Real-time RT-PCR, 535
Receptor tyrosine kinase, 179
Retinoblastoma protein (pRb), 527
Re-treatment, 489
Risk, 437
Risk factors, 383
RNA interference, 405
RT-PCR, 575

Selective estrogen receptor modulator (SERM), 251
Short-term treatment, 489
Sialidase, 289
Signal transduction, 179
siRNA, 507
Size distribution, 35
Skin cancer, 325
Solid tumors, 281
Soluble VEGF receptor 2(sVEGFR-2), 445
Splenocytes, 1
Synergism, 85
Synergistic action of vitamin B5, 389
Synergy, 361
Systemic circle, 375

Tamoxifen, 251
Target validation, 549
TAT peptide, 351
Testicular neoplasms, 383
Thymosin-beta-4 (TB4), 507
TNF-a, 375
TNM classification, 289
tNOX, 299, 557
Tobacco smoking, 333
Transgenic mice, 325
Treatment, 211
Tryosinase, 97
Tumor cell lines, 143
Tumor necrosis factor (TNF), 1
Tumor suppressor, 179

U-87 MG astrocytoma, 351

Valproic acid, 453
Vascular endothelial growth factor (VEGF), 235
Vascular smooth muscle, 569
VEGF-C, 445
VEGF-D, 445
VEGFR, 15
Vitamin B5, 389
Vitamin D receptor, 75


VOLUME 15

Author Index

Abe, T., 139
Abrial, C., 431
Adams, J., 281
Albanese, C., 113
Alves, P. A. G., 385
Amarantidis, K., 445
Anderson, G. R., 233
Ardizzoni, A., 39
Ather, A., 69

Bae, Y.-S., 327
Baek, K.-H., 161
Baguley, B. C., 291, 351
Barrachina, I., 129
Baumann, R. P., 313
Behnam-Motlagh, P., 423
Belli, C., 169
Bergoc, R., 301
Bergström, P., 423
Berrieman, H. K., 441
Bianchi, N., 373
Biava, P. M., 399
Bizzarri, M., 399
Bloomer, W. D., 219
Boratynski, J., 183
Borgatti, M., 373
Boyd, D. D., 265, 373
Bustuoabad, O. D., 169
Bustuoabad, V. de los A., 169

Cabrespine, A., 431
Cai, Q., 490
Camerano, G. V., 169
Campbell, A., 441 
Campisi, G., 249
Cao, J., 487
Capogreco, M., 249
Carinci, F., 249
Castel, V., 393
Cavenee, W. K., 456
Cawkwell, L., 441
Chang, E. H., 463
Chang, G., 501
Chapuis, J.-C., 11
Chatzaki, E., 445
Che, G.-W., 472
Chen, C.-L., 468
Chen, J., 501
Chen, Kan, 500
Chen, Ke, 476
Chen, L., 469
Chen, M. L., 465
Chen, M., 503
Chen, N., 233
Chen, Q., 492
Chen, S., 472
Chen, X., 490
Chen, Y., 503
Chen, Z., 489
Cheng, S., 460
Cheng, W.-P., 485
Ching, L.-M., 351
Chollet, P., 431
Cocca, C., 301
Cooper, L., 459
Cortes, D., 129
Costa, H., 169
Crescenti, E., 301
Cricco, G., 301
Croci, M., 301
Csömör, S., 215
Cuadrillero, C., 129
Cure, H., 431
Cutts, S. M., 199

Dabrowska, K., 183
da Rocha, A. B., 385
Deaver, M., 49
de Jong, S., 151
Deng, M.-Q., 471
Deng, Y., 481
DePedro, N., 129
De Rosa, G., 249
Dévényi, L., 215
de Vries, E. F. J., 151
di Gianni, P., 169
Ding, J., 461
Ding, W., 489
Ding, Y. Q., 478
Doubek, D. L., 11, 59
Dran, G., 169
Drummond, C. J., 351
Du, W., 503
Du, Y., 493
Du, Z., 468
Ducki, S., 11
Durando, X., 431
Dutt, S. S., 233
Dvorak, H., 455

Edakuni, N., 107
Engers, R., 257

Fabbri, E., 373
Falaschini, S., 249
Fan, L., 501
Fan, T.-P., 462
Fang, L., 501
Farina, A., 249
Favoni, R., 39
Feng, L.-F., 497, 498, 499
Feng, X., 475
Feng, X. L., 478
Feng, X. L., 479
Feng, Y., 486
Ferguson, J., 87
Ferriere, J. P., 431
Finn, P. W., 463
Florl, A. R., 257
Fokt, I., 265
Frati, L., 399
Freedman, R. S., 49
Frosi, A., 399
Fu, J.-K., 472
Fu, L., 486
Fukiki, M., 139

Gallo, M. A., 113
Gambari, R., 69, 373
Gao, L., 497
Gao, P., 333
Gao, R., 475
Gao, S.-Y., 484, 485, 486*
Gao, Y., 477, 481
Georgoulias, V., 445
Getoff, N., 295
Giorgi, G., 69
Girgis, A., 281 
Górski, A., 183
Grankvist, K., 423
Grass, L. B., 385
Grau, E., 393
Grivicich, I., 385
Grossi, F., 39
Guarnera, A., 409
Guo, A., 467
Guo, L., 471
Gutiérrez, A., 301

Han, W. N., 478, 479
Hang, J., 475
Hayashi, S., 365
He, G., 502
He, J., 475
He, Q., 501, 502
He, X., 502
He, Z., 489
He, Z. X., 465
Henriksson, R., 423
Henriques, J. A., 385
Herald, D. L., 11, 59
Hernández, P., 129
Hernández-Martí, M., 393
Hirst, D. G., 81
Hong, M.-H., 471
Hospers, G. A. P., 151
Hou, L., 488
Hu, H., 469
Hu, W., 49
Hu, Y., 502
Huang, B.-H., 477, 481
Huang, W., 496
Huang, W. L., 491
Hubay, M., 215
Hung, M.-C., 456

Ikeda, Y., 189
Inayama, M., 107
Inoue, R., 139
Isturiz, M. A., 169

Jahreis, G. P., 233
Jamaluddin, Md. S., 265
Jeong, S.-J., 161
Ji, C., 4861
Ji, H., 484
Ji, Q., 500
Ji, Y.-B., 484, 485, 486*
Jiang, J.-D., 457
Jiang, M., 472
Jiang, S., 494
Jin, J., 497
Jin, X., 496*
Johansson, A., 423
Johansson, D., 423
Johnston, D. A., 49 
Ju, C., 488

Kakiuchi, S., 107
Kaklamanis, L., 445
Kakolyris, S., 445
Karayiannakis, A., 445
Kavanagh, J. J., 49
Kawai, Y., 189
Kawase, I., 365
Kayser, G. B., 385
Kelland, L. R., 87
Khan, M. T. H., 69
Kieda, C., 351
Kim, C.-M., 161
Kim, Keun Sik, 343
Kim, Kil-Soo, 333
Kim, M.-O., 333
Kim, Soon-Hee, 327
Kim, Sung-Hyun, 333
Kim, Y. H., 327
Kimba, Y., 139
Kimura, S., 1
Kobayashi, H., 139
Kohno, K., 139
Koizumi, M., 1
Kong, Q., 484
Kou, B., 239
Kuroda, J., 1
Kwiatkowski, F., 431

Lambertini, E., 69
Lambris, J. D., 21
Lampronti, I., 69, 373
Laner, T., 257
Lang, L., 486
Laughton, C. A., 95
Lazzaroni, S., 399
Lee, B. W., 327
Lee, C.-W., 161
Lee, H.-T., 333
Lee, S.-R., 333
Lee, T.-H., 333
Leheurteur, M., 431
Lei, X.-Y., 497, 498, 499
Levovich, I., 199
Lewis, J. S., 113
Li, D.-B., 472
Li, Dian-dong, 475
Li, Dongjie, 495
Li, Hong, 478, 479
Li, Hong-wei, 481
Li, Jianfang, 490
Li, Jiyu, 492
Li, Jun, 463, 492, 496
Li, L.-R., 469
Li, N., 495
Li, W., 481
Li, X. F., 465
Li, X.-M., 470
Li, Yan, 491
Li, Yan, 494*, 496
Li, Yin, 472
Li, Yulin, 239
Liang, W.-J., 468, 471
Liang, X., 465
Liao, D.-F., 497, 498, 499
Lin, C., 465
Lin, J., 467
Lin, Z., 465
Liu, Bingya, 490
Liu, Bo, 476
Liu, G. T., 466
Liu, Jianwen, 492
Liu, Jun, 469
Liu, L., 496
Liu, L.-X., 472
Liu, Qiao, 476
Liu, Qi, 493, 494, 495
Liu, Q.-C., 471
Liu, R.-Y., 491
Liu, W., 500
Liu, Xiaorong, 489
Liu, Xiao-yun, 473
Liu, Xinfan, 497
Liu, Xiu-jun, 473
Livraghi, T., 399
Lo Muzio, L., 249
Lombardi, M. G., 169
Loncarek, J., 151
Loprevite, M., 39
Lou, J., 467
Lou, Y.-J., 483, 484
Lu, H., 493, 494, 496
Lu, W., 502
Lu, Y., 476
Lu, Z., 493, 494*, 496*
Luo, B., 477, 481
Luo, P., 502*
Lv, H., 489

Müller, M., 257
Ma, H., 492, 493*, 494, 495*, 496*
Ma, J., 494, 496
Ma, W., 465
Maekawa, T., 1
Mai, H.-Q., 471
Marasco, W. A., 458
Maraveyas, A., 441
Marshall, E., 291
Martín, G., 301
Martínez, F., 393
McKeon, F., 161
Medina, V., 301
Meijer, C., 151
Meiss, R. P., 169
Meloni, F., 399
Meng, K., 492, 493, 494*, 496*
Meng, P., 482
Meng, Y., 59
Mesnil, M., 151
Miao, Q., 474
Micheli, A., 445
Milasi, A., 409
Min, H.-Q., 471
Missailidis, S., 95
Modi, C., 95
Mohamad, N., 301
Mouret-Reynier, M. A., 431 
Mu, X., 475
Muguruma, H., 107
Mulder, N. H., 151

Núñez, M., 301
Nair, R. R., 265
Nakataki, E., 107, 365
Narviatz, M., 169
Nevozhay, D., 183
Nie, Q., 472
Nishikubo, N., 107
Niu, J., 467
Nogawa, M., 1
Nudelman, A., 199

Ohno, O., 189
Ohtsuka, S., 107
O'Kane, S. L., 441
Oltra, S., 393
Opolski, A., 183
Orellana, C., 393
Ouyang, Z., 473, 474

Pan, D.-X., 470
Pan, Q., 469
Pandolfi, A., 39
Papadopoulou, M. V., 219
Pappas, I. S., 21
Park, B.-J., 333
Park, H., 333
Park, J.-W., 161
Park, K. H., 327
Park, Y. S., 343
Patai, K., 215
Pedone, C., 373
Peláez, F., 129
Penault-Llorca, F., 431
Penketh, P. G., 313
Penolazzi, L., 69
Pestell, R. G., 113
Petrelli, N. J., 233
Pettit, G. R., 11, 59
Pettit, R. K., 59
Pezzetti, F., 249
Phillips, D. R., 199
Pillay, V., 199
Piva, R., 69
Priebe, W., 265

Qian, X., 476
Qin, H.-D., 471
Qu, Y., 490
Quan, Z., 492

Raghavakaimal, S., 457
Ran, Y., 469
Rayburn, E., 475
Reddy, C. B., 351
Regner, A., 385
Renis, M., 409
Rephaeli, A., 199
Robins, D. J., 87
Rodriguez-Bigas, M. A., 233
Rogers, P. M., 87
Romanelli, A., 373
Rosenzweig, H. S., 219
Royo, I., 129
Rubini, C., 249
Ruddock, M. W., 81
Ruggiero, R. A., 169
Ryoo, Z.-Y., 333

Sakurai, K., 189
Sartorelli, A. C., 313
Sato, K., 1
Saviano, M., 373
Schere-Levy, C., 169
Schmidt, J. M., 11
Schooltink, M. A., 351
Schulz, W. A., 257
Schwartsmann, G., 385
Scifo, C., 409
Scolaro, T., 39
Segawa, H., 1
Semino, C., 39
Sen, S., 49
Seow, H. A., 313
Shang, B., 474
Shao, K., 475
Shao, R.-G., 456
Shi, Q., 492, 493*, 494*, 495*, 496*
Shi, S., 475
Shi, Yi-kang, 475
Shi, Yingai, 239
Shi, Z., 494
Shima, Y., 189
Shin, H.-J., 161
Shu, G., 468
Shyam, K., 313
Sibbritt, D., 281
Sies, H., 462
Sinatra, F., 409
Sluiter, W. J., 151
Smith, L., 441
Sone, S., 107, 365
Song, X., 476
Spathari, N., 445
Spencer, D. M. S., 199
Stevens, A. M., 59
Stevens, M. F. G., 95
Stoler, D. L., 233
Suh, J.-G., 333
Sun, G., 493, 495*, 496
Sun, H., 466
Sun, L., 469
Sun, S.-H., 481
Switala-Jelen, K., 183
Szczaurska, K., 183

Tachibana, I., 365
Tang, S.-S., 497, 499
Thomas, T., 113
Thomas, T. J., 113
Tian, F.-Z., 491
Tiseo, M., 39
Tomimoto, H., 107
Tormo, J. R., 129
Trapani, V., 95
Trichas, M., 445
Tsiftsoglou, A. S., 21
Tu, Y., 498

Umezawa, K., 189

Vaalburg, W., 151
van Dillen, I. J., 151
van Rooijen, N., 169
Verschraegen, C. F., 49
Vijayanathan, V., 113
Vizirianakis, I. S., 21

Wan, D.-S., 469
Wang, D., 465
Wang, Heng, 265
Wang, Hui, 475
Wang, L., 479
Wang, L., 487, 488*
Wang, N., 495
Wang, Q. W., 465
Wang, S., 479
Wang, Wei, 475
Wang, Wen, 467
Wang, Xiao-ying, 500
Wang, Xi-cai, 503
Wang, Xinrui, 239
Wang, X.-F., 477
Wang, Yi-jun, 468
Wang, Yu-feng, 475
Wang, Yun, 477
Wang, Yunwei, 490
Wang, Yan, 496
Wang, Z., 503
Watanabe, K., 189
We, C., 468
Weinstein, I. B., 460
Wen, J., 467
Wietrzyk, J., 183
Winters, M. S., 21
Woon, S.-T., 351
Wu, B., 494, 495
Wu, J., 501
Wu, J. L., 139
Wu, L., 467
Wu, S., 239
Wu, Y.-D., 483, 484
Wu, Z., 503

Xia, J., 239
Xiang, Y.-Q., 471
Xiong, W., 465
Xu, G., 497
Xu, S.-F., 486
Xu, Y., 503

Yan, C., 498
Yang, Bao-feng, 484
Yang, Bo, 501, 502*
Yang, H., 481
Yang, M., 465
Yang, S., 467
Yang, W., 497
Yang, Xiaochun, 502
Yang, Xiao-feng, 500
Yang, Xing, 469
Yang, Xuyu, 479
Yang, Zhi-hong, 488
Yang, Zhihua, 469
Yano, S., 107, 365
Yao, D., 473
Yao, K., 478, 479
Yao, Y.-L., 468
Ye, L., 467
Yin, D., 481
Yin, F., 481
Yokota, A., 1
Yoon, S.-H., 327
Youm, C.-A., 333
Yu, Lei, 486
Yu, Long, 469
Yu, Y., 489
Yuan, Q., 468
Yuan, S., 501
Yuan, Z., 497
Yuasa, T., 1
Yue, W., 487, 488
Yue, W., 488

Zafra-Polo, M. C., 129
Zelkó, R., 215
Zeng, J., 468
Zeng, Y.-X., 471
Zhan, Q., 455
Zhang, B., 486
Zhang, C., 475
Zhang, F., 487, 488
Zhang, H. J., 478
Zhang, Helong, 365
Zhang, Hongying, 494, 496
Zhang, J., 493
Zhang, Sen, 475
Zhang, Shu-ping, 468
Zhang, Shuren, 465
Zhang, Wei, 457
Zhang, Wenjian, 467
Zhang, W.-D., 468
Zhang, X., 488
Zhang, X.-J., 484
Zhang, X.-S., 471
Zhang, Yuan-yuan, 486
Zhang, Yan, 492
Zhangh, Y., 465
Zhao, C., 475
Zhao, P., 477, 481
Zhao, Q., 476
Zhao, Xilu, 469
Zhao, Xinhua, 476
Zhe, B.-Y., 497, 499
Zhen, Y., 458, 472, 473*, 474*, 475*
Zheng, R., 365
Zheng, S., 482
Zheng, X., 500
Zhong, M., 497, 498, 499
Zhou, C., 465
Zhou, H., 496
Zhou, Min, 489
Zhou, Ming, 487, 488
Zhou, Q., 467, 472
Zhou, W., 478, 479
Zhou, X., 492. 493*, 494*, 495, 496*
Zhou, Z., 493, 496
Zhu, Wei, 481
Zhu, Wen, 472
Zhu, Z., 490
Zue, G., 491
 

*Indicates the author appears in more than one abstract on that page.

Subject Index

Acquired resistance, 107
Adenocarcinoma, 215
Adenylate cyclase toxin, 423
Administration routes, 183
Adriamycin, 199
Aegle marmelos, 69
Agelastatin A, 11
AGT, 313
Alveolar hemorrhage, 107
Amide, 87
AN9, 199
Anastrozole, 431
Aneuploidy, 49
Angiogenesis, 139, 239
Angiostatin, 343
Annonaceous acetogenins, 129
Antiangiogenesis, 343
Anticancer, 11
Anticancer activities, 59
Anticancer activity, 183
Anticancer drug, 327
Antimelanoma, 87
Antimicrobial activities, 59
Antitumor, 351
Apoptosis, 327, 385, 423, 441
Apoptotic cell death, 161
Artery, 81
ATF-2, 113

Bacteriophage HPA1, 183
Bacteriophage T4, 183
bcl-2, 249
Biological response modifiers, 399
Bioreductive drugs, 219
Bisphosphonate, 1
Breast cancer, 69, 431
5-Bromo-2´-deoxy-uridine (BrdU), 333
Bystander effect, 151

Cancer, 249, 281
Capparidaceae, 59
Carbamoylation, 313
Caspase-mediated cleavage, 161
Caspases, 385
CD9, 365
Cell cycle, 409
Cell cycle length, 291
Cell lines, 39
Centrosomal kinase, 49
Chloroethylation, 313
CI-994, 39
Circular dichroism, 95
Cisplatin, 423
CloretazineTM, 313
Colon cancer cells, 385
Colorectal cancer, 445 
Combined therapy, 39
Complementary and alternative therapies, 281
COX-2, 139
Cox analysis, 249
CPT-11/5-FU combination, 385
Cyclin D1, 113
Cysteaminylphenol, 87
Cytotoxic activity, 129
Cytotoxicity, 423

Deacetylase inhibitors, 39
Decoy, 69
DHMEQ, 189
Diabetes, 301
Differentiation, 21
Differentiation factors, 399
Dimethylbenzanthracene (DMBA), 333
DMXAA, 351
DNA adducts, 199
DNA binding, 95
DNA methylation, 257
DU145, 409
 

 

Emblica officinalis, 69
Embryo, 399
Endostatin, 343
Endothelial, 351
Energy dispersive X-ray spectroscopy, 215
Enzyme inhibitor, 327
E-selectin, 189
Estradiol, 113
Estrogen receptor a, 69
Euchrestaflavanone B, 327
Exemestane, 431
Extracellular superoxide dismutase (EC-SOD), 333

Flavones, 59
Fluorescence, 95
Folic acid (vitamin B11), 295
Formaldehyde, 199
Ganciclovir, 151
Gap junctional intercellular communication, 151
Gastric cancer, 441
Gene expression, 265
Gene silencing, 257
Gene therapy, 239, 373
Gene transcription, 373
Genomic instability, 233
Geranylgeranylation, 1
Gifitinib, 107
Glibenclamide, 301
Gynandropis gynandra, 59

Head and neck, 249
Hepatocellular carcinoma, 399
Herpes simplex virus thymidine kinase, 151
HIF-1H, 139
Human prostate cancer, 409
Human RD/TE-671 cells, 21
HUVEC, 189
Hydrodynamics-based transfection, 343
Hymenidin, 11
8-Hydroxy-2´-deoxyguanosine (8OH-dG), 333
Hypoxia, 139

ICAM-1, 189
Ileum, 81
Immunoblotting, 409
Immunohistochemistry, 441, 445
Inducer binding protein, 21
Inducers, 21
Inflammation, 169
Instability events, 233
Interaction, 219
Inter-(simple sequence repeat) PCR, 233
Intramolecular electron transfer, 295
Invasion, 365

Kinetics of FA, FNA, and MTX, 295

Letrozole, 431
Lisofylline, 81
Liver metastasis, 365
Lung cancer, 39, 107
Lupeol, 69
Lymphoid, 351

Malignant ascites, 365
Mammary tumors, 301
Marine sponge, 11
MCF-7 cells, 113
Medicinal plants, 69
Mesothelioma, 423
Mitochondrial complex I, 129
Mitochondrial membrane potential, 385
Mitotic checkpoint proteins, 161
Multidrug resistance, 151
Murine erythroleukemia (MEL) cells, 21
Myoma, 215

Negative feedback oscillation, 291
Neuroblastoma development, 393
NF-kB, 139, 189, 351
N-Nitroso-N-methylurea, 301

Ovarian neoplasm, 49
Overall survival, 431

p53, 151
Patients, 281
Pentoxifylline, 81
Peptide nucleic acids (PNA), 373
Phenylephrine, 81
Phosphor/sulphur ratio, 215
PNA-DNA chimeras, 373
Polyamines, 113
Polycyclic acridine derivatives, 95
Polyploidy, 161
Preclinical investigation, 39
Probability mechanism, 291
Proliferation, 365
Propolis, 409
Prostate cancer, 1
Prostate carcinoma, 257
Protein kinase CKII, 327
Pulse radiolysis of folic acid, 295

Ras, 1
Rats, 301
Resistance, 199
Resveratrol, 409
Retreatment, 107
Retrotransposon, 257
Retroviral vector, 239

SDHB gene, 393
Small-cell lung cancer, 423
Smooth muscle, 81
Soluble receptor, 239
Sp1, 265, 373
Spectrophotometric analysis, 95
Stem cells, 399
STK15/Aurora-A/BTAK, 49
Stomach, 441
Streptozotocin, 301
Strong DNA intercalators, 219
Structure-activity relationships, 129
Succinate dehydrogenase, 393
Sulfonylhydrazine prodrugs, 313
Survival, 249

Tamoxifen, 431
12-O-Tetradecanoylphorbol-13-acetate (TPA), 333
Thermal denaturation, 95
Topoisomerase II, 199
Topoisomerases, 219
Transcription, 265
Transcription factor decoy, 373
Transgenic mice, 333
Transmission electron microscopy, 409
Triplex DNA, 95
Tumor aggressiveness, 169
Tumor growth, 239
Tumor markers, 257
Tumor transition zone, 169
Tyrosinase, 87

Urokinase-type plasminogen activator receptor (uPAR), 265, 373
Utilization, 281
UV, 95

Vascular endothelial growth factor (VEGF), 139, 239, 445
Vascularization, 169
VCAM-1, 198

X-chromosome inactivation, 257

Zoledronic acid, 1

VOLUME 14

Author Index

Aggelakis, F., 439
Agnanti, N. J., 439
Akiyama, S., 39
Alvero, A. B., 567
Antony, V. B., 155
Aoki, S., 39
Arlucea, J., 363
Asumendi, A., 363

Bäckström, T., 321
Baba, M., 39
Baguley, B. C., 75, 297
Bailly, C., 235
Baker, A. F., 513
Balzarotti, M., 325
Bastert, G., 603
Bertino, J. R., 373
Bharathy, S., 61
Bisikirska, B., 133
Bloomer, W. D., 21
Boiardi, A., 325
Bologna, M., 101
Bordonaro, M., 427
Borowski, E., 469
Bossemeyer, D., 267
Bowman, E. D., 315
Boyano, M. D., 363
Bravo-Otero, E., 315
Breitenlechner, C., 267
Brown, L. M., 315
Butler, S. A., 93

Calatozzolo, C., 325
Cañete, A., 291
Capasso, F., 415
Carbone, R., 427
Cardile, V., 415
Castel, V., 291
Catanzaro, R. P., 133
Cavallaro, E., 579
Cecchi, F., 501
Chakraborty, A. K., 163
Chen, L., 355
Chen, W., 567
Ching, L.-M., 75
Cho, H. Y., 491
Choe, Y. H., 455
Choi, M. M., 227
Christensen, I. J., 611
Chung, F., 75
Chung, K. H., 227
Ciusani, E., 325
Cole, P., 373
Conney, A. H., 387
Conover, C. D., 455
Consoli, R., 415
Coon, A., 513
Cortes, D., 147
Coutts, R., 297
Croci, D., 325
Cuevas, C., 579
Cusano, G., 345
Cutts, S. M., 279

Damia, G., 579
Dardoufas, K., 439
Dassonneville, L., 235
Davilas, E., 439
Delipetar-Grudl, A., 559
de Rossi, T. M., 603
Diehl, S. R., 315
Di Francesco, A. M., 579
D'Incalci, M., 579
Ding, Y., 355
Di Silvio, A., 579
Dondi, D., 101
Duhé, R. J., 175
Dunne, A. L., 447
Dwipoyono, B., 567

Ehrsson, H., 113
Eichbaum, M. H. R., 603
Engh, R., 267
Erba, E., 579
Espreafico, E. M., 163

Faircloth, G. T., 579
Fenaux, P., 235
Ferlini, C., 345
Ferlini, C., 83
Fernández, J. M., 291
Ferrandina,G., 83
Ferrante, Jr., A. W., 133
Festuccia, C., 101
Finch, R. A., 331
Franchina, M., 399
French, K. J., 49
Fu, L., 355
Fuente-Pinedo, M. de la, 363
Furneaux, C. E., 297
Furukawa, T., 39

Gaßel, M., 267
Gallardo, T., 147
Gard, J. M., 513
Garg, M., 567
George, B. L., 513
Getoff, N., 559
Gilmore, J. L., 589
Gorlick, R., 373
Grau, E., 291
Greenwald, R. B., 455
Gridley, G., 315
Gu, B., 373
Gu, L.-Q., 355
Guan, S., 455
Guerini, V., 101
Gullbo, J., 113
 
 

Ha, W. S., 491
Haffty, B. G., 61
Hage, C., 155
Hao, X.-Y., 567
Haraguchi, M., 39
Hardwick, J., 155
Harris, A. L., 529
Harris, P. E., 133
Hayes, R. B., 315
Heider, I., 475
Hellberg, D., 321
Henklein, P., 475
Hernández, P., 147
Hesdorffer, C. S., 133
Hirata, K., 407
Hirst, D. G., 447, 483
Hou, L., 315
Huang, M.-T., 387
Huyghe, P., 235

Ihle, N., 513
Iles, R. K., 93
Inoue, Y., 407
Isaacs, R. J., 297
Itoh, H., 407
Ivery, M. T. G., 1
Izotova, L., 541

Jang, J. S., 491
Jangi, S.-M., 363
Ji, M., 21
Johnson, D. R., 331
Johnson, L. K., 331
Jose, C. C., 297

Kalb, E. N., 305
Kamsteeg, M., 567
Karabulut, B., 381
Karydas, I., 439
Katsuki, T., 407
Kaufmann, R., 475
Kaul, S., 603
Kay, P. H., 399
Kerrigan, J. E., 541
Kestell, P., 75
Kim, D., 61
Kim, D. S., 227
Kim, H. S., 227
Kim, H. W., 491
Kim, K. S., 227
Kim, S. I., 227
Kirker, J. A., 297
Kirkpatrick, L., 513
Kizoulis, M., 387
Kobayashi, M., 39
Koeffler, H. P., 345
Kohno, K., 407
Kolesnikova, N., 163
Kolipanos, A., 439
Kumar, R., 247

Larsson, R., 113
Lavoie, T. B., 541
Lazarova, D. L., 427
Lazo, J. S., 305
Le, T., 1
Lee, B. D., 49
Lee, Y. J., 491
Leffert, J. J., 331
Lewensohn, R., 113
Li, W., 373
Liang, Y., 355
Lin, C. B., 387
Lin, Z. P., 331
Lindström, A. K., 321
Longley, C. B., 455
Lown, J. W., 247
Lowndes, S. A., 529
Luthman, K., 113
Lykke, J., 611

Maffei, A., 133
Mahadevan, D., 513
Mamoon, N. M., 175
Man, H.-W., 75
Mantovani, R., 579
Marshall, E. S., 297
Martin, D. S., 373
Martínez, F., 291
Mastrangelo, R., 345
Matthews, J. H. L., 297
McKiernan, J. M., 133
Meuillet, E. J., 513
Minagawa, N., 407
Mitsuo, M., 39
Mizobuchi, H., 373
Mohammed, K. A., 155
Mor, G., 567
Morales, M. C., 363
Mori, M., 31
Morosetti, R., 345
Morton, R. P., 297
Moschella, F., 133
Mothersill, C., 447
Motta, M., 101
Muller, G. W., 75
Muramatsu, T., 331

Nagata, N., 407
Nagata, Y., 39
Nakajima, Y., 39
Nakayama, Y., 407
Nasioulas, G., 439
Nasreen, N., 155
Nielsen, H. J., 611
Nieto, N., 363
Noguchi, T., 39
Nudelman, A., 279
Nygren, P., 113
 

 

Ohie, S., 407
Okamura, S., 31
Oktem, G., 381
Oltra, S., 291
O'Malley, D., 567
Omay, S. B., 381
Onitsuka, K., 407
Orellana, C., 291
Oshimoto, H., 31
Oswald, E., 475

Pacini, S., 501
Paine, M. J. I., 469
Palmer, B. D., 75
Papadapoulos, K. P., 133
Papadopoulou, E., 439
Papadopoulou, M. V., 21
Park, Y. S., 227
Parker, B. S., 279
Pawlowska, J., 469
Pawelek, J., 163
Peláez, F., 147
Perez-Yarza, G., 363
Peronni, K. C., 163
Peruzzi, B., 501
Pestka, S., 541
Phillips, D. R., 279
Pini, J. T., 399
Pizzorno, G., 331
Poletti, A., 101
Powis, G., 513
Priebe, W., 469

Rai, D., 247
Ramirez-Icaza, C., 155
Ranelletti, F. O., 83
Rao, M. K., 21
Raspaglio, G., 83
Reiss, M., 61
Ren, X.-Q., 39
Renis, M., 415
Rephaeli, A., 279
Riccardi, R., 579
Rice, M. L., 297
Riese, II, D. J., 589
Rimm, D. L., 61
Robson, T., 447
Royo, I., 147
Ruan, J., 355
Ruddock, M. W., 483
Ruggiero, M., 501
Russo, A., 415
Rutherford, T., 567

Sako, T., 407
Salmaggi, A., 325
Sanders, K., 155
Sanli, U. A., 381
Sapi, E., 567
Sartorelli, A. C., 331, 427
Sawczuk, I. S., 133
Scaccianoce, E., 101
Scambia, G., 83, 345
Scheele, J., 475
Schulze, B., 475
Schwartz, B., 541
Scifo, C., 415
Seiberg, M., 387
Selvi, N., 381
Servidei, T., 345
Sezgin, C., 381
Shapiro, S., 387
Shaw, J. H. F., 297
Shi, Z., 355
Shibao, K., 407
Shields, P. G., 315
Smith, C. D., 49
Smith, J. K., 175
Sotiriou, V., 439
Sousa, J. F., 163
Sriram, P. S., 155
Staite, E. M., 93
Stamper, C., 513
Stendahl, U., 321
Su, D., 373
Sumizawa, T., 39
Svendsen, M. N., 611

Tarasiuk, J., 469
Taylor, J. M. E., 399
Tormo, J. R., 147
Tsurudome, Y., 407
Tullberg, M., 113

Uslu, R., 381

Våbenø, J., 113
Vancheri, C., 415
Vanella, A., 415
Van Horn, R. D., 155
Vannucchi, S., 501
Vogt, A., 305

Wang, X., 355
Werther, K., 611
White, J. B., 297
Whittaker, J. R., 297
Williams, R., 513
Wilson, G. D., 447
Winn, D. M., 315
Wolf, C. R., 469
Wu, W., 541
Wu, X.-P., 355

Xia, J., 455
Xie, H., 315
Xie, J.-G., 387
Xie, W., 61

Yadav, P., 541
Yoshida, M., 31
Yurtseven, M. E., 381

Zafra-Polo, M. C., 147
Zhao, H., 455
Zhao, Q., 455
Zhuang, Y., 49

Subject Index

Acetogenins, 147
Adenocarcinoma, 321
Adhesion molecules, 603
Agosterol A (AG-A), 39
Akt, 513
L-Alanosine, 373
Alkylating peptides, 113
AN-9, 279
Androgen receptor, 101
Angiogenesis, 155, 501, 529
Antagonist, 589
Antiangiogenesis, 227
Antiangiogenic therapy, 529
Anticancer agents, 305
Anticancer treatment, 93
Antitumor activity, 513
Apoptosis, 83, 235, 297, 345, 363, 447
Autoantigens, 133

Bcl-2, 235
Benzyl elimination, 455
Biomarker, 491
Bioreductive drug, 21
Butyrate, 427

Cancer, 147, 267
Cancer chemoprevention, 387
Carcinoembryonic antigen (CEA), 439
Carcinoma, 315
Cationic liposomes, 227
cDNA microarray, 133
Cehmosensitizer, 567
Cell cycle, 235, 345, 579
Cell lines, 113
Cervix neoplasms, 321
Chelation, 529
Chemotherapy, 567
Cimetidine, 363
Cis-platinum, 325
c-Met proto-oncogene, 163
Colon 38, 75
Colon cancer, 407, 427, 447
Colon carcinoma, 475
Colorectal cancer, 31
Copper, 529
Crystal structure, 267
Cystine knot growth factor, 93
Cytostatic efficiency, 559
Cytotoxic potency, 247
Cytotoxicity, 113, 147, 305, 381

Daunorubicin, 469
Decitabine, 279
D-3-Deoxy-phosphatidyl-myo-inositol ether lipid, 513
Diphenhydramine, 363
Disintegrin, 227
DMXAA, 75
DNA adducts, 279
DNA methylation, 279
DNA quantification, 439
Docetaxel, 381, 447
Doxorubicin, 325, 355, 381
Drug binding site, 39
Drug sensitivity, 373
DU145, 415
DU145 cells, 101

Enantiomers, 75
Endostatin, 155
Enzymatic reduction, 21
Enzymes, 315
Epidermal growth factor, 83
ErbB3, 589
ErbB4, 589
E-selectin, 603
ET-743 analog, 579

Folic acid (vitamin B11), 559
Free hCGb, 93
 
 
 
 

 

G2/M block, 447
Gene therapy, 227, 427
Genomic hypomethylation, 399
Glioma, 325
Glutathione-S-transferase P1 (GSTP1), 439
Glycosaminoglycans, 501

Head and neck cancer, 61
Heparin, 501
High-content screening, 305
Histamine antagonist, 363
Human plasma, 501
Human prostate cancer, 415
Human tumors, 297
Hybrid, 163
Hydroxyurea, 235
Hypermethylation, 399
Hypoxic cytotoxin, 21

Imidazole, 355
Inducible nitric oxide synthase (iNOS), 381
Inhibition of growth, 345
Inhibitor selectivity, 267
Interphase cell death, 297

J1, 113

Lithium, 427
Liver metastases, 603
Locoregional, 325

Malignant lymphoproliferative disorders, 399
MCF-7, 381
Melanocyte-stimulating hormone (MSH), 163
Melphalan, 113
6-Mercaptopurine, 455
Metastasis, 155, 163
Metastatic breast cancer, 603
Methylmercaptopurine riboside (MMPR), 373
Methylthioadenosine phosphorylase (MTAP), 373
Micrometastasis, 291
Microtubules, 1
Minimal residual disease, 291
Mitochondrial respiratory chain inhibitors, 147
Mitochondrion, 363
Mitogen-activated protein kinases, 83
Mitoxantrone, 279
Molecular marker, 291
Molecular modeling, 1, 541
Molecularly targeted PTKI therapy, 175
Motility, 163
Mouse solid tumor model, 49
Mrp1, 331
Multidrug resistance, 49, 331, 355
Mutagenesis, 267
Myf-3, 399
Myosin light chain kinase, 483
Myosin light chains, 483

NADH dehydrogenase, 469
NADPH cytochrome P450 reductase, 469
NAD(P)H oxidation, 469
Neuregulin, 589
Neuroblastoma, 345
Neutrophils, 611
Nicotinamide, 483
Nitric oxide, 381
NLCQ-1, 21
Nondenatured soymilk, 387
Nucleotide excision repair, 579

Ovarian cancer, 155, 567
 

P2, 113
p53, 235
Paclitaxel, 1, 297
PAR1, 475
Parenteral administration, 455
PAX7, 399
Peptichemio, 113
Peptides, 501
P-Glycoprotein (P-gp), 39, 49, 331, 355
Pharmacodynamics, 513
Phenotype, 345
Phenoxodiol, 567
Phosphate stability, 541
Phosphokinase recognition sites, 541
Phospholipase D (PLD), 31
Phospholipase D2 (PLD2), 31
Phosphorylated antibodies, 541
Photoaffinity labeling, 39
Pleural mesothelial cells, 155
Poly(ethylene glycol), 455
Polymorphism, 315
Poor prognosis, 93
Propolis, 415
Prostaglandin J2, 345
Prostate cancer, 101
Prostate-specific membrane antigen (PSMA), 439
Proteinase-activated receptors, 475
Protein kinase C, 475
Protein kinase C inhibitor, 267
Protein-tyrosine kinase inhibitors (PTKIs), 175
Proteolysis, 501
Proteome, 491
PX-316, 513

Quercetin, 83

Radiolysis, 559
Radiophosphate-labeled antibody, 541
Radiosensitivity, 297
Radiosensitization, 447
Radio therapeutic, 541
Reactive oxygen species formation, 469
Rectal cancer, 611
Resveratrol, 415
Rho-kinase inhibitor, 267
Rosiglitazone, 345
RT-PCR, 291

Salmosin, 227
Serine protease inhibitors, 387
Smad, 61
Smoking, 315
Soft tissue sarcoma cells, 373
Squamous cell carcinoma, 321
Stomach cancer, 491
Structure of interaction, 1
Sugar-modified derivatives, 469
Surrogate kinase, 267

TAC-101, 407
Tamoxifen, 83
Targeted cancer therapy, 175
Tcf, 427
Temozolomide, 325
Thalidomide, 75
Tissue microarray, 61
Topical application, 387
Topotecan, 325
Transforming growth factor-b, 61
L-Tryptophan, 247
L-Tryptophan dimmers, 247
L-Tryptophan-polyamide conjugates, 247
b-Tubulin, 1
Tumor antigens, 133
Tumor cell line growth inhibitors, 147
Tumor markers, 603
Tumor necrosis factor, 75
Tumor radiosensitizer, 483
Tumor vessels, 611

Vaccine development, 93
Vaccines, 133
Vascular endothelial growth factor (VEGF), 407, 611
Vascular endothelial growth factor receptor 1, 611
Vascular smooth muscle, 483
Vincristine, 355
Vincristine toxicity, 331
Vinorelbine, 415

Wnt, 427

Xanthine oxidase, 469
X-linked inhibitor of apoptosis protein (XIAP), 567

VOLUME 13

Author Index

Akçay, T., 205
Alademir, Z., 205
Alama, A., 455
Andres, M. L., 9
Antony, V. B., 71, 79
Arboscello, E., 55
Arimondo, P. B., 537
Astre, C., 211
Aterini, S., 19

Baguley, B. C., 95
Balabhadrapathruni, S., 123
Bando, Y., 289
Barbieri, F., 455
Barsotti, B. P., 55
Bernard-Poenaru, O., 137
Berthois, Y., 137
Bianchi, N., 279
Biedler, J. L., 87
Billson, F. A., 103
Bloomer, W. D., 47, 561
Bobrowska-Hägerstrand, M., 463
Bogliolo, G., 55
Bonner, E., 551
Borgatti, M., 279
Borowski, E., 245
Botta, M., 55
Boucaud, M., 211
Bouizar, Z., 137
Braca, III, J. A., 87
Breda, L., 279
Bressolle, F., 211
Bruzzo, C., 455
Bustuoabad, O. D., 147

Cataisson, C., 137
Chan, P. K. S., 161
Chang, C.-C., 353
Chang, R. L., 169
Chen, C.-T., 199
Chen, G. C., 161
Chevassut, T., 373
Ching, L.-M., 95
Cho, Y. M., 137
Chun, K.-S., 37
Claret, F.-X., 399
Clarke, A. R., 333
Conney, A. H., 61, 169
Conway, R. M., 103
Cortes, D., 521
Costes, N., 191
Cros, M., 137
Cross, H. S., 551
Cui, X. X., 169
Culine, S., 211
Cutts, S. M., 479

Dabelsteen, S., 393
D'Agnano, I., 25
de Bruijin, M., 315
Deng, H.-K., 359
Denne, M., 137
Denny, W. A., 491
DePedro, N., 521
De Vernejoul, M.-C., 137
Diamandis, E. P., 381
Díaz, G. S., 147
di Gianni, P. D., 147
Dinçer, Y., 205
Dufat, H., 191
Dupont, F., 437
Dziadyk, J. M., 113
Dzierzak, E., 315

El-Gewely, M. R., 429
Ellis, M. J., 175
Elomri, A., 191
Estornell, E., 521

Fan, W., 113
Fang, Y., 113
Feliciano, C., 405
Ferguson, J., 503
Ferguson, L. R., 491
Foley, J., 137
Folkers, G., 513
Fortunel, N. O., 445
Franco, M., 147
Fraser, J. D., 95

Gallo, M. A., 123
Gambari, R., 279
Gancberg, D., 437
Gartel, A. L., 405
Geromichalos, G., 261
Gigis, P., 261
Gogusoy, G., 205
Gomeni, R., 211
Graulet, A.-M., 137
Gray, P. J., 479
Gridley, D. S., 9
Grion, L. C., 147
Guillaumel, J., 537
Gulisano, F., 19
Gulisano, M., 19
Gurdon, J. B., 301

Hägerstrand, H., 463
Halaban, R., 3
Hardwick, J., 71, 79
Hatzfeld, A., 445
Hatzfeld, J. A., 445
Hein, A. M., 87
Hockl, P., 147
Horth, M., 437
Huang, B.-R., 471
Huang, S.-T., 199
Huang, Y., 113
Humeniuk, R., 269

Ishiguro, K., 235

Ji, M., 47, 561

Kaczmarek, ?, 269
Kajioka, E. H., 9
Kállay, E., 551
Kanematsu, T., 289
Kang, M., 37
Karim, A., 437
Kathuria, H., 71
Kelland, L. R., 503
Kimura, K., 479
King, N. J. C., 103
Klein, C. D. P., 513
Koch, M., 191
Komatsu, F., 235
Kordon, E. C., 147
Kotaka, M., 161
Kraus, M., 359
Kumar, R., 221
Kuo, H.-S., 199

Laccetti, P., 25
Lai, P. B. S., 161
Lampronti, I., 279
Lau, W. Y., 161
Laughton, C. A., 175
Lazo, J. S., 347
Lee, J., 37
Lee, K.-H., 471
Léonce, S., 191
Léonce, S., 537
Lerza, R., 55
Leung, T. W. T., 161
Li, A. K. C., 161
Li, X., 323
Li, X.-H., 61
Lim, B., 323, 373
Lin, C.-M., 199
Lin, Y., 61
Lin, Y.-L., 199
Liu, H.-Y., 359
Liu, L.-Q., 359
Loghmani, F., 71
Lombardi, M. G., 147
Lou, Y.-R., 61
Lown, J. W., 221
Lu, Y.-P., 61

Ma, X., 315
Madigan, M. C., 103
Mansouri, A., 399
Marcinkowska, E., 269
Meiss, R. P., 147
Michalak, K., 463
Michel, S., 191
Miller, G. M., 9
Mischiati, C., 279
Missailidis, S., 175
Modi, C., 175
Mohammed, K. A., 71, 79
Molnár, J., 463
Monier, M.-N., 445
Monneret, C., 537
Motohashi, N., 463
Mrówczynski, L., 463

Nasreen, N., 71, 79
Nastruzzi, C., 279
Natsis, K., 261
Norris, J. S., 113
Nosetto, S. H., 147
Novelli, F., 455

Olsen, J., 393
Önen, S., 205
Ottersbach, K., 315

Pacini, S., 19
Paine, M. J. I., 245
Palmer, B. D., 95
Pampalakis, G., 381
Pannacciulli, I., 55
Papadopoulou, M. V., 47, 561
Papadopoulou, M. V., 561
Pappas, I. S., 339
Park, K.-K., 37
Pasqualini, C. D., 147
Paterson, L., 303
Pawlowska, J., 245
Pearson, V. C., 503
Peczynska-Czoch, W., 269
Pedone, C., 279
Peláez, F., 521
Penfold, P. L., 103
Peng, Y.-C., 199
Peruchon, L., 537
Peterlik, M., 551
Pfeiffer, B., 191, 537
Phillips, D. R., 479
Pierré, A., 191, 537
Pinguet, F., 211
Portella, G., 25
Poujol, S., 211
Promyart, P., 253

Renard, P., 191, 537
Rider, K., 359
Ridgway, L. D., 399
Robin, C., 315
Robins, D. J., 503
Robins, R. A., 175
Rogakos, V., 381
Rogers, P. M., 503
Romanelli, A., 279
Rosenkranz, H. S., 529
Ross, R. A., 87
Royo, I., 521
Ruggiero, M., 19
Ruggiero, R. A., 147

Sahpazidou, D., 261
Sanders, K., 71, 79
Sansom, O. J., 333
Sardi, I., 19
Saviano, M., 279
Scammell, J. G., 87
Schenone, E., 55
Seguin, E., 191
Serfas, M. S., 409
Shi, M.-J., 359
Shih, W. J., 61
Shirataki, Y., 463
Simillides, G., 381
Söderström, T., 463
Sone, S., 289
Sorrentino, R., 25
Sotiropoulou, G., 381
Spalletti-Cernia, D., 25
Sparatore, A., 455
Sparatore, F., 455
Spegelaere, P., 437
Spencer, D. M. S., 479
Spengler, B. A., 87
Sposato, M., 359
Sriram, P. S., 79
Stanslas, J., 175
Stevens, M. F. G., 175
Stevens, Z., 359
Strair, R., 169
Stravoravdi, P., 261
Surh, Y.-J., 37
Suthiphongchai, T., 253

Tarasiuk, J., 245
Thakker, R. V., 551
Thampatty, B. P., 529
Thomas, T. J., 123
Thomas, T., 123
Tian, L., 399
Tillequin, F., 191
Tohtong, R., 253
Toliou, T., 261
Tormo, J. R., 521
Tortum, O. B., 205
Troelsen, J. T., 393
Trosko, J. E., 353
Truini, M., 55
Tsai, H.-D., 199
Tsetsenis, T., 381
Tsiftsoglou, A. S., 339
Tsujishita, Y., 421
Tyner, A. L., 405, 409

Uehara, H., 289

van der Horn, K., 315
Van Horn, R. D., 71, 79
Vanzulli, S. I., 147
Vaudrain, T., 359
Vecchio, G., 25
Virochrut, S., 253
Visser, J., 359
Vizirianakis, I. S., 339

Wakayama, T., 309
Weir, I. E., 491
Whiteside, G., 491
Wilairat, P., 253
Wilmut, I., 303
Wipf, P., 347
Wolf, C. R., 245
Woodward, D., 169
Woon, S.-T., 95
Wrba, F., 551
Wróbel, A., 463

Xie, J.-G., 61
Xu, H., 429

Yano, S., 289
Yiotakis, A., 381

Zafiriou, G., 261
Zafiropoulos, N., 381
Zeicher, M., 437
Zhang, Q., 399
Zheng, X., 169
Zupi, G., 25

 

Subject Index

Acetogenins, 521
Acronycine, 191
Adult stem cells, 353
Alkylating agents, 205
Alpinia oxyphylla Miguel, 37
Alternative splicing, 429
Amide, 503
Angiogenesis inhibition, 513
Angiostatin, 381
Anthracyclines, 479
Anthraquinone compounds, 245
Anticancer drugs, 123, 471
Antimelanoma, 503
Antitumor promotion, 37
Antivascular, 95
Aorta, 315
Aorta-gonads-mesonephros (AGM) region, 315
Apoptosis, 25, 113, 269, 399, 491
Apoptotic sunburn cells, 61
Asymmetric cell division, 353
Autonomous parvovirus, 437
Autotumor cell line, 235
5-Azadeoxycytidine, 373

Barminomycin, 479
Basic ether, 537
BCPCF, 463
Benzbromarone, 463
Benz[5,6]isoindolo[2,1-a]indole, 537
Benzo[b]acronycine, 191
Bioassay, 169
Bioreductive drugs, 561
bis-Aziridinylnaphthoquinone derivatives, 199
Bisbenzimidazole, 491
bis(ethyl)Polyamines, 123
Blood levels, 169
Breast cancer, 137
BRK, 409

Caco-2 cells, 551
Cancer, 521, 537
Cancer and RhoGTPases, 323
Cancer biomarkers, 381
Cancer therapy, 437
CaR gene expression, 551
Caspase 3, 61
CC chemokine receptor 6 (CCR6), 393
CD4/CD8 ratio, 9
CD44 receptor, 71
Cell-cell adhesion killing, 235
Cell cycle, 269, 491
Cell growth, 19
Cell signaling pathways, 347
Cellular phone, 19
Chemoprevention, 61, 261
Chemoresistance, 399
Chemotherapeutic agents, 561
Chromogranins, 87
Circular dichroism, 175
Cisplatin, 399
Clone, 309
Colon carcinoma progression, 551
Connexins, 353
Costimulation, 437
COX-2 inhibition, 529
Cysteaminylphenol, 503
Cytokines, 137
Cytotoxic activity, 455
Cytotoxicity, 191, 221, 269, 521

Decoy, 279
Development program, 339
Dexamethasone, 87
6-Diakylaminoalkylamino side chains, 191
Diarylheptanoids, 37
Differential display, 429
Differentiation, 87, 103, 309, 339
Disease model, 309
DNA adducts, 479
DNA alkylation, 199
DNA binding, 175
DNA minor groove binders, 221
DNA repair, 205
DNMT3A, 373
Doxorubicin, 479
Drug resistance, 25, 205
Drug uptake, 95

Early killing, 235
Embryo, 315
Embryo stem cells, 303
Embryonal mass, 147
Embryonic stem cell(s), 309, 373
Endothelial cells, 359
Endothelium, 315
Enterocytes, 393
Epidermal growth factor receptor (EGFR), 289
Etoposide, 269
Evolution of multicellular organisms, 353
Expression profile(s), 393, 429
Extracellular signal-regulated kinase (ERK), 253 

Fas-L, 399
Fibroblasts, 137
Flavanone, 463
Flavone acetic acid, 95
Flavonoids, 529
Fluorescence, 175
Free radical formation, 245
Frk, 409

b-Galactosidase, 405
Gap junctions, 353
Gastric tumors, 205
Gene expression, 19
Gene expression and mutation, 323
Genetic changes, 3
Glucocorticoid, 87
Granulomatosis, 55
GTPase regulators and effectors, 323

Haptotaxis, 71
Hematopoietic stem cells, 315, 339, 445
Hepatitis C virus, 161
Hepatocellular carcinoma, 161
HER2, 289
Hormone regulation, 147
Human kallikrein 6, 381
Human kallikrein 13, 381
Human neuroblastoma, 87
Hyaluronan, 71
Hypoxic cytotoxins, 47

Immunohistochemistry, 289
Immunotherapy, 103
Indoloquinolines, 269
Indomethacin, 463
Inhibitory RhoGTPases, 323
Insulin-like growth factor binding protein-3, 359
Intercalating agent, 537
Invasion, 253
IPP5C domain, 421
Irreversible inhibitors, 513
Isoindolo[2,1-a]indole, 537

Keratinocytes, 393
Killikreins, 381

LAK cells, 235
Late killing, 235
Limited sampling strategy, 211
Lung tumor, 9
Lymphoma, 55
Lysosome, 235

Malignant mesothelioma, 71
Mast cells, 103
MCF-7, 455
MDA-MB 231, 455
Membrane potentials, 25
Mesothelial cells, 79
Metabolic changes, 3
Metalloproteinases, 137
Metastases-derived thyroid cells, 25
Metastasis, 253
a-Methylene-g-butyrolactone, 471
Methionine aminopeptidase, 513
Methylation, 373
O6-Methylguanine DNA methyltransferase, 205
MHC-II, 103
Microglia, 103
Microinjection, 309
Mitochondrial respiratory chain inhibitors, 521
Mitotic arrest, 113
Molecular dynamics simulation, 513
Mouse skin tumor promotion, 37
Multidrug resistance, 463
Multivariate analysis, 289
Murine erythroleukemia cells, 339
Murine small intestine, 333
Murine tumors, 147
Mutation(s), 405, 429
Myelocytic leukemia, 169

N-myc, 87
NADH dehydrogenase, 245
NADPH cytochrome P450 reductase, 245
NF-kB, 95
NF-kB/IkB, 113
Nitrogen mustard, 491
NKT cells, 9
NLCPQ-1, 561
NLCQ-1, 47
Non-Hodgkin's lymphoma, 55
Nonionizing radiation, 19
Non-small cell lung cancer, 289
Nuclear transfer (nt), 309
Nuclear transfer, 303

Oncoselective, 437
Ovarian cancer cells, 79
Ovarian carincoma, 399

p53, 61, 405, 429
p53 deficiency, 333
Paclitaxel, 113
Parathyroid hormone-related protein (PTHrP), 137
PBD-polyamide conjugate, 221
Peptide nucleic acid (PNA), 279
Peptide nucleic acid (PNA)-DNA chimeras, 279
Pharmacophore mapping, 471
Pharmacophores, 529
Phosphorylated EGFR, 289
Pigmentation, 3
Plasma, 211
Polyamide, 221
Polyamine analogs, 123
Polyamines, 123
Polycyclic acridine derivatives, 175
Population pharmacokinetics, 211
Potentiation, 561
Preclinical study, 261
Pregnancy, 147
Progenitor cells, 445
Proliferation, 71, 551
Prostate cancer, 253
Protein permeability, 79
Protein phosphatases, 347
Pyrrolo[2,1-\I\c][1,4]benzodiazepines, 221
Pyrrolo[1,2-a]indole, 537

Rak, 409
ras transformation, 25
Real-time PCR, 479
Red blood cell, 463
Reproductive cloning, 303
Reprogramming, 309
Retina, 103
Retrovirus, 405
Runx1, 315

Saliva, 211
Self-renewal, 445
Serine proteases, 381
Sigma receptor ligands, 455
Signal transduction, 253, 551
Signaling domains, 421
Sik, 409
Small molecules, 347
Somatic cells, 303
Spectrophotometric analysis, 175
Spontaneous tumors, 261
Src42A, 409
Srm, 409
START domain, 421
Stem cell diseases, 353
Stem cell expansion in vitro, 359
Structural genomics, 421
Structure-activity analysis, 463
Structure-activity relationship, 529
Suppression subtractive hybridization, 161
Synergism, 47

Taxol, 47
tet, 373
12-O-Tetradecanoylphorbol-13-acetate (TPA), 169
Therapeutic cloning, 303
Thymidine kinase, 437
Tirapazamine, 47
T lymphocytes, 9
Topoisomerase I, 491
Topoisomerase II, 269
Topotecan, 211
Total-body irradiation, 9
Transcription, 405
Transforming growth factor-b, 445
Transient expression, 429
Tumor cell line growth inhibitors, 521
Tumor dormancy, 147
Tumor hypoxia, 199
Tumor predisposition, 333
Tumor suppressor activity, 333
Tyrosinase, 3, 503

UV, 175
UV carcinogenesis, 61

Vascular endothelial growth factor, 79
Vaculature, 103
Vector, 437
Verapamil, 25

Wittig reaction, 537

Xanthine oxidase, 245
XIAP, 399

Yakuchinone, 37

VOLUME 12

Author Index

Akutsu, H., 255
Akutsu, M., 137
Andrei, G., 397
Ansell, J., 281, 282, 283, 297
Antzaklis, A. I., 287, 288
Avivi-Green, C., 83
Avner, P., 292
Azare, J., 315

Backus, H. H. J., 231
Bae, D. K., 5
Baguley, B. C., 149
Baird, J., 297
Bando, M., 173
Banerjee, D., 309
Bartel, F., 451
Baxevanis, C. N., 287, 288
Bermudes, D., 127, 501
Bertino, J. R., 11, 309
Bialik, S., 262
Bie, W., 294
Bishop, J. M., 263
Blank, M., 409
Bloomer, W. D., 185, 325
Boller, Y. C., 383
Borselli, C., 347
Brandes, L. M., 383
Brown, K. W., 441
Brunk, B., 270

Caciagli, B., 361
Cacoullos, N. T., 287
Cambray, N., 297
Carmen, M., 11
Carotti, S., 361
Castagnetti, G., 43
Cesinaro, A. M., 43
Chang, C. C., 277
Chang, R. L., 419
Changeux, J.-P., 292
Charest, A., 275
Charters, G. A., 149
Chen, G., 59
Chen, J., 501
Chevassut, T., 280, 281
Chi, S. G., 5
Chiarugi, V., 1
Claret, F.-X., 291, 295
Clarke, A. R., 264
Cohen, D., 315
Collard, G. J., 260
Conney, A. H., 419
Coronnello, M., 361
Cui, X.-X., 419

Dabelsteen, S., 289
D'Armiento, M. R., 347
De Bari, C., 284
De Clercq, E., 397
De Gaetani, C., 43
De Vincenzo, R., 355
Dell'Accio, F., 284
Deng, H., 278
Derry, J. J., 294
Desponts, C., 285
Dilley, R. J., 193
Distefano, M., 355
Dotti, A., 43
Dréau, D., 241
Dube, S. K., 11
Dumont, J. E., 347
Dvorak, P., 299
Dvorakova, D., 299
Dzierzak, E., 258

Eggan, K., 255
El-Gewely, M. R., 304
Erhardt, S., 256
Ernst, R., 270

Felsher, D., 263
Feng, M., 127
Ferlini, C., 355, 429
Ferrandina, G., 429
Ferrari, G., 43
Ferrari, P., 43
Fidler, I. J., 97
Filippini, P., 429
Flescher, E., 315
Fodstad, Ø., 113
Foley, J., 71
Forrester, L., 281, 282, 297
Foster, M., 241
Freedman, R. S., 429
Fruscella, E., 429
Fukushima, S., 121
Furukawa, Y., 137, 469
Furuse, M., 469
Fusco, A., 347

Gaggini, C., 355
Gallimore, P. H., 298
Garcia, A. M., 477
Gartel, A. L., 293
Gatter, K. C., 33, 203
Georgoulias, V. A., 33, 203
Gerbasio, D., 347
Ghansah, T., 285
Giatromanolaki, A., 33, 203
Gika, D. G., 287
Gorbea, C., 298
Gorlick, R., 309
Goufman, E., 293
Grabarek, J. B., 286
Graham, G., 297
Grand, R. J. A., 298
Gritzapis, A. D., 287
Gurdon, J. B., 253

Hackney, J., 270
Hampl, A., 299
Han, Z. T., 419
Hanibuchi, M., 173, 209
Harris, A. L., 33, 203
Harris, L. C., 451
Hay, N., 293
Hochedlinger, K., 255
Hogg, M., 241
Holdaway, K. M., 149
Holder, W. D., 241
Hollis, K., 294
Honda, H., 270
Hosono, M., 121
Housman, D., 275
Howson, J., 285
Huang, T. H.-M., 441
Huncharek, M., 107
Hurley, J. H., 302

Ide, S., 296
Iijima, R., 51
Ikuta, Y., 25
Inbal, B., 262
Ioannidis, P., 288
Ishiguro, T., 181, 343
Ishihara, H., 477
Ittensohn, M., 127, 501
Ivanova, N., 270
Iwakura, Y., 121
Izzo, J., 309

Jackson, M., 282, 297
Jaenisch, R., 255
Jansen, G., 231
Jhanwar, S. C., 309
Ji, M., 185, 325
Jiménez, J. A., 71

Kajiwara, M., 17
Kaklamanis, L. G., 203
Kakolyris, S. A., 33, 203
Kano, Y., 137
Kapsoritakis, A., 33
Karasiewicz, J., 286
Kavalakis, J. G., 287, 288
Kawakami, K., 459
Kawakami, M., 459
Keisari, Y., 409
Keller, G., 259
Kelly, K. A., 419
Kennedy, K. A., 383
Kennedy, M., 259
Kerr, W. G., 285
Kheifets, V., 275
Kimchi, A., 262
King, C. S., 71
King, I. C., 127, 501
Kittappa, R., 270
Koezuka, Y., 51
Komatsu, F., 17, 371
Koukourakis, M. I., 33
Koukourakis, M. J., 203
Kowalczyk, J. J., 477
Krassowska, A., 283
Kraus, M., 278
Kuiper, C. M., 231
Kupelnick, B., 107

Lai, P. B. S., 59
Lane, K., 275
Lau, W., 59
Lavie, G., 409
Lawrence D. S., 219
Lazo, J. S., 274
Le Novère, N., 292
Le, T., 127, 501
Ledent, C., 347
Lee, C. W., 5
Leet, C. S. F., 193
Lehrach, H., 269
Leland, P., 459
Lemischka, I., 270
Leung, B. C. S., 59
Leung, M., 59
Leung, T. W. T., 59
Lewis, M. D., 477
Li, E., 282
Li, Z., 127, 501
Liew, C., 59
Lim, B., 261, 280, 281
Lim, S.-K., 279
Lim, Y. K., 279
Lin, H.-Y., 270
Lin, S. L., 127, 501
Lin, Y., 419
Lin, Z. P., 383
Liu, H., 278
Liu, L., 278
Lodie, T. A., 266
Loi, T. H., 300
Longo, G. S. A., 309
Lorico, A., 113
Lun, Y., 270
Luo, X., 127, 501
Luyten, F. P., 284

Ma, D. D. F., 300
Madar, Z., 83
Maggiano, N., 429
Magnelli, L., 1
Makino, S., 121
Malik, K., 441
Mancuso, S., 355, 429
Mandel, M., 409
Mansouri, A., 291, 295
Marcon, G., 361
Marshall, E. S., 149
Masuda, T., 371
Matushansky, I., 272
May, S. L., 285
Mayer, J., 299
Mazzei, T., 361
McKay, R., 267
McMahon, K., 275
Medvinsky, A., 283
Messori, L., 361
Migaldi, M., 43
Miki, K., 335
Miki, T., 209
Mini, E., 361
Miwa, N., 469
Modlinski, J. A., 286
Molotkov, A., 169
Moore, K., 270
Mori, S., 121
Motoki, K., 51
Mozzetti, S., 429
Mulligan, R. C., 268
Murai, T., 121
Murakami, T., 25
Myers, C. B., 219
Mymryk, J. S., 298

Nagasu, T., 477
Nagawa, H., 181, 343
Najmabadi, F., 293
Nakagawa, R., 51
Nakamura, H., 51
Nakamura, K., 477
Nakamura, Y., 469
Namiki, M., 477
Neys, J., 284
Ng, S. C., 279
Nguyen, K. H. T., 285
Niikawa, N., 469
Ninos, J. M., 285
Nishioka, Y., 173
Nitta, Y., 25

Olsen, J., 289
Oohara, T., 121
Orioli, P., 361
Ouzounis, C., 271
Overton, C., 270

Pabst, T., 266
Palis, J., 259
Pampalakis, G., 290
Pankova-Kholmyansky, I., 315
Papadopoulou, L., 273
Papadopoulou, M. V., 185, 325
Papalexi, E. A., 287, 288
Papamichail, M., 287, 288
Pappas, I., 273
Parajuli, P., 173
Park, J., 275
Park, Y.-K., 5
Parmar, J., 149
Paspatis, G., 33
Patierno, S. R., 383
Pelletier, J., 275
Perez, S. A., 287, 288
Peters, G. J., 231
Philbrick, W. M., 71
Phillips, R., 270
Phillips, W. A., 193
Pinedo, H. M., 231
Plusa, B., 286
Polak-Charcon, S., 83
Polymeropoulos, M., 296
Portella, G., 347
Pritzker, M., 270
Puri, R. K., 459

Röpke, A., 491
Rabbitts, T., 265
Rabson, A., 419
Radomska, H. S., 266
Radparvar, F., 272
Ramsahoye, B., 282
Ranelletti, F. O., 429
Rao, M. K., 185, 325
Rappa, G., 113
Rassidakis, G. Z., 295
Raveh, T., 262
Rayburn, H., 275
Rede, T., 300
Refaeli, Y., 263
Reiss, M., 157
Reppa, D. K., 203
Reyes, N. I., 193
Richard, S., 294
Rideout, W. M. III, 255
Rider, K., 278
Ridgway, L. D., 291, 295
Rogner, U. C., 292
Rothstein, J. L., 347
Rousomoustakaki, M., 203
Ruggiero, M., 1
Runyab, J. D., 501
Russell, R. L., 383

Saitou, M., 256
Salnikow, K., 315
Salto-Tellez, M., 279
Samuel, K., 283
Santoro, M., 347
Sartorelli, A. C., 113
Sato, M., 51
Satoh, M., 169
Scambia, G., 355, 429
Schols, D., 397
Schwartz, B., 83
Sell, C., 491
Serizawa, I., 51
Shani, G., 262
Shelling, A. N., 149
Shen, S., 501
Shianov, P., 293
Shih, W. J., 419
Shimizu, E., 335
Shimosaka, A., 51
Shoat, G., 262
Shyam, K., 113
Sidiropoulou, A., 273
Simillides, G., 290
Sivridis, E., 33
Skoultchi, A. I., 272
Smith, C. D., 219
Smith, S. N., 219
Snoeck, H.-W., 301
Snoeck, R., 397
Sone, S., 173, 209, 335
Sotiropoulou, G., 290
Sotiropoulou, P. A., 287, 288
Souglakos, J. C., 203
Spivak, T., 262
Spyropoulos, D., 292
Srimatkandada, S., 11
Stanier, P., 292
Stathopoulos, G. P., 33
Stevens, Z., 278
Stoeckert, C., 270
Stoler, A. B., 429
Strair, R., 419
Stumm, M., 491
Sugita, T., 25
Suh, J., 419
Surani, M. A., 256
Suzuki, K., 137
Swiggett, J., 241

Takashima, A., 121
Takeda, R., 121
Tani, K., 335
Taubert, H., 451
Taylor, A. C., 451
Tenen, D. G., 266
Thomas, R. J. S., 193
Thomson, I., 283
Tiang, L., 295
Tohyama, C., 169
Trailsmith, M., 127
Trentini, G. P., 43
Troelsen, J. T., 289
Trosko, J. E., 277
Trumpp, A., 263
Tsetsenis, T., 290
Tsiftsoglou, A. S., 273, 296
Tsujishita, Y., 302
Tsukita, S., 469
Tsunoda, S., 137
Turnell, A. S., 298
Tyner, A. L., 293, 294

Ueno, H., 51
Unni, K. K., 5

van Groeningen, C. J., 231
Vanosdol, M., 278
Vecchio, G., 347
Vellucci, V. F., 157
Vincan, E., 193
Vizirianakis, I., 273

Wakayama, T., 257
Wang, J.-W., 285
Weidle, U. H., 491
Western, P., 256
White, R. L., 241
Wieacker, P. F., 491
Wieland, I., 491
Wilmut, I., 254
Wong, N., 59
Wouters, D., 231
Wysolmerski, J. J., 71

Xu, H., 304
Xu, L., 97
Xu, Y., 485

Yamaguchi, A., 477
Yan, P., 441
Yan, W., 157
Yanagawa, H., 173
Yanagimachi, R., 255
Yano, S., 173, 209, 335
Yaspo, M.-L., 303
Yazawa, Y., 137
Ye, X., 293
Yin, Y., 279
Ying, H., 485
Yoshimatsu, K., 477
Yu, Y., 485

Zeicher, M., 305
Zhang, P., 266
Zhang, Q., 291, 295
Zhang, X., 298
Zheng, L., 127, 501
Zheng, X., 419
Zilfou, J. T., 219
 
 

Subject Index

Adenocarcinoma, 309
Adhesion molecules, 17, 459
AG337, 231
Angiogenesis, 1, 33, 203
Antagonism, 355
Antibody, 241
Antifolate, 309
Antitumor effect, 501
Apoptosis, 83, 231, 315, 371, 397
ATF3 gene, 181, 343
ATP synthase subunit e, 485
Autocrine growth factor, 97
Autophagic cell death, 371
5-aza-2´-deoxycitidine (5-azadC), 335

Basic fibroblast growth factor, 241
bcl-2, 43
Bioreductive drug(s), 185, 325
Cancer, 127, 193, 219
b-Catenin, 193, 469

CD20, 241
cDNA microarray analysis, 59
Cell-cell adhesion-independent killing, 371
Cell cycle, 355
Cell form, 343
Cell migration, 343
Ceramide, 315
Cervical cancer, 429
Claudin-1, 469
Clinical epidemiology, 107
Clotting factors, 1
Coamplification, 11
Colon, 193, 231
Colon cancer, 83, 469
Colorectal, 309
Colorectal cancer, 203
COMET assay, 361
Cytokines, 409
Cytotoxicity, 361

DEAD box, 491
Delivery, 127
Differential display, 485
Differentiation, 193, 419
Dihydrofolate reductase, 11
DNA damage, 231
DNA sequencing, 149
Drug combination, 137
Drug efflux, 113
Drug resistance, 219, 383

E7 oncogene, 347
Ehrlich ascites carcinoma, 169
Endothelial cell polarity, 1
Epigenetics, 441
Epithelium, 193
ER-51785, 477
Etoposide, 383

Farnesyl transferase, 477
Fatty aromatic acids, 429
Flow cytometry, 149, 361
5-Fluorouracil, 137, 231

Gain of function, 71
a-Galactosylceramide, 51
Ganglioside GM2, 173
Gastric cancer, 33
Gemcitabine, 355
Gene amplification, 107
Gene expression, 59, 181
Genomics, 441
Glioblastoma multiforme, 459
Glioma, 107
Goiter, 347
Gold(III) complexes, 361
Growth inhibition, 485
Growth, 419
GSK-3b, 193

Hamster, 25
Head & neck cancer, 157
Hepatocarcinogenesis, 121
Hepatocellular carcinoma, 59, 485
HLA-DR, 241
Hormonal therapy, 43
Hormone resistance, 43
HPMPC (cidofovir), 397
HT29 colon cancer cells, 343
Human interferon-g, 173
Human papillomavirus (HPV), 397
Humoral hypercalcemia of malignancy, 71
Hypericin, 409
Hypoxic cytotoxin(s), 185, 325

IL-6-null mice, 169
Immunohistochemistry, 203
Immunotherapy, 241
Inflammation, 409
Interferon-a2b, 241
Interleukin-8, 97, 241
Interleukin-13, 459
Interleukin-13 receptors, 459
Isobologram, 137
Isoforms, 451

KRN7000, 51

LAK cells, 371
Leukemia, 419
Liposome, 25
Lung cancer, 173
Lung cancer cell line, 335
Lung metastasis, 25
Lymphokine-activated killer cell, 17
Lymphoma, 315

Macrophages, 51
mdm2, 451
MDP-Lys, 25
Melanoma, 149, 241
Mesenchymal chondrosarcoma, 5
Metallotioneins, 169
Metastases, 181, 409
Methotrexate, 11
Mitogen-activated protein kinase, 485
MRP1, 219
Multitargeted antifolate, 231
Murine tumor model, 501
Mutant p53, 71
Mutation, 157
Myelocytic leukemia cell lines, 11

Necrotic-like cell death, 371
Neoplasia, 347
N-Nitrosomorpholine, 121
NK-92, 17
NK cells, 51, 209
NKT cells, 51
NLCQ-1, 185, 325
Novobiocin, 113
Nuclear factor-kB, 383
Nuclear localization, 491

Osteosarcoma, 25
Ovarian cancer, 97
 
 

 

p16CDKN2A tumor suppressor gene, 5
p16INK4A, 335
p53, 33, 43, 149, 203, 451
Parathyroid hormone-related protein (PTHrP), 71, 209
PCR-SSCP, 459
Pediatric, 451
P-glycoprotein, 219, 315
Photodynamic therapy, 409
Platelet-derived endothelial cell growth factor (PD-ECGF), 33
PMA, 419
Polymorphism, 149
Prodrug-converting enzyme, 127
Prognosis, 43, 107
Promoter hypermethylation, 491
Prostaglandin A1, 383
Prostate cancer, 43
Protein isoprenylation, 429
PSC 833, 315

13q14, 491

Radiation, 149
Radiosensitizers, 325
Ralitrexed, 137
ras, 477
Receptor, 157
RET/PTC3 oncogene, 347
Rhabdomyosarcoma, 451
RT-PCR, 409

Salmonella, 127
Salmonella typhimurium, 501
SCID mice, 209
Short-chain fatty acid, 83
Single-strand conformation analysis (SSCP), 149
Smad, 157
Small-cell lung cancer, 209
Sodium butyrate, 83
Soluble fiber, 83
Spontaneous lung metastasis, 121
Squamous cell carcinoma, 71, 157
Stress, 383

T98G, 17
Targeting, 127
Thymidine phosphorylase, 33
Thymidylate synthase, 309
Thyroid, 347
Tight junction, 469
Tirapazamine, 325
T lymphocytes, 315
Topoisomerase II, 113
Topotecan, 355
TPA, 419
Transforming growth factor-b, 157
Tumor-bearing mice, 169
Tumorigenesis, 347
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 17
Tumor regressions, 477
Tumor suppressor gene(s), 441, 491

U373MG, 17

Vascular endothelial growth factor, 241
Vector, 127
VEGF, 33, 335
VNP20009, 501
VP-16, 113

Weak DNA intercalation, 185
Wilms' tumor, 441
Wnt/wingless signaling pathway, 469
WT1, 441

Xenograft, 477

VOLUME 11, 1999

Author Index

Adachi, E., 179
Ahmad, I., 273
Ahn, W. S., 9
Albini, A., 17
Ali, S., 273
Angel, L. P., 489
Angelucci, A., 17
Anthony, S. P., 303
Antony, V. B., 187
Aoki, D., 71, 233
Arab, S., 33
Arakawa, H., 281, 513
Aterini, S., 265
Atwell, G. J., 249
Azrak, R. G., 91

Baguley, B. C., 115, 249, 287
Balzarini, J., 195
Barraclough, R., 311
Bentrem, D. J., 401
Bertoni, F., 297
Bharadwaj, T. P. R., 101
Biondi, C., 437
Bishayee, A., 41
Bloomer, W. D., 345
Bologna, M., 17
Bombardelli, E., 145, 471
Bonanno, G., 471
Borselli, C., 421
Bosserhoff, A. K., 55
Broggini, M., 297
Brower, S. T., 489
Buettner, R., 55

Cabral, F., 455
Cañete, M., 447
Cao, S., 91
Capaccioli, S., 437
Capelli, G., 145
Carbone, E., 339
Caspani, G., 297
Chambers, A. F., 161
Chandra, J., 455
Chatterjee, M., 41
Chaudhri, G., 331
Chen, B., 133
Chen, S.-H., 489
Chong, D., 133
Cianchi, F., 437
Codegoni, A. M., 297
Colella, G., 297
Colosetti, P., 375
Conway, R. M., 331
Cortesini, C., 437
Cowan, K. H., 153
Cross, H. S., 77

D'Andrea, E., 529
D'Incalci, M., 297
Danieli, B., 145
Davis, S. A., 303
De Celrcq, E., 195
De Vincenzo, R., 145
Ding, L., 287
Distefano, M., 145, 471
Divino, C. M., 489
Domínguez, V., 447
Dréau, D., 55

Ellinger, A., 77

Faraone, S., 529
Ferlini, C., 145, 471
Festuccia, C., 17
Ficari, F., 437
Finance, C., 375
Finlay, G. J., 115, 249
Fodor, I., 133
Fujiwara, N., 497
Funahashi, Y., 319
Fusco, A., 421

Gaggini, C., 145
Galettis, P., 287
Galffy, G., 187
Gatter, K. C., 205
Georgoulias, V., 205
Giatromanolaki, A., 205
Gitsch, G., 367
Giunciuglio, D., 17
Gnainsky, J., 255
Gomes-Marcondes, M. C. C., 359
Gopinath, P. M., 101
Gougoumas, D., 409
Grassi, L., 297
Gridley, D. S., 133
Guerra, F., 17
Gulisano, M., 265
Guo, B., 91

Haddad, G. G., 287
Hamilton, J. W., 303
Hanibuchi, M., 219
Hardell, L., 539
Harris, A. L., 205
Hatse, S., 195
Hayashi, K., 461
Hirabayashi, K., 497
Hofer, H., 77
Holder, W. D., 55
Hotfilder, M., 513
Hwu, W.-J., 529

Ihnat, M. A., 303
Iida, S.-i., 233
Irimura, T., 233, 497
Irimura, T., 497

James, W. I., 505
Janoff, A. S., 273
Ji, M., 345
Jordan, V. C., 401
Juarranz, A., 447

Kageyama, K., 479
Kaltreider, R. C., 303
Kannan, K., 101
Kataoka, S., 71
Khan, S. H., 345
Kim, H. S., 9
Kitoh, K., 319
Knüpfer, H., 523
Knüpfer, M. M., 523
Kobayashi, E., 71
Komatsu, F., 213
Koukourakis, M. I., 205
Koyama, K., 281
Kozu, A., 71
Kuiper, C. M., 383

Langridge, W. H. R., 133
Lariviere, J. P., 303
Leffert, J. J., 529
Leodolter, S., 367
Li, G.-M., 393
Li, J., 133
Li, W., 243
Liel, Y., 255
Linde, A., 539
Lingwood, C., 33
Liu, J.-W., 479

Madigan, M. C., 331
Mancuso, S., 145, 471
Manduca, P., 17
Marchal, S., 375
Marsh, J. C., 529
Marshall, E. S., 115
Masters, G. R., 273
Mayhew, E., 273
Mazzei, T., 437
Mazzoni, P., 437
McConkey, D. J., 455
McKeage, M. J., 287
Melillo, R. M., 421
Merlin, J.-L., 375
Mineura, K., 513
Mini, E., 437
Miwa, N., 479
Miyoshi, Y., 125
Mohammed, K. A., 187
Monden, M., 281
Morazzoni, P., 145
Morganti, M., 437
Mori, T., 513
Multani, A. S., 455
Munirajan, A. K., 101
Murakami, K., 461
Murata, J., 461

Naesens, L., 195
Nagao, N., 479
Nakamura, Y., 125, 281, 513
Nam, S. M., 9
Napoli, C., 437
Nasca, R., 339
Näsman, Å., 539
Nasreen, N., 187
Nervi, A. M., 303
Ng, C. C., 281
Nguyen, J., 273
Nishimura, N., 219
Nishioka, Y., 219
Nokihara, H., 219
Nordström, M., 539
Nozawa, S., 71, 233

Obermair, A., 367
Ogasawara, M., 461
Oie, S., 71
Ojima, I., 471
Okamura, S., 281

Pacini, P., 265
Pacini, S., 265
Papadopoulou, M. V., 345
Pappas, I. S., 409
Parajuli, P., 219
Park, Y. S., 9
Pathak, S., 455
Penfold, P. L., 331
Pesce, C. A., 303
Peterlik, M., 77
Peters, G. J., 383
Pierelli, L., 471
Pitzer, C., 85
Pizzorno, G., 529
Pollak, J., 529
Polo, S., 447
Portella, G., 421
Pradheepkumar, C. P., 225
Preiß, R., 513

Quattrone, A., 437

Riva, A., 145, 471
Rosenblatt, M., 529
Rossi, S., 437
Rothstein, J. L., 421
Roy, S., 41
Ru, K., 505
Rudland, P. S., 311
Ruggiero, C., 265
Ruggiero, M., 265
Russo, I. H., 169
Russo, J., 169
Rustum, Y. M., 91
Rutka, J., 33

Saiki, I., 461
Salem, R. R., 529
Salvatore, D., 421
Sane, S., 455
Santoro, M., 421
Sanz, C., 447
Sartorelli, A. C., 429
Scambia, G., 145, 471
Schiebel, I., 367
Schloss, L., 539
Schmid, B. C., 367
Schmitt, S., 505
Schupsky, J. J., 273
Schwartz, B., 255
Screnci, D., 287
Segers, C., 195
Semba, T., 319
Sen, S., 455
Shanmugam, G., 101, 225
Shany, S., 255
Shen, D., 63
Shen, F., 243
Sinha, B. K., 153
Sivridis, E., 205
Smirnoff, P., 255
Sone, S., 219
Song, K., 153
Sonoda, J., 319
Stassar, M. J. J. G., 85
Stimpfl, M., 367
Stockert, J. C., 447

Takahashi, M., 71
Takei, Y., 281
Takesue, H., 497
Tamada, Y., 233
Tannock, I. F., 179
Taylor, S. L., 311
Teti, A., 17
Tharu, R., 101
Thompson, T. C., 1
Timiryasova, T. M., 133
Tokino, T., 125, 513
Toledo, M. T., 359
Tonelli, F., 437
Tong, D., 367
Tong, W.-M., 77
Tóth, K., 91
Tsiftsoglou, A. S., 409
Tsuchida, N., 101

Udagawa, Y., 71
Ueda, K., 125
Utsugi, T., 219

Vadgama, J. V., 63
van der Wilt, C., 383
Vecchio, G., 421
Vendrell, V. D., 447
Verbeken, E., 195
Villanova, I., 17
Villanueva, A., 447
Vitagliano, D., 421
Vizirianakis, I. S., 409

Waer, M., 195
Wakabayashi, T., 319
Wang, J. H., 505
Ward, M. J., 187
Warren, A. J., 303
Watatani, M., 125
Weber, G., 243
Weinberg, E. D., 109
White, R. L., 55
Wu, W., 461

Xiao, H. H., 429
Xu, J., 429

Yamaura, T., 461
Yano, J., 497
Yano, S., 219
Yin, B.-b., 91
Yoshida, S., 213
Yoshimatsu, K., 319

Zeillinger, R., 367
Zhuang, L., 287
Zöller, M., 85

Subject Index

Acyclic nucleoside phosphonate, 195
Adenovirus, 1, 153
Adenovirus vector, 513
Amsacrine, 249
Angiogenesis, 33, 205, 319
Animal models, 161
Animals, 539
Anticancer drugs, 71
Anticancer effects, 225
Antiestrogens, 401
Antineoplastic, 33
Antisense, 505
Antitumoral, 195
Apoptosis, 71, 91, 115, 125, 145, 219, 225, 297, 331, 393, 409, 447, 489, 497
Asbestos, 109
Ascorbic acid, 471

Bax dimerization, 91
bcl-2, 205
Bioreductive drugs, 345
Blood, 55
Bone metastasis, 17
Borrelidin, 319
BRCA1, 63
BRCA2, 63
Breast, 169
Breast cancer, 265, 311, 401, 505
Breast Cancer Information Core (BIC), 55

Caco-2 cells, 77
Cancer, 9, 169, 393, 523
Cancer chemotherapy, 303
Carbohydrate epitope, 233
Carboplatin, 115
Caspase, 91
Caspase-3, 71
Cationic liposome, 497
CD40, 339
cDNA cloning, 409
c-erbB-2, 311
Cell cycle, 243, 249, 297
Cell cycle block, 471
Cell death, 455
Cell proliferation, 169
Cell transformation, 169
Chemical carcinogenesis, 169
Chemotherapy, 345
CHO mutant cell lines, 455
Choriocarcinoma, 195
cis-Platinum, 153
Cleistanthin A, 225
Clinical, 115
Colchicine analogs, 145
Colon cancer, 461
Colorectal cancer, 77, 255
Colorectal carcinoma, 437
Combination gene therapy, 153
Competitive PCR, 311
Cremophor EL, 273
Cyclin D1, 77
CYP, 523
Cytochrome c, 91
Cytokinetics, 115
Cytotoxicity, 243, 339, 471

Development, 169
Diethylnitrosamine, 41
Differential display, 85, 281
Differential expression, 85
Differentiation, 331, 409, 421, 429
1a,25-Dihydorxyvitamin D3, 77
DNA methylation, 255
Docetaxel, 471
Doubling time, 115
Doxorubicin, 9, 249
Drug interactions, 287
Drug resistance, 153
Drug response, 91

Early antigen (EA), 539
EBNA-1, 539
Electromagnetic fields, 265
ELISA, 55
Endometrial adenocarcinoma, 205
Epidermal growth factor receptor, 77
Epithelial markers, 367
Epstein-Barr virus (EBV), 539
Estrogen, 255
Estrogen receptor, 169
Evaluation of detection methods, 367
Exhausts, 539
Expression, 409
Extracellular domain, 513

fhit, 101
Fluoroquinolone, 375
5-Fluorouracil, 437
Folylpolyglutamate synthetase, 437
 

 

Gene alterations, 101
Gene expression, 133, 303
Gene therapy, 1, 153
Genomic instability, 393
Glioblastoma multiforme, 33
Glioma, 133
Glioma cells, 513
Globotriaosyl ceramide, 33
GML, 125
Growth inhibition, 331
GW 1843U89, 383

hCAR, 513
HeLa cells, 447
Hematopoietic progenitors, 471
Hemofiltration, 529
Hepatocarcinogenesis, 41
HL-60 leukemia, 429
HSP70 multiple gene family, 429
Human breast epithelial cell, 169
Human cancer cells, 145
Human myeloma 8226 cells, 243
Human ovarian carcinoma OVCAR-5 cells, 243
Human T-lymphotropic virus type 1 (HTLV-1), 213
Human tumor models, 273
Hypoxia, 319IFN-a2b, 55

IL-2, 55
Immunoblotting, 331
Immunocytochemistry, 311
Immunocytolytic factor, 489
Immunoliposome, 9
Immunomagnetic separation, 367
Immunotherapy, 55
IMP DH, 243
In situ hybridization, 311
In vivo model, 319
Infectivity, 513
Inhaled iron withholding, 109
Interleukin-8, 187
Interleukins, 523
Intra-arterial chemotherapy, 529
Invasion, 461, 471
IP3, 243

Ki67, 169
Killer inhibitory receptor, 339

Lobules, 169
Low molecular weight proteins, 85
Lung cancer, 109, 219
Lymphocytes, 489
Lymphokine-activated killer (LAK), 213

Marker, 55
Matrix metalloprotease, 471
Matrix metalloproteinase (MMP), 461
MCF-10F, 169
MDA-MDB-435 breast cancer cell line, 303
MDS, 101
Mechanisms, 345
MEL cells, 409
Melanoma, 55, 339
Melanoma-inhibitory activity protein (MIA), 55
Mesothelioma, 187
Metalloproteinase-9, 17
Metastasis, 461, 471
Metastatic inefficiency, 161
Metastatic liver cancer, 497
MHC class I, 339
Microsatellites, 297
Mismatch repair, 393
Mitochondrial chaperone HSP70, 429
Monoclonal antibody, 233
MT-2, 213
MTA, 383
Mucins, 233
Multidrug resistance (MDR), 145, 219, 303, 375
Multidrug resistance-associated protein, 375
Mutation(s), 63, 297

Natural killer cell inhibitory receptor, 213
Natural killer cells, 339
Necrosis, 447
Neoplasms, 265
Neurotoxicity, 287
NK-92, 213
Nolatrexed, 383
Nucleotide analogue, 195
Nude mouse model, 187

Olfoxacin, 375
Ovarian cancer, 297
Ovarian carcinoma, 153, 233
Oxazaphosphorines, 523

 

p16, 101
p53, 101
p53, 133, 205, 281
p53 gene, 153
p53 target, 125
p53 target gene, 281
Paclitaxel, 115, 455, 471
Pancreatic cancer, 489
Pathogenesis, 169
PCR, 523
Pesticides, 539
P-glycoprotein, 303, 375
pH, 179
Pharmacokinetics, 529
Photodynamic therapy, 447
Photosensitizers, 447
Placenta, 359
Platinums, 287
Poly-DNP-RNA, 505
Poly(I):poly(C), 497
Potentiation, 345
Pregnancy, 359
Primary culture(s), 77, 115
Prodrug, 195
Progesterone receptor, 169
Prognosis, 233
Prostate cancer, 1, 17
Psychological stress, 461

Quantification, 319
Quercetin, 243

Raloxifene, 401
Raltitrexed, 383
ras, 421
Rats, 41
RD/TE-671 cells, 409
Reactive oxygen species, 471
Renal cell carcinoma, 85
Resistance, 437
RET, 421
Reverse transcription-polymerase chain reaction, 233
Ribavirin, 243

S5 ribosomal protein, 409
SCID mice, 505
Sensitivity testing, 115
Signal transduction, 243
SKG-3a, 71
SKG-3b, 71
Social isolation, 461
Steroid receptors, 255

T98G, 125
Tamoxifen, 401
Target sensitivity, 9
TAS-103, 219
Tax-18, 455
Tax-2-4, 455
Taxanes, 287, 471
Taxol, 273
Telomere erosion, 455
Therapeutics, 273
Thiocolchicone, 145
THNLA-1, 345
Threshold, 55
Thymidylate synthase, 383, 437
Thyroid, 421
Timing of surgery relative to menstrual cycle, 161
Tobacco smoking, 109
Topoisomerase II, 249, 375
Topoisomerase inhibitor, 219
Toxicity, 273
TRAP-2, 85
TRK, 421
a- and b tubulin, 145
Tumor, 133
Tumor-associated antigen(s), 9, 85
Tumor dormancy, 161
Tumor necrosis factor-a (TNF-a), 461
Tumor physiology, 179
Tumor suppressor genes, 101
Tumorigenesis, 421

Urokinase, 17
Urokinase-type plasminogen activator (u-PA), 461
Vaccina virus, 133

Vaccine, 55
Vanadium, 41
Vasodilating drugs, 179
VEGF, 319
Venous isolation, 529
Videomicroscopy, 161
Vitamin D, 255, 265

Walker 256 tumor, 359

Xenobiotic biotransforming enzymes, 41
Xenografts, 273

Zinc(II)-phthalocyanine, 447


 

 

 

 

 

 

Oncology Research: Featuring Preclinical and Clinical Cancer Therapeutics (ISSN 0965-0407 and E-ISSN 1555-3906)) is published by Cognizant Communication Corporation, Robert N. Miranda, Publisher, P.O. Box 37, 18 Peekskill Hollow Road, Putnam Valley, NY 10579, U.S.A., Tel (845) 603-6440; Fax (845) 603-6442; Email This e-mail address is being protected from spambots. You need JavaScript enabled to view it

2014 Subscriptions: Published 6 numbers per year and sold on a calendar basis by the volume number designated for that year. Subscription price now includes full text online. Contact the publisher for subscriber access code.

Institution (Online only) $925
Institution (Online + hard copy) $1,075
Professional (Online only) $115 

Back Issues & Back Volumes
:
Single back issues (hard copy) $65 each + shipping.  Order here>
Back volumes (Vols 12-21) in online version $660 per volume.  Order here>
Back volumes available in hard copy at $900 per volume + shipping. Contact publisher directly for shipping charges.

Download Order Form or order by mail or fax>

Payment by check in U.S. dollars drawn on a U.S. bank or by International Money Order. Credit cards accepted: Visa and MasterCard only. Invoices will be issued on receipt of an institutional purchase order.

Pay to the order of:

Cognizant LLC
P.O. Box 37
18 Peekskill Hollow Road
Putnam Valley, NY 10579

*Must be paid by personal check or personal credit card only. No purchase orders accepted.

Publishing Information

Advertisement:Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics will accept advertisements. All advertisements are subject to approval by the Editor-in-Chief. For details and rates contact the Publisher.

Disclaimer: Although every effort is made by the publisher and editorial board to see that no inaccurate or misleading data, opinion, or statement appears in this journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the sole responsibility of the contributor or advertiser concerned. Accordingly, the publisher, editors, editorial board, and their respective employees, officers, and agents accept no responsibility or liability whatsoever for the consequences of any such inaccurate or misleading data, opinions, or statements.

Copyright Notice: It is a condition of publication that manuscripts submitted to this Journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for the articles is transferred to the publisher, if and when the article is accepted for publication. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform, or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording, or otherwise, without permission in writing from the copyright holder.

Photocopying information for users in the USA: The Item Fee Code for this publication indicates that authorization to photocopy item for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of $90.00 per copy per article is paid directly to the Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, MA 01923. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt, please contact Cognizant Communication Corporation. The Item Fee Code for this publication is 0965-0407/10 $90.00

Copyright © 2011, Cognizant Communication Corporation

Printed in the USA

Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics is indexed and abstracted in: Current Contents/Life Sciences, Science Search, Science Citation Index, Research Alert, MEDLARS, MEDLINE, Index Medicus, BIOSIS, SIIC (Sociedad Iberoamericana de Información Cientifica) Database, and CABS (Current Awareness in Biological Sciences).

 

Volume 21, Number 3
Volume 21, Number 2
Volume 21, Number 1
Volume 20, Number 12
Volume 20, Number 11
Volume 20, Number 10
Volume 20, Number 9
Volume 20, Number 8
Volume 20, Number 7
Volume 20, Numbers 5/6
Volume 20, Number 4
Volume 20, Number 2/3
Volume 20, Number 1
Volume 19, Number 12
Volume 19, Numbers 10/11
Volume 19, Numbers 8/9
Volume 19, Number 7
Volume 19, Number 6
Volume 19, Number 5
Volume 19, Numbers 3/4
Volume 19, Numbers 1/2
 
Volume 18, Numbers 11/12
Volume 18, Number 10
Volume 18, Number 9
Volume 18, Number 8
Volume 18, Number 7
Volume 18, Numbers 5/6
Volume 18, Number 4
Volume 18, Numbers 2/3
Volume 18, Number 1
Volume 17, Numbers 11/12
Volume 17, Number 10
Volume 17, Number 9
Volume 17, Number 8
Volume 17, Number 7
Volume 17, Number 6
Volume 17, Number 5
Volume 17, Number 4
Volume 17, Number 3
Volume 17, Number 2
Volume 17, Number 1
Volume 16, Number 12
Volume 16, Number 11
Volume 16, Number 10
Volume 16, Number 9
Volume 16, Number 8
Volume 16, Number 7
Volume 16, Number 6
Volume 16, Number 5
Volume 16, Number 4
Volume 16, Number 3
Volume 16, Number 2
Volume 16, Number 1
Volume 15, Numbers 10-12
Volume 15, Number 9
Volume 15, Numbers 7/8
Volume 15, Number 6
Volume 15, Number 5
Volume 15, Number 4
Volume 15, Number 3
Volume 15, Number 2

 




 

Volume 14, Numbers 11/12
Volume 14, Number 10
Volume 14, Number 9
Volume 14, Numbers 7/8
Volume 14, Number 6
Volume 14, Numbers 4/5
Volume 14, Number 3
Volume 14, Number 2
Volume 14, Number 1

Volume 13, Number 12
Volume 13, Number 11
Volume 13, Numbers 6-10
Volume 13, Number 5
Volume 13, Number 4
Volume 13, Number 3
Volume 13, Number 2
Volume 13, Number 1

Volume 12, Numbers 11/12
Volume 12, Numbers 9/10
Volume 12, Number 8
Volume 12, Numbers 6/7
Volume 12, Number 5, 2000
Volume 12, Number 4, 2000
Volume 12, Number 3, 2000
Volume 12, Number 2, 2000
Volume 12, Number 1, 2000

Volume 11, Numbers 1-12, 1999





Full text articles available: CLICK HERE>

Back Issues of this journal are available in hard copy at $65 each + shipping.  Order here>

Back volumes of this journal (Volumes 12-21) are available in online version at $660 per volume.  Order here>

Request a quotation for availability of hard copy back volumes.

Or order by phone, fax or mail: Download the Journal Order Form>

Cognizant Communication Corporation
P.O. Box 37
Putnam Valley, NY 10579 U.S.A.

Phone: (845) 603-6440
Fax: (845) 603-6442

Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

Items viewed per month for this Journal through Ingenta Connect: February 2014

Table of Contents: 1,045
Abstracts: 6,436
Full Text Downloads: 188